var title_f12_45_13008="Normal prostate on ultrasound";
var content_f12_45_13008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse view of normal prostate on ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of RN Alheid.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13008=[""].join("\n");
var outline_f12_45_13008=null;
var title_f12_45_13009="Halofantrine: International drug information";
var content_f12_45_13009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Halofantrine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Halfan (AT, BE, DE, ES, FR, GB, LU, NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F4089094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Halofantrine Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4089095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimalarial Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4089096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild-to-moderate acute malaria caused by susceptible strains of",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     and",
"     <i>",
"      Plasmodium vivax",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4089098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;37 kg: 8 mg/kg every 6 hours for 3 doses; repeat in 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;37 kg: 500 mg every 6 hours for 3 doses; repeat in 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 500 mg every 6 hours for 3 doses; repeat in 1 week",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4089099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, as hydrochloride: 250 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10455 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13009=[""].join("\n");
var outline_f12_45_13009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369784\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089094\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089095\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089096\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089098\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821074\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089099\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10455\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10455|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_45_13010="Scaphoid fracture";
var content_f12_45_13010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scaphoid fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 15-year-old suffered acute pain and swelling in the wrist after a fall on an outstretched arm. Initial x-rays were normal, but this film taken two weeks after the injury demonstrates a fracture line through the middle third of the scaphoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal wrist radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anterior-posterior view of the wrist is normal. The width of the articular cartilage is 2 mm and is identical to the width of the intercarpal joints.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13010=[""].join("\n");
var outline_f12_45_13010=null;
var title_f12_45_13011="Crotamiton: Drug information";
var content_f12_45_13011=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Crotamiton: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/38/12900?source=see_link\">",
"    see \"Crotamiton: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/5/4179?source=see_link\">",
"    see \"Crotamiton: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F155020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eurax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14959735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eurax Cream",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F155051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Scabicidal Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F155022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Scabies:",
"     </b>",
"     Topical: Wash thoroughly and scrub away loose scales, then towel dry; apply a thin layer and massage drug onto skin of the entire body from the neck to the toes (with special attention to skin folds, creases, and interdigital spaces). Repeat application in 24 hours. Take a cleansing bath 48 hours after the final application. Treatment may be repeated after 7-10 days if live mites are still present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pruritus:",
"     </b>",
"     Topical: Massage into affected areas until medication is completely absorbed; repeat as necessary",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F155038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/5/4179?source=see_link\">",
"      see \"Crotamiton: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F155023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eurax&reg;: 10% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eurax&reg;: 10% (60 mL, 480 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F802621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only. Shake lotion well before using. Avoid contact with face, eyes, mucous membranes, and urethral meatus.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F155010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of scabies (",
"     <i>",
"      Sarcoptes scabiei",
"     </i>",
"     ) and symptomatic treatment of pruritus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F155058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Eurax&reg; may be confused with Efudex&reg;, Eulexin, Evoxac&reg;, Serax, Urex",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Eurax [U.S., Canada, and multiple international markets] may be confused with Urex brand name for furosemide [Australia, China,Turkey] and methenamine [U.S., Canada]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F155049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Local irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic sensitivity reactions, warm sensation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F155012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to crotamiton or any component of the formulation; patients who manifest a primary irritation response to topical medications",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F154999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; avoid contact with face, eyes, mucous membranes, and urethral meatus. Do not apply to acutely inflamed or raw skin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F155006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F155015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted; use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F155025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F155014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Eurax External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (60 g): $104.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Eurax External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (60 g): $104.94",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F155016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A-Bite (MY);",
"     </li>",
"     <li>",
"      Acomexol (MX);",
"     </li>",
"     <li>",
"      Congen (PH);",
"     </li>",
"     <li>",
"      Crotamitex (DE);",
"     </li>",
"     <li>",
"      Crotamiton (PL);",
"     </li>",
"     <li>",
"      Crotan (PK);",
"     </li>",
"     <li>",
"      Crotanol (VE);",
"     </li>",
"     <li>",
"      Crotorax (IN);",
"     </li>",
"     <li>",
"      Eurax (AE, AT, AU, BB, BE, BF, BH, BJ, BM, BS, BZ, CH, CI, CN, CO, CY, EG, ET, FR, GB, GH, GM, GN, GR, GY, HK, HR, IE, IL, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PL, PT, QA, SA, SC, SD, SG, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Eurax-Lotio (AT);",
"     </li>",
"     <li>",
"      Euraxil (ES);",
"     </li>",
"     <li>",
"      Moz-Bite (MY, SG);",
"     </li>",
"     <li>",
"      Scabicin (IL);",
"     </li>",
"     <li>",
"      Ulex (TW);",
"     </li>",
"     <li>",
"      Uracin (KP);",
"     </li>",
"     <li>",
"      Youlifu (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F154998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Crotamiton has scabicidal activity against",
"     <i>",
"      Sarcoptes scabiei",
"     </i>",
"     ; mechanism of action unknown",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Eichenfield LF, Honig PJ, &ldquo;Blistering Disorders in Childhood,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(4):959-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/45/13011/abstract-text/1651468/pubmed\" id=\"1651468\" target=\"_blank\">",
"        1651468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hogan DJ, Schachner L, Tanglertsampan C, &ldquo;Diagnosis and Treatment of Childhood Scabies and Pediculosis,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(4):941-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/45/13011/abstract-text/1870912/pubmed\" id=\"1870912\" target=\"_blank\">",
"        1870912",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9301 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13011=[""].join("\n");
var outline_f12_45_13011=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155020\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14959735\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155051\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155022\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155038\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155023\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155009\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154995\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802621\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155010\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155058\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155049\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155012\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154999\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299103\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155004\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155006\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155015\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155025\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155014\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155016\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154998\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9301\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9301|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/38/12900?source=related_link\">",
"      Crotamiton: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/5/4179?source=related_link\">",
"      Crotamiton: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_45_13012="Alopecia areata eyebrow";
var content_f12_45_13012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Alopecia areata involving the eyebrow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCsqkk27KmCOducGkDnyljG7bE2N7EHP0FOssLbtE0m4lhk/eP406ZI5HkQbfLB3/MOgFeQtj3r62Ii+yMxBfk3g7u5BBxgCrACNCigSrbHBclcZbntSwQqxi8k7t0QG5+inORjp+tTfuSqSTPuQ8YXHB4q9kLW42zthIoktrZOASeATj1xT7eUR+ZmbMnK/Io4z1FNgWI+Z50csfzDZtYk4IPHHWnPEYbaSUny4w6jIGTk/rQn2EIfJuQluEeQxuCABkKM0ttFDJJh4nV0f5s8/KP84p0pjSOP/SEPmNuJQYZMHH1/OoxGkSNCZFVi27LNgjnPPvii7QWuRxzRzzqqttIc/LGvRewGKeYZZpZJDH9m4JbeeOO575pjShoGVCVRAQ7x/IG6d6iiwYJpN5KLgKqnl+/U0k1axVupNblPs8cSscEkk7CxORz+tJNbQ2+x7oPKxU7fOb8qrwXCxWs1wDEsrc85YjJ5HHFTWiwkxtcssf8AExkIH0wBTT6A421HxQPDCkwKRgAPw25j7DJotJJZZbmPcwV+WOcv7DFV2MbzyBLlXK/dZkKjJ4zmq3ns/mDdHK6ttZgGOVHfNUrrUSV9C/IGkLyzzERRKCAzE5PfgVHFKJLkfvMKwG0JH3z6H+tZqXGJ0kRIlQnCjBbGPbOPzqYzvLM8snmRgngAqMt2zioTV2ynFrc0JpLiOZvKM4AOBtOAT+A/rVeRhA/k3E6yMfmG1ic+oBJ4/Gqf2i4RT9plb94cfO2D9cdKRGUJKMxnncJFIJz6dKl2HGPc0oyl26bAkYAx1/I9aPtDW1wyCQGVh82FUn8MVXhedyjBmYovygDbipdn2gedLKcLgnYf5U7qw7WY2fYJAZtshOGOVzj689akUGF2iIh8tmz8pJ61WMm9jiN2QHKAoufpinxxKQjSpsIBKrINvf2FJPqElYs7o1zHtIUZHysM/lTrZl2OsbJgA4JH9M0kG5JN5UJMSPmV849hUTQq2597NvPHmIG/L0ouTp1F8iYcqISpGf3fRgPUYqfEC25DjY/VdrZAPuAePxqBYWTG0vHj+HkLmrMUKsHlUuCOw7nuPQ1cXbYTXcrqmfNdMsDyBkkH2HUfnR92P960pZ+Np6D+lT/ZyiuVOAcD+6T/AEqpKglm2mR1B7djUO61BJEgjRnCKyII+WJOKsLEHc5CEqOVBzn3yKilCR7IvKdmC5DnnA/rSCJlz5bIRgfKOCfwpp2E1crmKILnf9Sr8D696gicsXWQ4cHBz39/erF4Cvy+X5b+pHBNQyRRpdBBOjBlBwM8E9QKV76hYqTSFMbGz8wOCOvr9abdsqEqowXwQgGcH+lXHWJ8wbe3O48k1AzwmLlsOMqQ36fUUrpj2IG+Uh9hJAxnOPz96hlMZLyI20knDL1/GrEcpiQoCrREYzt6USRrGhhkUO+3hlHalo9AM0tKYnGwDHUDg1XJLMpUhXU56dRWhDbLhmZsKy7WOePbHvVRrcbFkQs20YYN1HvQ0UlchXBlJZAULHg9OarTxpIXCkDDdD1q0STGEjBVwT83YrVGWEK7bmAweg9aWyE4kMsSlQzkE9O9QW0buGGRkDPzVZm3IUXhjgkDHWo2kwMKoDd/erWmxDRVCNI+2UDHXI7U1EQYEru6k8YPSpJoh5pAztIwBUksJQJGg+bqfYVrF9DNojeIQjMQMoIJqlMCVYr98noO1aM7uIdqjcOmQcZqsuI48HDP7elabEPUzpUl3BZiABztqRS3yeacqelI5Znc7QSBxkUmDIg/uCtXsZiyuT8q5C9qjiVmJJbn6U6WYrwoOV4HvTYnLJ8xwc9KuKJCTeI32rgnvUoThcjdkc1BLujUYJJ6/Wnx72Un24qrASsModvGO1LCoHJPPpUK7gTuOAfWn+ZtGAQTSsTc9mCsLdleADeQ429+eM4qSCBojIDwxjBVs4Hc9fX2qzCG2IsjrHF9zeeTx1FV5YZJo8/MxUZPpj3rzIqzuehcUlVTczO7MwJC/rinBEAlkZCJA+5Q5+UD3A+lJNHuZ5EwMjIiU4Ve3WlCYuseYjRmPDqhO0kjpnuRV3YxtncKlyWkwZWX5SoJwccGpzFL8+FaaQ8A527vU8d6aod5IkDBdxG3nHSrFuzrJLCwEUrnLMw3E/7tJL+YUvIzZDKI0FvCkag8SSdS3+FEiypJH5jI8jNy7Dv64FTzI/lviIyKMnzmblfaoZGn3L8o3fewo244/wAKnZstK42CHzHneTlS5O5huLewGapTxLNII8yhFG4DG3H1qbaIY1IMbyuSFJJAHpwKexZomkuIw7sPL8sdvfFEl0GlYqW+wKyqhdnGWGTwfX0qRVdo9yqhYdGkAz9KcpJs3Rg3lr92NQPzOKY45QW+wMBnAUhfz6k0mURtmSN0DbnCsOV4U/l/Oqgg8xXikfc/UsDnJxxgDtVttkcpV3Lh8hgMHFEcJhZ3aMYb5VIYkr1o5hrQrTf6yNY4lQbMkYzkD/Z9aJJN6q77dw42k4/MVYkiKRxOkalFJBfg5/z0p62fmBiShRAH+5gsT7d6XO9kNpETRs4WWVUQOMHPIOPrzUtuF8ySSAo8ZG3DA8j15qeaBwkW6OOR2X7v9f8AJpXiDxrkqhQ/IgGAT+FNXbBPQjijCqm124OTwGz/APWp88oM7BY28xkJ+V9oyelSStGqnzXG4/x4z+lVXQxnzWy4dsjswHr7DimSKh81WMgRJFGfmOTn2pkAjSVWmEeR947mA4/rUxuLRZRHcBRIVxGWkJP54xUxMLLGJmkiRDuVsnn26UOw/kRGdXQtHJ+7LZx/+uomuw9woG4R524OCB9OasxozoxNxgKRtVuOD+FNuLR3l5MaN2AOMkUmmNWHebFI2JEcL/DmMrj8ealE6SqDGudp+VUfIHvg1HHbtIQ8gKsAeCdwz9R2qKKKSVlEB25zuRl7Z7Gndom0WXrWVwSzEgL1ycN/n3qY7syyQqFZhkcbl59BWa7xrOfnf7vCMdwJp8F0jxjLykrwEJ3Dr2HUClz20J5OqJEzkSXTb5G5GwYJ9cimyK0e1kbjptPQj2Pap5ZIxggKdp4z39fpSRFdpDArk5U5yP8A61F+jC3UVElHyS8rIM7AcHHriqP2eKSZo9nmKikBSOc+1WSD5kn759+fk9x7VGCqlfLVn6EsQQc+g9Kbd0LlIJIerE/vE+UM5ySPSonUTRl9i7wfmBHH5VNKu+eR5GRRnG3GBntxUZkRlbYDsKgdep9KT0CxV+YQmLC7sYOOSR2p4gkKLudPkIwCeRRIdyEAxsThSSMcelKokLFQDljg8dM9D7076CK89pIHEhbajfMuCPX0qvIuWIY4ZuOOh9c1oSxkRhcbsHn8KzpuN27OR0AqWw2KUkHktIN2QpwAe9RNFGOdzFwM+taDxvKADtC7cHPGaqsiiAxvneOcjmjlLvcqErEclfmxjnnn2qm2MkkKd2Rj0rUnkB2gop+XGFPWs102sSwwueeKrYlortEVXdhsE8kc0Bjt3OgOeKteYVQnIxnv0xVeZdjEKwxVXMrEKxn5ixK8Hgf41HwibumRt+tW8xPhYuPLXJB6E1TlVnYEKVUmtU7kWK0yk8ghR93FJAjjJHQ9qllQcsePb39arspG3DHNbRZlJa3EIy7ZyOKhVN7n5tp9qssE2bVJZ/pUTwsshKAHAzj0rSLIIg25xnkDgUMzA5DY9hTYVDyHIIWpI1VsLnnsa0IY1i0pA9KVIzgn0pZEw23PPrSYKDaBk0iT3pin7xWPmSuoZdp6HHSlVWaGTysSRrGPMGABk/zqMXKcO4G7d8jD26insiKuICxGd7Z+93OMV5qkeixsmG2i3QldgDk8An/61NnkjMp8hR9nwMkj9fSpNLUxTLIclXynOeuODQ8cZjZdo8wdADwOec+9F7q5T3sNf5ysjL5qDO0ng4qP7QpiVQMyuSCycfqelWUnVSPPZGAXJyfyHuaqMQqN9lj8sFt2X+Ur7Um7bDUbiTboQFHl5wWKZ79uaidt6KWhkRVPLAjL/Sn7ZJ0t0SNGkPG0nrz3qvcI4IBJX5trnsPbHoKhtlpLqJcqgYuSAF+QBTyn403gAtOCEADCMnlu341YkgNvLIsspmGPkaMcN78+1RTki6ErcKwyFXGFPbJPFVZ7sG7DIopkt3PmAIWyqjg89sUjoEkAhIYMuHAbDj60xDLJK88gKjqEB4b/AOtT7eGWaF5o0YiNh86kA4PXrS9CrdbjpkgjYLDtKsPm2nJJ6YJ/wqC5IeYCONvJT7ysM5NXIbNraNp2XZCGDBScsc9/an6fo9vHbzTT3DpLJ8yqhJJ5oUJS0SDmSRXkglE8axgojLwrHHPsKfDB5uBHA32lThnBJHt14/KrFwpt2j+yRXE1xnGyVipHbIIqxEDNbbJ1lVyTlWO3bz6DknNaxgiHJ2IHdxIPtEqMvIIA6H2xSQWwaAyx4KAYOWAH4GrBslWZg+VwgAjkbHt0FWPsAhiIgd4iu0q5JIA9NvehRu9Qv1KUVt5cQkMTy85Xy0zn2JPp60t1EhYpMI4E43Fg2R7cd60xbqqhoVeWYjJdunTpjqKlitFt7bIISQtyC3U9qfI9g5le5xjQpNuhh2yM3yqWjyV9MVY05pYIooZ5IVMmQruMgc4Oe4NdGtgsczG7CyzMN52LgD6U240dNjeREd2cqd/U9enrS5Laj576XKLFXk2uiytGCvyPjIA68iqYLPMi+VKZDwoDEk/QVujSZDCA213PYqSd3oajn0gxxpNbLNHNuGRCwAx34qZRb6C5kmUIXjQu3myEsRwoGM068tZNh8or5pHzBuWAx2FbqaejQpjYpB5DL830pt9ZSG3ZYgYjjJRlzu+velyOxKaTuc1cIv2YsxwTj51XPPuPWkSGONASGWVhwyfNn61tQaaiyAwoFDICyg8A/XvUyWilijMdwByuBz+Hek1c0ukc/bskuxDKuQMBjyoP0NRiN9zeYSWXqytjb6cH+lbqWpeQgRIkecEqMEemc1lywqt28bo8kxXnaMY9OKh6K5SsypHMGuHToy4zt6D0qxcMWKDGJmID5JH4g/40kEIjkQwuvLYcMvQeuDQ8WXVvmXy84OcgjpSUgaI5QBJslKEkcjPJ9/WmIpd18ohV+783oOlS+Z52xofmRMqQfvKfY96fFE07kKuAQT6Hgfzqt9iWmUOI/N2fxfNtAz83rTQAqM+B8pJyen0qx5SLcO+RsJwrNwSMVHGXab51Qxgn5SPlNF2hcpAjlYlkEYYuOR2//XVadWY+asiBSQAp9avAGOEq6gEnO3+6f8KpqjyNJsVV8vrzxt6d6bJSGXiFNozjHOPQ1QkRhghScnJNa0oPlkyEbuxxjiqdxEy4K7sAZwaT3CL6FMjbCWyPlwvAzgZqGSEITwxz3PIq1Jbjdul3oCM8Dgiowkhjxu3qF79aooz5oGWEKi/JnkYxUMsam3UjCnoa0cebjzOBjIqBo0k4Bw2eR2p3MmZU0YVQipy3VqAdsDKuWbPfsKtXAYkLjAHXHJphI4Y4LYwVPFXFkNFWb5FAO0+nGarj5QQ6hlbvV6dFjRXJI9R3qsykuu3GDwCelbR0M5disEwxKgHPAOKJFAQFmGe4HWp1Zo8FgHiyRt9PeqhAO5xgg+tbR3MmMCIORgY5prgbsqc96HBKjIAPrmkkBQh1OSRzWhm0Rk5fgYFORW3H0pqKSScc9x6UwbmlIAx7etMk9zYKLdVywkIJGT+BBHrVl5AjQGyDCTyx5xc9WHeiNJJL7y2ABcGR9xA38ZwD68ZoggjaMoWB2uCCT/Ac9T9a83luz0romtRvU4Yhe65wc/WoU3xZMRQPICRv6FTTZLgiEgxZJX5hn7rA9qY372S3jQrISvJ9GycL7Ch72KiupPHJAWwVLJECcycA++KiFubzVYIfM2Qy/MWxhVwOuTRLC7WrS3IzcNMFZB1Ixge2M1btpLprmK3mSNQnG0pxjPWqhG71E5JK6Kdu1vBHKqDfNu2qSD8wz1+tWYUlFjK0jJIpIJjzhnB9T7UvmrvdAoWaCQv5jnLP7L6CrckASOFlk/fuPnJ5OCM8djVqHUnnuZEkUoYT7VkiLYVNudoH61JDEzwPjISb5DLINqAUqRSc+WrojSGPzmbryQRjtSvFNb/aLeVS67giYORzzx/gKmKWrG5Eb2kUd5BCQEiiUFsn/WHsamgycLbqSm7IEg59fpjrU9sp8yWW4IWc5iUHkIMdqbL5LyJaFxG8jEjc2MYHTNXy3DmIJJFit0Eu8yycvtI24qypdFtZSCny/KpYkgeuPWmK8+5IktAEJI3h1AA+vrUNrHqSXEpieGJUBG6Qb/MU/wC0On5U1BXHzaGhAh3u7xSwHbyfMyZCfwp6oLaWNVLb5VB2xjcd3ufXFNtHee2UwHbIpyyyDp/unuD61Jc2moS3RY3EiIhBGVz+BxRrsJu+qL8capJJl0WQ/JluTjrj/wCvVa/RoovNhdlkByMgvx9Kmt7NpYsO7uMZIGAM/wA6ntIIY422zsz9f9ZwPxq1G5N7FWOObyy9tEC2BjLYJzyaZHuOBeWax55fZIGY1qm1t4kd/JIkdhuYsRg1ajhhjaVYV+QfM5XkH0yf6U/Z9SLnOwpZvK6R3siFBuKPIEJ/DvWnax2UKqkdzCcfeLyk7T6g1NLpME2LpIF+0J8yv3GO+DVqaOVEjEe4Rchhgfjz70KKT1Q9yg620khX7TEwPRlkwc9qfb2/kkRzbVyM7lPUetTXFrHPO8v2VHRBtAdAdvvxTbe0jgO+JiM9Q2SBjn5QelS4ooWW3LI0aljtBO4gUy3jUw/voyv93JJ/Wrc8nlKk2XeLqcdceuO9JIVlKumXBy2FGAoPrUtWGymbVo42MceATuX0NV1DtFhVZZAckEZ49KuWyMrckMpY7AT93tjFSTvGH3CRgv8AEeuaxsijI8naC8ZUKceYh5HHem3MCXVsVRGWU5I2r37fhVi5gMkSNEowThst1GadzDcuFkAkGMKBwT9am9tBpamLFaSyWrRT4DrwTGACDn9RWbLFJGZYSG4HJPX6CurmVnuiZCPNOOMcH3qjcwMWLRqQ+fmLHKkD2rNxuWpWepz7wOgI2srsvLng5pZopYwhYjOcEgdMdsVbvJHjn8p4sp96Mg46fWq4lDTtEUmV2YZ8wYC4H5VMVYvcinQTwRuAI4z8pbHSqxjIR4yDuXB/HsavsjbVbawhXJLA/wAqh3SF5ZHjLjABcYPy+9DlcSVjLk3I4fBLE9G4GO9JGozI0SDAQ7lPvWjMskiIC2V+8oGM1WaIK7Sqcx5OEyAacboTV0U4vkUxOMuv3cD1p7hCiqScn8wO4qZYeCsbYYLuOT70kwidXYoWfAGMY/SqSvqzNqxTvg2EQvkpwoA7VQNu5YZXaGP3vWtVFUByjcE8Z65ApjoZVlZmbj7me5+lMadkZU8HlHDsHVRxjsaiYKm44XkAg5q9LEXUgId/pnrVZYwkfmHmUjAz/hVEtFG5jGGkUHLDsOlU3ifKtICFPRvWtaRNzKGxkcmq1xEN6yBSVbPy575oIZmu6OHDtllAwp71ArvnYUwvY+lX5Y1VixXceePSqkjSFxgKoxwQK2TuZtaleWJN2Ebg9zVeSIKjMTx2J6Vbmf5v3igAde+aruCVEaA4PUHnitoOxnNFbZGY+SPoKjdEUBQxAxUuBG/JGPSmlgxA4IrZGTRCxVVK5P1FRCUIeck+uKmG3JPVT0FRvggAAACrSM2e63Z8pWYNuZG4Rf4gPun8fWiQP9oZh93aHKYwD9PoaiTCxLJgsNx3ZPU9Gx7Y5pVlZYiZkV0jLcjjGfT8OleZoz0rWJ7iVG8hZyQ065yvLbh7dqSSGK2hG3f5koKwgLzu3d6bLbDyJFlZDN99GJ+8f/1YqWNWluoHjZjcgqF9C2Pm4xx0q7XYKRLDb3DyGKWQsyxFwAOVYDJ5744pbZZtkE/mxiZiUZSOWz0P0zTry88xzLI4nEhIAC7WHGCuO31qOIefaRhl2vECrRyfLtGM5B9K0itdxdCysnkWryhNz+Ydxbgj1FXLVYwzRt5e0IZCvZcj1/rVA2q3Gn28kF1ERI20hnGcn361lwajFp2sJYvGIo8/NJICcOPQ91I7fStLqPxEJXvY2Zxb2bwwOrSCUZlBOQCD1B96lngkht1t35DZYIfm7ZBPvimw3ETWsyIgkEc+4M4wD1rIv7hkW7jRrhcEEuW+VF7cehqdI6FRLkdz5ccjvG6CTGGKfL/kU6Z5XljZI4n8kGPa3Qkjv1rnGl1O6eSRbqSC1gYOGVgevcKadb2E/wBuMst5c3CzKdsv+rTP4flU3sM1Sl3avKYdPh3nIHlTYHqQQamt9YeMrFLA8cmciFTndjviqVs8t3dyBHkt/LyoZSSM45Az3q3YRM2bGZQ1sj5XAw8jcZJbt7VLmkx2uNubm5nRp4UeJokJaInIIB7kdMjtW/YC4eJ2nJG5esXzcfSqyGNI/LZPmQ7NpPI5/i/CrMfmGGWSA/KOsW7BGPSqjLW4muhYDnYwjDcAbucHJ/8ArU8h7d2bY0R4KjaDkCs0ErcF2fZEyj5CefxzVtbghxvRmGAd2Mj/AOvV8wrWRpW9wJUw2/lsMx6ZIp4QJG+AvlsSSR1HYYqpDLNbxGRP3kSkPuDY+bPGf8KlQyzMRukjaQ7iVXj3zmrWqsCJoVuLTeSY/ITqXGcdO9Xz5UuRGDyCGcjIX3x0FZzMLaN4kZmmLDa5xnPoOxp+6RiPKk2tsyVC/wAXqTTbtoDRPLFFB/x6OoaMfMGPD59u/FRRyG4iUTZTusQ4x7k9qJJEKklCXC5EjfMT9B6UkccqIGnAwfuhcHOfp2qJajXmNjZI5VDhgWBChBvB/GlWLiXzJWRguduOSO3NLOfJQkZe46kgAADPao4LqNUDB/3gOW3JgDtyT9azasyulyRxG0MTPJtJJVyi4J9OfyqmGWQOhik3R/3hgEenvVp1aNFckluuHwAeeMCoFmdnaSaTO3jhehqXoylsDlEVpEgkaIdVHJFV3t4rhU2zEEYbcvBX8KsAckHIVv4if1pP3YXMR3cckfyz61nJFx3IULMcyyI7qSCMflUDFov3i7TGMgqckj6VdkOFJjiVmXC7m9fp61A8inOdgBBLHrjtUS2FbUxzMsomWPJKHhiOlMJWSCNGJBzgYOQxFWmtIUt2j2goxHXjHviqJtUtstDLIi5wAGyPrisWupoMVDkhS3l7TuBGRiqcgZSQRtGCCP71aRKgAYJAAU4/z0qjdriLI4Cn8hSemwyjKwkWNl3EoOeKS9bzFBC4YnnavbFOdNnRgytySO1V1lG7LDfGv3uuMZ60kKw+FdsqoSi553E8Ee9PudoLbAvy8DHUntSLtEyIudp/l6ZqaYII9jRbumPXIrZMykjPaKPJi3/eO7PcGmEDCb2Zcty+M1MNmWZ1dTt5+X8sU3zsEKNzITwMfzouSV/KD3Uf2fcZBkk54zTJYVmlYuqoW+72GferjI5BIXC7sBQcEfSofLEiAzI249Ce3PWncCrPCyxkFR7FTjmqMrvHGwMYY464rVlVlxHJjK85J4xUNwpTnKuD0zQnqQzCTBX9583+NVrq2jRF3qWyMlQelacihgrbQDnge9VbnI+fZlj7cVrFroS0ZRCjKkExkcdzUKqiy+WWxnp9atNEXYDAVupJ6USmMo4aIMy8Aj1raBlPaxnTIkb4kG4gcH1qAOC3yJgnjPar06KQMj5CMD61X2lT5R+UE9a1izMqNHsDE9ScYpjALwwHSrLxgM+ST7iqrhd55J9B61qmYyR7lZhWaRSd8UZKuWGCVPAIHfBNKq4sbPzEaZXkMDMDksB/CfQ+lRgkXqqVxLJhY5AMcjoaAYo9wmkdH3HzUU9/7w9/pXCmloeluhiXTxXFxGFSV2UxrvGSMdOvTpStMJoUuEWUTHlJFPceuOBzxVOd4TaQuSZDI5XzlXPHb8BUcWrtb6YllEhd/M2g4xjvwPbrSjaMrSHZtXiSWst1K0gnAtpJHxjHzB+xBNJea27GJ760d2iYIzqAuR05Q9eKtu5lZWmZXJTc47jtuHqOc0y6eIwxRRG3+0SJ99eMj/IzzVJv4ULrctz3EdvbrOsKQqwykTxhiUPdcHrRNYwfaLZpkMe5AVDNuTjvnrk1HYW32RRJfxpOYk27y/XI4Yf/AFuKr3ty8QeMq0kKoGLbASvY49eO9U5X0FGPckutTudOun05JDdPKnmQbcYVCfmye2DV23VJIFlaaOUIPmidCPfHofqawrKCTfLJZQSRrja7S8kDjBU9c+9XbK5klt2TyYhKHID+Z6+x/nWcptO5SStY1ZLdGvT5XlrG6b8EfL9P0qsHuZ4/IG4AH78fG0H2PP41aujLNDCZonVPuM6MMFu/HaoLu5bzv9cJVKgYVOc+n4VMmt2Uo3JFla0kjhjSMIpABx19zUsrzx/w+YCeCE4Hvnqaz5JNyeaEBZMblGOtWpFkjZS0kcRKn92rEjp0I7ZzWal0Zpy9izA9tL5iGFXlP8RJAyKkZMXKmPY5Cbg6Pg+496oCYywfPHGqqwOFO0cdakby4pPO5Q9V2sDkent1ojK6Jsy/NcSPkPsG5cqCMlsDrz0qVZXKLIGcAMNpIPp3qrLOY5A9u5XYmBzuwmOTzTovMkR9svyuwYM4yMkeoNdUNTJmlbyokwgMnDqWzgAbj057VJPJMRJtzLPGo3qCNvfFZpEjxx7tkQLbiq8/zFSJIhdyIipzklASx7DHrVpXJLttOZpR5ke6UqCSGxsHtnpVs+dFamKZdhBBJOcsMYGDWa5EM4iClGyEyvJH1HrV2Et9oeIyEgqAzlTIc/0xVKLejH5lgy/ZpCLiTynVNykAZP1HrStKdiTTvvMijy3f7wz3wPpVe6jigikga4HnSEZIIchRx8xIzye1NjhktrbDo/7pgPNLYyDyAAPWjls7CTui1czPtkDzK0TA7WZdmfr/AIVWs3+0Q4kLGXAHyj5QP730pQZJNkrAklvlDNu2nHXB6mo5ZNyxeYweQHKhBnavUkjFJpJ3KTurDJ5ysqmUbcqTHKzFtwH8qHUPbq7NsAUMqxnHze/rSXU0bNAYYwBzkD7x/wA9ajaTyVJdAVZsDGOD07d6yk1e7NFqSS3CxsFLCR9wVjj6dqfNMDJHJG0eASGAXAX3IqBom2hyGDnG4H7wpmoKuQAE2EfMf7vH86ybuUok7zJMBGHGA2WwPahjG6llOSFy3oB2qnGI8tHuIfAwR0NMBW2TaQf3hJJB5P19qhxKtqTq5kcM6YXbtGf0qPcTMQo34HGf51C1y64V0Al3cD2I4qGC4kSRQy5ccgZwMZrPToMS9LKH+Ybw2Bz/AF/GqvyMItzEAnbjtTryVpZI5D9OmB14qB2ZWjLcRryMd/eo6jIRHtKAKBnnGc5FRvh4dsrZPXH41PuMjmVEfanIJzwKhcqq+Ywy5xuUDiqtqIfHIsLAyAnIBGDyppg2Es5yTwox6+tP8obCWc7cZUAZyaeXK25OwGQgYJHINUkRLYhuAmwSqPnOMAH8KqygFUKKUKnBK88+9XXjJyMYCDJJ4NIhYI5LBC/PI/pS3dxR2ICyvKWCbnHZetNR8SSM0YYEY2ntUsu6MY3fNjG8DjOetVrmSUhcnJHGQPvU1oiCJoszO0Z+Xp81Rz28ixsQuOhI9PpVry1GTJkEHIA5pJEWQOZXIx0pJsTMO4Q4Zc7lxwccmq42j7xByOfatVoxEpG3fu7Z5WqMkKvGSFweg461pFsVkZ00Ry0iDd2K9sVSlt22qxyB/d9q1Xcp8oQhQOR61Dl2cltowOnXgdK2RElqZc0MkgZ3C47AGqA3hdzKGY9zWjcL5hfgq3cVnyKCFBY5HqK2i7mElqMCuY26BDVUgfMVQcVbe3cYDt8h55qJ8PKDjYmOK2RlJdT2W5kAlMcqvjG7zBzgY4PuCKoJlZ5Vkb5XPEgOQx6CraII5Zkhll+TPl7TzGvY+4pfL2SkKFXcoIaJso7euOx9q4Vqz0OXQo6W8lpA1sZBCrrwqLkEDnGO2SKrrFHdawLplNvMka7flzu7Hd6VqSqipujP2hE+VkAxgeoPsc0QyRu5k3M7coApwecdMfyqrrZsWtrom+zLJK0k7SMIwdgjGEOfUDoDVDabCWT7O0K+byI5lBI7cVZM0cU5MMsivtG5SdpJ6E+hpXLpKWjvI3/iAcYxkVDsthp2KcsP7i4gna5EJQvEwTPzDovsKXTbCG0EbbRIJ4/K3lsFueqg9KmkK28EMaGSNi53YyVXJ6+9KI4DFuZ90SjAYAjaezDt+FF0tirkrmcRSABt6HGyRevbGe1U55lik2yQvOTjbgkMo+nb6mphI05V3LbipG/IOfr/AI0xmKSFIWJkU7VYSZ4J9azGlrqToZChYS/uWIMiI2SvbcTihTiIphwWcsu0jsOuarAKPNhntyrgYODzu9fcU0XEb6ekEkBDKMGUdx1ApN3LSsWI7uNEbymZAwBY7QcEnFPllNvMqhgSy5GRnFVVSQqjBo/LB7A9u5qN7g+YgeTcr5+8M7c9TUjujQiAR9xj3Lkrhm4J70RS7JD5qARSDAxyTz3P61ThkNw3kOwdxyABz3H61Pby/vWFvh5EO4EnHQYOfWrjG+pL0LEEyR2zN0k5Vf8AaHUY9q0YWbCv5haENtbKfLnH8u1Z8JSORZLhsE5cfL3xwKs2Vwszxv5oJHzFAnGc8Z9q3jpoZSVzStLgSTybEQx7QQSMsD2x60y2i3Xe1xIEkGWk24APoKjSVvvBApOSOMA47E+1TrOnmxyTqDt5PlZA/A1onoTaw6OFJLdnVh5gfo7EE+mK0LG3Nw8kyzQoq/OIh3PORn8KpP8Av42mVGCYPV8/mPqetOtpSyxxO8JCx4CMMhfb3NauVhJN3L8FusoEjiJIC2d0bbyD7j1qqswlvCWIxjLNkkgenpn2p915s9mI3khS3iI2x4wx9CMe46Uy0lxGIBI8aN8rblxj6f40m7jirE0c2wzteo6xyghQMZA659ulRojzh5xhYmPCZ2tgDv6VVmgOEgSU+Zv3HzOo9v06VbaQYAYeaD96RuMH/d9KzbbL2WgW+9d8hIGcBQB/L396guP9SR8+9HBCOc/iaJvOVCm1XKjIZBk4GOlQAyMsowERDuyM5f296znZoqG5I86qHdmDMuecnBPNV3KxPnDSvJhi2MqvHTNIswkMZA3MGLGJefzFNEzkh5WCHbyOuemOPxrFmq0HmQs5WNnU+XyfX2qoWZdyjO9D/DyBj1NTzurSOqMAM7go4z9T26dKZvSOPIXYzDOO3/66h6sY6aNIHU5ypXIABGSenXnimmELkF1MjDkdfwqFp5ZCMYeUEN85+8Pel+0Et5OMT4L5xzj1IqfQBwTzomBDBV6ADnGagmJ2nADIMBcD0/lUpkdCSgJPO4npj0x3qBmZcR5bzDjgjOf/AK1TcYyU7gOdu4dAfy/Gq3kuknlNLu3Doe5HP6Vb+cysTtBHHPamzlWlQgBQvy7umMD/APVVJiI1jYSKoUg7OSvcd6lfyysahSpyee+fekDPJIju2wngH274qZ8MOgJZcj69c0+hErFQxuYJGBzubnP6U6Vd8gz1UYII74qYR7oGYP8AePQj+dGGQFky2wAkkc0CK75CEswIYYKjnBqKUMVEe4KpJbHpU4y8pzgFhnOMCmgBxh1UsDjj0oZLsV2aM5VM5Iz04qFsmIh1AH3SD/Op1/1ygo2wE4JphB8yQIoKtz+FCJZVdS5UKQBnHJ6iq7EKpBbr07irLlkdW+Uqf4e9Q3UySbgUIUcADtWiaRLWplXauF+VNyZ6461B5qd1AJ4LelWWcgYmDADpjvUEqsJBiP3B/wAauOrBoz7ofvc/w/3h3rOkZGdyU4xge1bU+fLVY1+Zh83FZlxEQDsQBj6962g9TGSKO3IwWPHAzUVxhQq4zgYNWLiNlC7yNw4IFQtgZjxyRXSmYNdz22OFxJFLgIkikK2McDsfyqvt2XBS42mMjcCDySB3PSn2gZIdiyMcE5VjuUemf8aeZmlwJljk3YIDA+mNuK4t0dmtyk0cg2TbwFH8UQ5I69KjdJvlmlBJfLRzRDBH4VbZVZENt5aESFQm/k/T/wCvSvcPHIULxkOMYwd0ePQjpUSir6lXKttbTXLs6yq9xB8zb2GQPcGm3rhlyTAzb8thANvbnHBzSXR+ZDLGkpYZV1IBx9R1/Gqr5Ksrbc54yvJ69xSTsrDsSebELoKksqxEndsTG09uCelQwXMsSzCOWRcsNylRjHrgUisQiJcJHjGMFArVXTDSEW65Vyc7jtIxRdl2uyeSRt+7dHtRgRj5c01pVfewdFDdEC4x9DUDbtiytHksM5Jzt+tQecpYhyQhIZlPXI9KizvqVoXLmR/MQSksygqH39B2FTpKZllhichBIp2uMknuRis2BUa5dS7RqWLDcucH3qVG2BmIfKnnYemaFe4NaF+SaUW5jMu6LgDcvIHpmq3mOCVJURyZ4A/kabFPuIUttRT68j3pomQq7SOEOwsBtzk5wB+tJ3ewRRYuHMf7xuuQSVPqKt2CjEsnyoAu/B6nnFZJUuqbwOcAbR94H+tSRTOqMCQxJ++wyV9R70+bUbjdGmyyKfOuAd2TvI7LjjHrUlldC3YiWJpkmXJ2/Lz2ANZ0krPbm2SWRlYkouewH6c1JDI8vlgkfJwoyxAAHSrU0ncThodDEQNqhseWSNw5LZHQD+tIpURyxwFclsBS+SgX+Ik9if5VlWsu2LfGZmfPJHB9sVeihkcxsFzu4YMqkLjsea1Ur7Ecli8xVIQyyp5iZ3ncCSSf4QDU8EUa8LJKfm3BtvY9T6+tWbb7LCnyoN4IJIjVVA4ONx/pUqrNcPlZLWyTBfakhJfHoM9fat1a1zFuxFbGBZwLIMZNx/eOjBifUYz/AD71HI1x55LzK7btrfN93jjk1pWyzLsh82F0k6bcIVPuTWZqUbm4eGcbjGQjbP8AVqBz1XvVSgSpXkNaO4S7jEEsm2IjLFsjfnr+Iqe4uCSoaTyUyd+SCCc88jrg1VlkgAmWGaSNVALswz046nv+FEgeNVKMmDht6qRx3GD+tYWttoarXUsqA0jRWTKwONsnJLE9QPpVS4l8qNlUk3DMMZ6cdz79sVF5j4jEUZdQSRxs259/61DcvKzyIu0SbjkKe49KTsaRXUm4t7qWOPDsQN3OQe55qGFlBy4bBbaPpSgEptjZQC4GcYZgQMj2qHzo4nUJgqjH93nLOfSsZMpFi6EMpzEzM2R143DHrVS4uFACsQXbncBkKCeRTnlI2lm5IADA/cx2qtdzMFWR8bn/AIT2HYkVEi0WYhGFkZdoL8ZPJC/TtzTCH3F2Z87gGCjt71CjKkGSi/O20vnnp0PtStIphcEsCv3sH7xz0FStAuTzSPPPvby4lUBFUfwgdsdzSOjC7k2gngYYnAB9ajjBkcgq5dRkBc8YqZ8SIZQw3t1GevoB6fWjluwEh2sh8x8Z4PHXmq5kEbkEbgG6DnA9acYgGchD5YfpnpT0QggdeRk+n+NS9dBDoogUIXh2GMkZwSacGCQkudpHAAHTtinI7qMx/eBxyKdGpd0kcksMs5I9O36VUSZK46beV3omeu1geOOtRnHmAKm4Njd2pDysW1skk4GOMmnBMxyGVgGHT3p2uxWsRlP3hVlKxjkDOc5FRD5VJUlVHGD/AEqwyjyn/ebm7ZGTmoCgkZQ2Q3Rm7UpC5SCUxgHYWORzxjmmcOoAHJ6kdxU7I6qVZRgn5uc8UxNoiAV8En5eOQaSuS0Z9xEhXGCGXnrVRS0YKsoLD0rRu1LSMFUBF5I/wqlOGAbcq46A96qIMoyLI4MYA29dpplxFhskbSV4Gakn8wsC52n1HehZNi4kUDtlvStYsTM9lwpEn+sPUZ6Cs+VB8+0sBn0rSlfex7553Y6VWukVl+R2JHJrSLMmZrW/+jtPiRwrbS2DjPYZ9aS/gWAoqrMk4T98ky7Sr5PAHXGMda6WP7Pf6HZWa6jDZtbO7PHOCElJPDZA6jkc1l+Krhbu4tUS4N09tbiGS4YEGVsk5GeSBnGT6V0wdzCep6VGoEk8f7iEtkZBPTGOD0pBHLb5GAXUYOBuB981OIoGeTYEkJGVUKTj1J54qQWnnxxOAEUDLbFJIGO4rBU3ayOhyKEw2sBcoEBI3Oo3YPqcGm35tURXt5rgS5/1jqMMPXHX2q19l3xOsMaeYBtVhw2Tzk+1NEPnRlAtpbvGBlt2DzUuLehUWrXMsqbqPL4cq3RVCdT29vaob5cyIs8ax84CkbTt9Mjpz61au4xGFJ2GTJDMXyGP9arTuEwdjKOmGxhvTrzUcllqUpFVj5AKzZ4JG2T5gPy9u9VN8rSvGfkGQ3Kcn6ev0p0oJ+WMMrvwRn5StJdmTbD5pLiP5gwbOB25FLlLT6lWeQsFhDkIWY9CBmkVSyHe+HUYZWHzAevvU1zbzQGMyOhQj5H3Z21SmlZGVowxbBJx39cVD03HvsWAQCdpbIba2G59j9KIpPlLNk8E8HHPHaqf2gSnfIQsm9cFRjAweKninBMabVYIQN2OwHOfxpeY2yVLlyDgo2fl2sBk5HY0+Q/vGUndGBknvj0H40wsrKky/fD9MfrUjxkE7znA5Oe9S5MpEtvJ5YLwn54/u7unPfFWPIzb7nBVQegPB/8A11RjUeYS+5gSCef5VfeV3UBFJHY+n1qXIetxbePezSzYI4XAPU/X6VYJKBtyAZOEA4P1PrS20A37RhsgsFbp/nirtpatPcImW8yQ8bjtAAHcnpTjdibSGt58P7vOJGI3KpGOnHI71eiiVY1DXA3HnCruw/pz396jso4/tcfnhDHzujB5/P171piGJbiJwnlWgyg8pcsT6jPOfeuiMX30MpT1NaG1S1Ns7Ws04EZkkaVlYKPUAe/Smxw2LRQrtjuHlnaQpcoYyD0zuB6e3amQvGuZJhczOFwikFTtzkH1IpouHe8dhbK23GZW45I7j+ddfurU53GRFqBVnbYsNvGh8vNrKWBbrk7u1QXCRK0Y88L5m1zLG427TnOQvGRVl71o7WV7a10wu6Y2mQMy5HJA9azniEduTbtKXyGkUjCjnAx61DklqjRRsVwFMiIXjlMfDlWIZwTjj14oCSxCaIMfnbapZtxwOnB7YNXZZmsv30csRJ2sJAvz8Dp1+tVry/VNk1oM+a29t2CB2Hbj8PWspJat7mqbexG32iCORS+IVPVeGX6e1RRTqszSyBw4GAyrzk9T+NSNcv5ZL24TcplDsT83OD68ZqhNemeNxGoJOWIyMnpnB7VzybWzLinbUsLt+ysbtmBZiRsPX0PFNtyEBcuN3IVwcHOOn4iqUciCMJmQAEBgCDt9P/11K2EucTOERufnX8iBS5myupaX5bcS4DHd8yDrVQurRSHO6ZeoPIx6YoknV2LKw27dxC9T9RUSKGl809yc7T29qXNYEhYHMiBWO1TjAOMsM9anRlVAIufmKn6etRPMYoSqKvly8Ekfz/8ArUqMqQKYcBsn5ieo/wAipbAt286x5cFt5IG7pu/wpgIK8Y552gcioXnillWRIwFxtPu3qaYSS4GQB2J/wobYWNENs4GDtHzjuT6+lImwJGi5z1JXnBNVxI4RkULzxkdAT2qysAjxIMLhsFT/AJ5p2EOnP7qONVHDE+YAQcDpmpDn51iDBDj+LP1qvMiLNG0cqMeQ8ZyMCkXJkVQSGU/NkcUNsQsbNM4O8hUJ+WnKw+XdGTyRt9RTofLkZjlQ2eM9D9alcEgHCliSVPuKF3EyKZVjKFGwxPKkY60yaMeQjs/OTn8Km+eTLYG7PRuuKhcO8BKlSSTkf1HtQ+4iKQnaTHjPTIPUVFhXd88ED6c+1PkVwuCpAyfxP+FMl3qVV/u+x6c/ypktEbmQwxgMu8nDY71V1BCys652g5CmrLhRnzZB82cbRVV5Bt2syk5xj2pp30DlZVlVSqkn514FVZmDoA7EnPFXrteCseSccGqWwKNrjzCnJNUiSo5GSoXaccnNQy+WFGTgCrE8QUr5u4A88c1BuRJY2EYdQdzI44Yeh9q2iQze04Xw8PWR0O4s7Vi7mfe8Ydzng/N2xxiuY8VPfNeRnVpop5/L+R4mVhjJ4+XjrmtObXLNCyf2DpZzxkI2P51jarcpezj7PZW9mAmNsAIDe/Pet4WMZRPUkTZFbMQxkkXax3epwAcdqVYpIFARXz0zvOG9wfX2NRyJFFDOQpmVQMkg/LV24u5GtxNB+8fooH3RxURXc0lvoRRbSX83YTk5cZJ/Gqsvkx7IWEZLD/WMp478irHkkgkCKOXHzbeMGmmKNZUAJGScsOc/iat3sCepSDuipJuLSK21Q2ApHtVOe02zEurbjncQQo/+vWiys0JjURguSQwUHp6f4VWdHaLamTjs/UfT2rJq6KvZ3M6TzlAgiVQgAOR3Ocdz/Kqhj3scOJRt+793HbFaEytGoAO/jO0/0rPu5ikuXTbjqy/L2qGralpXKZyrPGykAj5l+8Rj0NVjuDBQ5Zd/cf0pLkyRz47uM7iM59800zM427DHgNxj7xHSsXqapWIEQlXRvkJcE8fdz/nrT4p2lj2EY2k42+/Wq888izDawLEZx13e1MV+QFdmZT90jBHsaTVtA3ZZtpHFxJjdgLtAPQ1pRchUU53DJHpWSqKoDlyCMAqe5q3aSF3Ac4j9utJR7lGg7BIY8uFI6ZHTmrKS+ZbvsXKtwM1SSJQQoXc3XJ9PYVr2gTeBL/qwBnZz/wDqpuIc1tSayQGNfN25X76qOevHNXRlz5ZDqWIPOOo7Z7cUkVsfLQlVKk5BA4yOeT/SthIftGEUIpwuGwWzxzmrhB7GcppaoS1tkEgIZFZm+5CNzYJwSPf61p2VpuvnhzdCSclYlJCkIOnXjJqtE8loZU0yVShcSNJjaGwONvfHJq3FbSMpyjrGEOxtoJb1J5456n0rsgk+mxi3pqywtqFZxeXvkyphNpGVY55xjoOOTVnTLJJbidJmt9jpnZHGzE8/Tg+9PsrEwrDdgi1WKNioX5iQeDz+OBVmayQI4vsW8D5JZ5wXC9TtH5Gt1HyMObpczls7Tz0kt0eO4lJ2rAgfKkD5STjkVWvLaye5eCBZ/tC5d2cBHQg4G3HDH9Oanu9ZtTE9rJdLGduy3Kx84J5yR0OAPrWPqV1CrutnJcv5ilGcjAY46HPp7VnNxSNIKTGamZbBl+05lnIZnL4wV9F9D71nGOBJlyhiRDiKNuQeByT3FWGvo/K8oBeV2uMF2YZ7+npVa5vlUH5080HKgJ95SOo9h0wK55STehvFStZjUjWFZQQ8khQiNVbp3z6YrOmtPMkLCNo2KjKgcqPf1q01yZo8QQPiPlmUEZf+79KhivZ3nYZaCFTkEnjn1NZSktrGiTHRJHGCY0DSSAhhjkg+g7UlyWkktUnYhI1CKjnkcdzUHnTgPcvHlGJVWXg59feoXnuJIJArRhGKgLtAbPQYx2pbdBWFjOJSGA35Jbb90CpJVRYIXjVwrZ3Pu6+2PT3qs+5C6TuQsfBKevp71EFdwgb7jfMu4Ywo7Vk1fYtFkSK8ZbaMZP8ALtTo5FimQxurkDg4z1qvJJFEsSK7KZmYquPu88f/AF6lRii/MgDN8ygDp1qdnYdyW2CEPtOVBOR7mnZZlAyGfpyP5GoxsWMc7X28gf560xSxQBpSFC7cjjPtim1oBaWUqijbnblgP5HNWF3Pn73Tc/PeqdnuRhISBj5eR2x0+tXw2/BXOWAJLD8KcdRMfCv70FiSxB9O3pU0KDesm8g453f3sVGgDy4VWkGMFl4zT9rb1j2MQ7YwWHT0qkiW9CSJNse7JbB29M596lZliaNXViASRgdc+9RH5ZCEQrj5Tg5HFOmmaVlEhBRWyFVuM464pOyRK1InfM58lTtb+Hdkj8e1MP3vlzgHGN3IqYBkRTsHlscAk/5NRzwYBdZNuVwVU5zS1sUiKWPqzEvzkgelVQoZHK4wCePrV6OFkhIwSyAcg52+tQyBI5GUkSE8blHSqWwmVdqSCRQCGWq00IimIXG4tnPXipFRUnZPMyvQk8YHWklVUjeQOVfI29xjvS3QFWT5pASgzjHB6npVd1+UrgcH72auksMELuY8c9aqD5pMSKFQclR2pojYqurlXUc+9U5wu1SmQcfMDWjNzvIIXnjHcVUnbb1wSBjkdK2i7IhooC3aVl8qF5C52DaCct6fWjUo4LWJYTaXVteIo8zzWHJ9lxkD8a6rSr+GDSYmj89rixSZhFFEWUyPwJCw6YGetYfieWKWW0iSSWd4IBE00oIZzknODz34zW0djJ72PUtOtgbmZolZzLwBtyD3HBprQu8nlSxCKPJO3jbn6dqmgjV7giKRSiktnJByOePrUN+qh28t2dZBhw4zj6Gui1kRzXZBbyPcNIhtwxLEKdwAAHrxzUcLGUMUMbsn984xjuB0qSNmhhP7v90pLYY/M2RUC26IpmkDAN0ROmPep10NEyKeMy7AwZmALAK2Mex4qLyNz5mbJwP3Yf5j9K0GDPMUYAKRwqntjpioTAu0rGpZ+m7vz2NRa47mH9mkdpIvL2L1OfvY9c1iXUGycxzfLGcjcTkY/wAa6ycBin7s+Wvysokxk9+ax9RhdYXmVEaI/KQOTj19j71nKCKjKxzcqIIfKB+YdA/U+n4+9ZkshQFnLFguc55xVi9kEz7NxBHOW4I9AfWsy9Y7yTJu3KCOe/cVzySub3srlgMGUYHIHyn+6agaUrK+z5nY/fA596jG5k8scAfMMcjkVZsxIYgfLA5x16cHP9KErkc1tSW2d2DovzE87ye3sK0IQY41L/KrfxEdai0+3Ecwy4H7rJyM5b0qyJPNiWF1ACgsCevBqeXqVzdi+gVvIdSgIXBHoTnmtGyVElDffVRnB4yaxIGAjRj16sAeo7flWxHuZGj2jAYMuTyOPWjqhmvAz7ZCm5okG4r6GtO1mXG2KQhHILqrfMV5/wDr5+tYMLykCNELSSMQeT8ox1961tIuThAg3ysnl4bpjOTk9ugrWmlsRNaXNGe8Uq0cECxQQjETL8xz/vd60bGe6iVI4oXgIyBDIm4yHB5C+9UEkZFZnjDWyMf3nXlueKtrLJcyBmd2uiAUm3kkL1z+I44rphdPRmMtVaxYnupBOu+Z1hm+VgI8D3x689qdcWhim+aQCykBAcwj5z3xnoeK1IoJ51jtnto1ZYCYw0nG1u49Dk1kbUa2+ytKYhbMTJlSQz+g55rWUTJO+xVvrWBPMCCK4W2I2TpgEE/wnvx3qC8S0tljheSSeAoWtwxAIlJ5LY6VJqccS3ZtIAXWRhtYkDPHXAqL7NGlm3nIsjknLsT1BwP5dKzkrt2RteyWpBb3SRzOLZR9ojADM4HOfvA4HIxxWJc2ylnlhDySLIWIU4jiUnoO9aCyW73INjcBHYEM4U4XPYD0qK3hQTSxwOAmQhLHPmn/AB4NZWc9y1LlvYY2pOjqXjVGAVMnO1QB1IHU+9UpZikii4DMjOfnBzwR1x6VLqMUjXMcSsYI9oyrngAdz+dUY2njYQRS7SxJLNgjjriplpuPzH3ErlHtw4eINlyv3fr+AqtC0ZjklKscbmTHykseh+mBRPG88XlhcBACADjLZ5BPrS+XuQS24MbBQrburH0X6+napWruCdlYhlSUlcghyuWyATg9Mdu9IXRm/dncFxljxkjp/WpJXTzWUNuZ8GRz0Ueg/wAKz3uVbMabGmRucdz6D2FTy3LjLQuIrKyMV3PuYrzzg/0qVZY23AksMEhvVj2+lZovCDOozK3H+r6e4HrWlawskZluGiyxGI8/NjHoOgqXSbK5tNSNpRtUAbsjlicY7ZqyreXu2hgkeGBI69uKkS1MNwJok8zyVEiE/MFHH3qFjZz5jzAgH5WbgKO2frScLaFJpkttvkJypwefmYYUnpVx7eX7PIwKhYW7dwTVVDtQMo+Vx93JwwHOc9+alW6eTmXG3GGQHHbqaSSQnfoXbcNJFGyhgAeT2z0xROMvygK427gMfhUMEsiyR7cqpXhWPcd6dNKstxtAK5GTuPBP1otoQ9yy0cxXKxgkkEDPP5VWTPmF0IyCQyAcinpK4YYXPIOR0HaoJPMSQMAB7g9Peob6hFdB7gGVmQKq4yR6etDSiRMHbkcccUkjFgSyxkngY6Vn291IZnSVM7DgVKdjRI2JcbcAncQDgfxVSlVi78cZOe1OWUxuGiwMJtBbvQ7K8W4kgLxn1NVclqzKcyHczfLxjkc8VBMplKc5JGAe2OlW5EQERjIVuQx71UlOxjGRg7sZHQjtTiDGsVSRjIN2OBg8VFKA3GwIe4xSORGzRlB8x69cGkuOmxn2jORnrTRm9WVnO1ASef7o7VXk385G/HJPWrL7EJVWyCufaqUgLMUR8Z9DWy2EdHoUyTaalrb3MNvtinWeKSQJ5jsPkbnqO3tWF4qaN5bKMXCXE0FusU0yHcGYE9++BgZrZtY2TQbU2el2t9NvdZWa3ErIQeFI69Oc07XreCTTLsTada2rwWqSs0KBTFMWx5ZI65HOO1bROfZ3O2tLcpGZopXkZsbYwQO/fvUzo80rWi4VsliAAN3Hc/4VPbaoPOd3Y3RbgOpxj1JHFSXkswhZ3uLcu38RUMwHautJdzG77GHcXLghnXZgnBRS2P6VCs0bW42lZWVst5hIBX+lXJr+SbMVzcxSSnChkAJA7dB/Wqd8vlvMkaiUhclWBzz1zis53XvdDePYr397G9xHMZCkI/hB3Z9vpRbXkex5UD5/gO3A+hHrWZKd6eUSI8jjzOg4rJimPmLBI7LzkY4Wub2zizdUro6X/XRmTiHJXJQ4Y885FVtYiURhILhXDIW2vwuOhHsadpzQKUW4kBBwRt6n9ak8TXJjt5ZgUQx4jRUIO7P9K3jaUW2YSk1KyPNdYUI2PlAI6entWK3zbRtOR37VvajaSyzFyvyknAHQE9qYmlyvGoB2jB5bgZ715/xPQ6m7KzMq3DgmPPBG4j0xVokBEViQXOXfvjp0/CpPs6R7WYkKDjAXr6c/WnHaVI+XKqRgdueK1V0tTHctpgT3LfN8gHJHI6Z/KntMryMYFJ+RRuPY96zw+IjskPnv8rE9GTHr61IJnAZgCVk4bHTpiiTLhvqaIY7rhwMBSFPOcAf/AKjWnp9xsTdks0qkEAcKe1YUM6R6e2T+8Z8sR0wB0+taVthLfeSdyqCwB6AH/A1C8im7nSW674No3GboDn5gD0xVuwTZIdw24QgYPXHOT7Vk6XcGS73wkiRuE55GeB+lbVkyxyFQokbIjXdz0zmrhHUhvoalqzRWYjZVaJXAeIn5vmHHTt1NacIiSWCQlWYMoUIR845/I1hQjzIAJED3FzNuWVTgKgGMVbhmgkupZX3PaWmY0jTgFz3/ADrqja5jLU3NR1CS4aeWF7klEKphxkEHnpWbNJFvtzDlUTDESkfMx/vVJHYXLsrTl7eV48x+Wu5Rz3A9feoL9bkThriSMmEKojdclmPB4A61vyS3kZqUVsFxOMzSzrFtdMEqnAI6bcfzqhau1+MzuQEAdUc4B9+O5q+9vKyeSXCXAO2JQcbVb69/aqsCrGJrWJgk3+rix/H6nntUOOqK51YqRTLMfLgheDc21ZexXuPc84px3qsSI0ahCY04wx93HQY6ZqbUdQSO2MVsoEYIiQ7ckAdT9ayb/UEAaGzIjjdQsmMfPjOBz+JNZycYrcIuUi3LaN5Mc0csk81xMRGu0gEgdQT2FZM7hJysgR5kb96y9B2/Ss661yG3hcTyFCF8tAH4QemffvXEat42jQzQ2RaXcCvHT8+9Q7y2Q+ZQ+JnaX97Y2oQCWUwscuSeSe5/lXMa34wRW2wkDauyMD+Htn8a4zWdWkuAjQXDPF8u/ghhkZI9ODmqNrMbLUIphF5sRztM643ZGCD271SoW3IeIWyR2nm6tLbLIiFIy3Zsn1zxV2z0vVZUim+yS4bLDdwGxVfTpLvT4FnhXzLVRueMEh4v93PBHtXT2N1cTQGfSdskbjcySLuj9yD2/CotC2xtFzi9w01LyF45ZIYV2/cRiMH361pqR9rlFzMFDqAXQc8jlR/KoYbaeUL9qVI2J3bYuBk+9altYLC5CwohHQMM89s561LqxWhtZvVkceyDekcEhgBGDJ9fQdqbJH5gBdAhJx22genrWvbRPKY3ly3sVGAfTFTOPlVGIxvyBtx+WKyk7oadmZE0DGIBpclDyoPCr/WkiRYYSiryDkEN94ZrRnjQ71CMGAwNwAI9fwquYkkhQlcRKTkAc5/wNZF3IFm+UurDPTBNKJ2fiV9ygdD2NPngjcKFiBwRyB269ahCAtsAEY5z3zU3d7DsWEkIjVRICo/vZ4pShCF+MnIIqCXcobzFLFfUdaWF1JCscDPQHpUvsFhwbzrdgRhl5G760hQFnARVJGRtORTZl2YKMc5x9Kg3HnBOQc7ieufakMeMhcsq5B+Y025lkVmBXaOoA7k0pKrzkNxn3pgzuLyKSCMZY9qYmIGDJE6r5hx0JqCRmkxvBbHQ+3pUiHOSOgPGaY8RUkuxCgj7vQ1SQmQht2AzAFjz7VHcKP3mecdT7U/MRjdyrBiMAjnmlDRncHb5sc+9aJGZRnEYUBcMexNVmVShP3SePWrUigEvtJTOBxjJqsX80gKoyTyM4rQk6HRbWwit7Qvb3E1zdJMwkjmaNQUzheO5xWL4iS3R7OWxgaK3ubcTGN5Cx3ZIJOe/H5Vo2TQWelWs1xdXwMkzOiWxULGynGST/F/SsnxHcx314s8U1zN8oVjcFcj2G3gCtkZLc9MZozO7TxNLJIBgMzLu9cEDvRHdLb20nlhPPJGARlVP481VgeKG3kumJaQybvLkcncCP7vT3qtugRdnlBZZGwxDlilauTWwuXuXrzzrh8u4WRQMtCnBOO3GDVabd9mMTMHlxkliQ2KMQLErSyuzf880c7l9+tRRRssoeWSIRchdwJY/hipleWw4q25TlSSODbIFwAQSQCOn5msmVidpkw2DyAvPNbF7G4lTypI5VxkAcbfbFVLlJju+4PlwFIGR9BXI9TeMlYzom5z5blc4GODUc32m9c5DNkAjc+cClMOZSqBdq8tk8ZqzFNabF8iYLyNzY4Bx3H1oppydm9Am7aomt7WOCFmkXzNv3g4xz0/Gua1fWbaNxECvl44Rm6H2Nanim8nktQkCRblH3t/3vp3ArzGay1CSKZ7iPz9/+rYuRtPsO9dPKr8qdjlu7czRq3OqRyIVMinGQuG6n3qumoKg2OBuPf29KwZdIu7ZQ0yPnqUHHHrUlnpt3IxLQuEOcbm4HvT9lGS3J9o0b0Ll5FXcMHuTj86twXXlErMqurds9DjgjHvXF3MdxaStGs0mQm79ammu54ZdikAom5sDp60LDp7MPbW3OxWYAsnDDGauW8zFy2QQ2EbB5HFcHba+7SKJE9gV6mtq316KMNvLDPJ3Doe9ZuhJapFxxMWjvbVzbXUkkDlU24BxyMjBrRt5Zo2jdMOEcZYn3rj7LxHZGRUWRBkAMp4zWpH4qsYXD+YgdRyp5yP61PI0X7ZPVHdWjvBJcDBeQgtFt4AJ/wD106GeOH5R0O1yv+0DnpXHf8Jdp1rGUnuvLV8HCn7w9ahl8b6eik+aXOwtz97g4rZKa1sYuqm7XPSv7dma1KTPIscp+8oyRnnAptzrS+RboHhiiRg25lJavJW8dxiF7xYHeGNxGR1BJBI/Ck1vUfElpYS37aatvAsaTbpDkFW5XGD6HNaxVaa2MZ1KMN2eh3+rRfaC1vcyTHcTuK7cnH8qyL7xLZWMxSWVIyoz+8bkn0H+FeYvruqXumIztIHkRpVMLAAIhO7PcEYBrjLm4neZ/PkaRt2SWOaboT3myPrMfsnruqeM0FqXjLvsHzFeAFzgfqetcl/wl93qEjJCkUQB3EsT6HAH4/zpdX8L3KeGdJ8QWjrPZ3sTRT7T/qnHVcduQT+FN8BeHTqPiGCwcxv9rifbKhyYyBkN/KtPYJPYTxEpPR2MnxAlzLBY3SGR4LqLd8zhvnGdw4/QHmsFiuFIJLEfNkdDntXf6l4W1m1v9Z01wiyQMbpYnH3mTBOz0JVt2O4rkJIopJ551yuV82LcMByPvD+dXy8q1MG3J6HReHo7f+xZYJXIF2EMfyZw4fkfpmuon0EaxosUBVtwQhJCOjDjJ9BXN+CbyNrh4UQPDbkzRJIefm4x/wDq9a9a0m1aKxZJW2/IPMAPOTzt9e9cNRtSPSopSicd8P8AT3ltri2vgxubWUxZbPA7H3HpXZWNhHpmobYvMkt5V3NFkL+8z0x6HrUWlaWsF/56iTzrsMjLtwARjaT6ccZrpYLAtLhlLHbwygKAe5z3rOV27o1WmhFNHC0jvEjl26ouBgeh/wAKalvlS77W4J54x/WrEUUgjMcRkLgElQowB7VNBbuu11Pnxsp3ADCt7cfrUyi27stNW0K0cBSNCpVOM/Kc/jQ6JhsHewbqF24H+NWSyxOw2BBIR8u7p7A025hVmZG3BgclQQxP61LWmhVylIFVFUqyKR13A5qAQMigRg4I4Pb86slUZWAyXHRWGOPam+QiIu9gvpkf1rLVFJlMKwjYFWTnIIPBFNugxwXZZNw5+UZPpg1LJKwLRhSGPQgkio5SgcqSgUfwD1/Gs+a5oiOcuwygKlTn3P8AjUTq5TG0ZHqBz71I6ucEshAOQCOtMlDbTtIKnjAwcjtSAjYkoAwxk5YZxzRcIkUW58KAKbvRWCgZAGee+e1ISpU7seUw6dwaBjSAAVZgwPRhQzM0QD9RwB260KSq7Qg2scA9TTVl27lPVT6daaEyOZ0lBORg8HaOlQx/fLEt0xSne0jPEduD+VMLtk7XDDvgdKqJI1ZGXYv3V5z6GkMjHa+1S2eD7dqcSCn3sHHJ9RSSRkxAI42j+IVoRLQiuJX24f5sD07VWMJk5Vdq8YIp4kMp2tJ0HBNPSYwurBVkQMDsbocdvxrSKRLN7T3nTRLaKwv7KxkV3MySuu5zngnIPbisDxALp7mNry7t7l9nDxMpULk8cAc1oHVrBkJk0SyRupyXOf1rG1G4S+cNbWUVogGDHGSQTzzzW17mSWp2Erx2zttWMOPvR5Oc+nPpV+yJhdbi9WeBSchgMeYfY9KxTNawyMkjpI/VpCjH5vTnpUy3EVwUMkplWMfdchFA9vep59S+VtF4W8Ul1L5UbLIOd+AyH6nqTz0pPLuZIHjEzGFCSjIpGD6Y71DHdTQl1s2WNWAbhyAuPc1SWa7nuwyJJKGOOCTz3IAolNW21BRd9zVMf+jrcSSlySBgR5yfrVKeJ7llzvOGIDFfz5qzCyRHy4xIGU5Ct8y5+nWmSSylUjflcklcbc55JFZyWmgamLdo4Z3ChCjZAx1+tYz5ViV2qW53bQcV0kieYrAAgPn5WPasKe3GNgyAemD0/CoV+hpG3Uih8sRCViseB0C5dvcdhVyx2Sxxtb2cJnkPloki8RD++3qaqyP8zrIMgLjOR/nNRW955bMqqigrs55P1zXVTdmZTjdWLN/p5ubd4lTzJfNZIyABvC8s3vVGK6sks0kSHfco+2KJ+Qq4yT6Ek1PaXvkyhP8AV3Dr5UaspPlburDsKzNRsHGzewMaKUieMYLYY/MRnnvWl7rQx5ejMK4Ciz8+SItPcXIDNgbgqnOB6VR161MEQZm3zzI7y4IADE4wPXFbt3pcsMVyYJor1YmEapjAAbkP9Qa53Uopxd/Z7jzI4wQuQNy5GScGmotGcrWszE0uDzdQRBwqlmyR6DvVy3to5dInleTLbyI0xyxPANTWkJhnmKqcS5jQZyTnrnv/APqrcvWtLPT44iqg8fVdoz+OcVUpapIyjSsnzHH2sJuI5i5YGJAMk+9RsrPdRxOykEhcr3GauabJ5VtcI+FZioyc9M5z+VOi22koMoBuAxkboQBt+Xp65zWnMY8iaSIrkbrglnGIY9wJGNxBxjH1rTudPWfw7d6vJOfta3CfIOBhh2+n9KrBYXt74lM+RAsYz2Ynk/nmuj0u0Evg6QkRu8gyNw2kHO0DJ69Oo96UqjtoVGmrsltfD6atpNrEjMl3DDMMAg7jGd5zjkgox6+lamdS1bRn0jxBqP2WOKDZbvkCOcJ0z7gFTz1FZumSOkKTxN5DxSxo+M5YNGUPzfjj3ql4guZhYW1reeW3lDaXXHzfIQDn1wcf8Bq44jSz3FLDa6GzomjQ6j8FrrUbIsdR0q9Z5lVckwsuG/DB/SvPtEiW6uZbd2x5kT7flySwUkYrY8L63e2mmXukpPLHa3akvGGIDgjByB16CsvQLWWS5M6j92gZSc4ySp4FN1dvIzjQbtbqen/DjUoLHT9V8La1GqyXMPmxbmyoYcqV6jJGOnpXNeG9SNj4y0Zo4vJntpntpYzwNpzjgemTz7CtG7sHHhnTLxFRL2whWcELg8feUn6VW0iG31HxvZXLyO0hhaYqiZJcDC89wRg59qj20paG6oW1Z0Pj97k6m2r28sxQxESmLjceQefXaa4BNKmk0OWOdds1r++jH91SfmB+oGa9lubEXkEiMrxwtjdGw3ncOhwOn9ao6X4fgSZomE6gxoZJNuWJ3k9/UVmm3qzd0kmYfhDwjE2r2uopE9wyoXjjiG1W+YgEnvwa9QitZ0tm/dxW/lktuIG7nqB2qhbEW905tLOVY4UESjeAF5zxz0+taCNcbY3WHc7coTJu/ocVMrGkItDYIkNwXuJd0DHbguBx6j61ZmjjV3S3lZojkKFYiPr7DmoI0kd8+RCZSD1JJzT70TFEhmlj2AABEYoD9aybsrWNUtSRhuRFwgIPLeXgn+tRgM4yjxDGQqM+GwP1pIpLcllCiQsOA7FuB15qOeRFCmFoCGIC4iAIx29cVk2rF+RI20xPmNW5OQqb8e4JqORZCjHGIh13R9/rmktiZA4YQbjkkJwPpxT2DKY2nSQKONqPuU/h61F7lEcskckatC6r0RlLfnyBVW5j2Iu0khuxH61alKoQ8ckTYGGRlxVVQyhv3QKnJUg8g+1Zy1ZcURbVQFDuO/q4OM/4U1wvRpGyuR81CSEAtE6gMcMH+THtg027TMiFQ0TEbvUNz0rOxZFhZVEW47xkHtk+3pUbrtYyIpXHO3ceanZMNuiQFiArKx4PuKpSIch5VZQWwcHrijyGPmyATGd0fAz1PHeoyUyTuyCDwO1G0pA7FABjhgcfiPeng7lOQpYDAPtRYCPLFQnC55B9RUTfK/zZz0O3nJpyAsMnPHXHYUyXb5jKHKhefm707CEfYCwycH5iM1CQsYUhchm6A06SMBC2/nGMDvUMRWQqjDDgcEcc01ckWPDI3mYDn7gK0+4MZACs6nvx1NDIu4q4ztIxikmUqoKsWYYO01aM27lZ0jRNxUgk8e9PjaNZI3lUtGSPlzjd7Z7Usv8Aqju6HkD/AAqqJtgO9eM5HPQVrEh7HR21jHf25ntdALxEkbmvSoJHXrWD4ihe1vI4BZrY5jDGMTeb3PJPb6VsWupxrZWDSx3HkwNJbvtXKMkgPf8AvD0rI8RtDDc21mizM9rCIWkmTYznJIyPocVujNOzNOyMpkmFww4PI6lefWpUnRZzEGjc7uH6j88VSgeaTDpeouRkIeuB7YqSHBt4oTGFYAkOBhjn1PeuNTsjrcLl1S0E7COZ4o5F/gAcnPp3ojuZXfZG7IR3B2Hn09/WqttK9vdpJHK+4ryUI5+nFaJMcDyPcRu8pP3c4Y1UXd3bIkrbC3xkhBj84FyOcKGPHQk0yJI2j2SYd24GTgiq906zSCQ27xo2M5GWJHSp4FEZJjxDcfxeaw796d+Z6C5dBsY2oqje0eeA54qpPGBI4gjZkZsFQO9WYbYBSzOA2SSNvXmnkrGsjRylznJ4zj3pJNasVrM5m6gdyyzo27PGFqO4VURdpSJeNoEeee4Oa2ZlAxK/yyHjbu4P4VmXMB2ybxHnPylTzn3FXGXKDRlM3klkRiI5QCdp6H9SaRpI3+zBj5TKu0gg8jgk496dPiBlc7nGMEgHbn644pioIzGY5hIrdJCvK+vHp71aZLWtxs8rlgzsI45QfnRSOM4HHpWLc6g1m0X2aISLEGADoD5hbgZ9QOtbxLy2nlER71Y7C2c9euT2qhcWbSXHmoiIYUAZd3Qeo9a0jJ7kSjdGfpum28rnbchLog7ZGBVQcZOD6k5Az61k6vbC71JbW0Z5MZeRXPQjqM+tdDc6bLcS5VLfCnKqrn5vx6msmTS5rq7dHQRRlss0WDge3qa0jNW94ylStokYEcW+8dUAaISfKucbyOn4Uk0RluDMC6qv32KYGQM4FdtY6KqY+zrcbYxn923QH1z15NJqNrI1sI4Ydg27X2R52j396aqxuR9XdjjbdWOntbIwM11MAU5yAOck16Hp3mR6UImtUa2ZkjiViQUwfvcd8A8GsXw/oE1o/nXCb5m42sCdg6108UQcxPLaFfLIyVYjPv161M5qTsiqdFxV5HMWixwQXQl3kPeBUUsV+VWzg8elVPFMK3Ys/JMokmlKsDkgD6Y7c9K6WySGXUJ5xFP5UVy7Dc2A7dAB64GavxaVF/aMWoXc8wmCs2Fb/VjGNoPrVRaTu2KVNyjZHFWfh8z6jttluHs1XY07kgDnGBgcn2rvvC/g6K0iiRoQ0MTFpTMSS7nGR8vRQAK0LASwhBE+FDZQYXbnHX6+9aSXt1CXBkzuXqT0z34NL2q6AqDvfY09QEL2stustrBFIjExxwYHOeM/SsDwvp8dkiKt2rvZxhYP9HLZRhnGfY5/Kr81zcTpskkgkXHUryB3p4vpV+SCdYxJ8u2GI8g845pe3S3NVRlc3Ldhkqglm6HeEZM474J4pkt00ckrCON3l+UFucY9PpWbJdbVOZ234CncBuGfoapvdSECR5pWcHaBnH4jFZSxGlkWqV3qbs97POY4lU8L94KTj0wDx+NNhldpN7eYUUHq6gnsRisGWSJCokkmyxyA2Bx2qSLy+gjfCgkkuAP0rCVVmvJZXN2SYA7d0Yw3zAsC49hUUmXEhCz57hWAyM9/WqNqYsbvs7t1+ZnPJ9cU5pVafBUszcLjgD6VDm2CRft0YbgzT9MDgKMdutPEhCNEWcORyFj5GD6+lRRlAoASd5CPmOeAPqKQgK8YMbkuOHimHI9CKrm00Cw1yhkZYJnfPVACoz+VTOsggBaKWMY5kJJ6e4oeZLdCJN6hhg5TKj8afE1s6qLViZPZyxZvoccVCRQrf67MaOR1ErLuz+VUpkRH2wuvqWRs8+mOMVLF5p83zJuVY4HKEUpg87iZDGh4y3O49uR1zS1KQl0PMXO0SMwyxzznpkd6rt5W1Cw5A5AyMmiQAELkhlHY/wBKih2hl2A7Gz1+bn8elRcoWT5k3g8528nBxVKaNoRlD5gzlkY5FXZSVlO75VIyGJzgVFI25DtYKD1HWpYzPmIkMjAYA/gAyAPSmW0ZkfJ4Yg554/8A14q6FO3CAfMPXOagjAVgSCCDwQO9VrYBIz5W36dc9faq8iMdrkgDlT6/jUs6hgGyQQ2SmccmmsBgfdORyDnpVLYgqyBN5+f2OR2qFSPNX5BgdGPap2Kcgkr74qCT9yDt5TryKpCe1iaWVQykpkAjGD1qQsHJyTuAwcVVD/MCmDlaaXZJAUzV8pmPulUZZ2//AFVVLGQHahHQDA5xVmVi68rkHr61U3vBcrJBKy7CGyBggjoa1RBpoItQ0q2spb1rJrZ3yrxsySbjnd8v8Q6VT8Q3EcklrDE8k/2eARefIpUynJOcHnAzgfSta0vGtdIt5rjWr6zEzyFYooQ5PPLZz3JqHW7BbmA3X9rT38iW4nXzotuYi2OCPQ9Qa1MtmR3TwecXEfBxkBeeOgq3DY3El/CscKM7jkNldnHTPSqETzW5NutwWjDAiNQcs31GcfnTv9LilLLuMgPKEnOO9cd0tWdtm1ZE8kN0is5hcjJTcvTPt60wTFWXzEJZCOWj6/jVhbyfZhBMJJTtyrZwKsCWUQiGSNgruPmcYxj37Unyt6Maut0VRKFLSiczk4zsJIXnsKsO0UUH/HxL5bnLgR4/WoUSNZpC0IiTOMKwO76Zq8BEfLYINnGfNb7xpXE12HRKZFjkkkBhHQ8Z47Gq80okuWEdpGR1yH5NSbhtYtbqu0k5z1HpUYgS6O23Id0G4noV/Him3d6MSj1Y5olIWQ7QEwCXTIJ9Oao3AHlec2WYcnaoXBP0q0vmujRK0u0EnOBg+nTpVdDdZdJZMDnILHj8ad9dhcpjXUUkcG0SERhiSHHBz2rLNrOxZrUxsT1UHr6Yrp7i3uGiMLgGMYbcOn61Rnsgq/KqEkcHONtPm1swsYsZ3FPtO/zo22qCuePUmoyYndfnSMLxjAJP5VeaybcJFhBwOAMgmoZdPcSfJCSFGTycVTm7aBylZ28l2WGZwgOAynBxUti6QBfs5Cdmwex96lSOTePK8s7eoHzbQRgk5FBEsbhZYiyD1x/IVPM+pXKmT+ZDKGMoeRwPlG7aAOwzVqIII3kVo2d/l/vY/OqEMRQkygeWTnDHj34qxEFyVWJXZuSwHAFNTYnAsxEE/dZ36YHIY/UdqlRkRFDnknkIxz+faq/ltGisX+RiVXY2cfSgQgSARoSzcKB1b60KoxuF1Ynt7WBAEgZ5Ah6qo4PtnvS3kxiI/wBGGcjOSOfrjpSLJIgVZ1DOzfdPB9Kll2MMMIhIuflRjjPrVKoupHJYInMg3HZj7qqSBj2xU6O8TgKBERnPbnvUFu+7Mk3lMAoAyOnrUqQwySKxZlVeQVU5/EVDl2KSsODo5k8w/KDk8kE/U4p5aMKMthuCqqcUTRlgAyMyE4Gf4j6kVGQof5jIX+6SRnaPpWfOXZEiTKVJSIFs9+g71JEBOxZAoKjpuqqQhXBUlV+6VAXJ9+9TRgEIgXKqM5xkH2o5rByk8Zw29oVYfdXgsasRRPKwONvcnYCD9B3qFFZ1z5BRT/dbGPpmrkKbI2aXKjoAy5//AFVLkFhETDq7ggc8lCD9anQM0TNIzCMHP7o8n8DTWmYDZ1CjcoJOB/SpN8UgPmyP2OEGM/TtSuihN0OwNuMXOBtBDn09qHlTzUbexkzgEoGGO+aiScJKBEGIXou7J/XpU9rcQ3IkkaPyZCdpYfKVz3I6GlzLow5b7kqRvIcxMAxGdsT4HHsamgMST4KDzWOSwPlsM8Z9KjmdTESACikKZDxz7Y4p6Tnyy7XCOMhdsoxj3z6fjVrQWo9UlVnVZZJYQNrbh/SqsiyKnyOVQcYAq1Evk78oqZ4UA/16GolEkbkSqwLcBhyCf6020RykcW4YUKrPnIYDr+HrTRGphkUybNxBC9yfr+fWrB2KEVisfB3MudpP9DVd12TOFON69icfUUtBrYZIoRXUFm7hc4IqsqbZFm4MhXnj9CKtIZMKjtuyCGyMbcVESwdATuCr94HJA/rSdrlFSYHBjRNpzlOfemb2fAkUnB5I9askA73GSR3I7dqgky67ioUkcYNAiF33uCu3cOATVVwRJIw+WIjrnpU0SAEk7eCc1HJGSm0ADd1PpVJ3JehE4+QGMgjr07VFIwOOpJAGKsSAZA24xwPSq0h+YqAOf4v8KpEvUGK/LkjP8qVQFUN97P8AOoYiRkFcnrk9xSMQsXAIYnqKtO+hDFnmdDlDxt5x61Sk3A73Yhm6E/1qaUyBQTgkHtUTtgsH5BHStUiGbukzLHpUQ1h9PFiXb7OJ42dyf4iu05C59e9Ra1e3cJmhb7I8V1AghmgUhfJB4VfQZHPfNUob+yNlDZ6jazzrCW8qWGQIwUnJU5GCM0uts0/2LZEsFqLcG3jD7js3Hkn1JBrZGVtR7N5VmIjLtVxuEaLkk+hYdKlt7eYKmHUySLk7SSVHoTVmykN6/wA0MMQUFXYPx164P9KmjigR2UXbK27G0R7RXA19x3t20GrG6FXuZo0AAHyc/wAquW9yEaOXykcJyZFcjPtzVZrq3tXXERLBcblIBI9fapp5obsKYgyIq7SgYdfXHemny7MVm9xI9QhfzZJrVWkBBj3jODUt2r3hiea2cSn7vlgKpqJ7q4l3xQFiQdoRVwcDpkdRTIp5PMT5prdgfmYncHPYD0o5+4W/lJZwVVVmWZd2CiOC2T9ajELOpLiSPquFI+8fY0ksM900Ti4EqA4bknFWXi8qBQCPLzy0p5yfQd8VNr62HddSuG8lDHLJg7SB5SHIHuRVUK6yxFvNiT+Fyc8+taDOswUT+WgVflXcetQBL92ceUoVhxkbFHuTQ3doAASzP72dnfGdx5+mKqsbdo2IZmOcEBef/r1ZwJEkhmVWYkAlDkL+NMhaGI5+yhmVTht2T6CnuHKUrrynRXWMKFBwoXP51UV42UqEI3L05Un8q1vmaNTEnA67uCf0prRy4LyE592AwaV3sCRhCGSN9zIi8ZCMCcj8ad5cRc4YNkDJUZZfatTZI7SN9nVgech/mb6GoDGgK72lCoOMFSRTQzJlbyd8gIUHI2kZLe/pmpIJhJCCGZQfy+hq6hkVv3cCqvTzHZWJBpTHEoIMZye7sduPUfSjcCBYpXlVViTyzxl+n4VNLEyb/wB98qZCsvIz6VGY0G1g7M4Py85UCicxRptMxwMn0Ab+tJtJahYfCN1s7FIxH93ex+b8BUgRViBKhI2HGAefXHqfrUEsUgiEmVbgbSD90e9TrK0MaebBGGxgdz9fY1SS6g0+g6BiBtWNOTwD6/SrcbptcHMzYydpIAxWeCWlkk8xkRRgjPzEn+lNRw2Cv8PGe341DepXKWlnYIyx7jJuGB7fWrMVu4BdgxlJ+XgYHrUEM25UgUhSTz5a5yauJBiby3dVUcZ3HNTew+Uf5BEgxEFCgcMfvHuacUIzjByckgdPb3qONZAowV3Mx2jqcVc+zyJEFcuY252qckClcOW3UYOeVklwOoPBqxEVjdVDFyR1f5QP8aeygEqkXlcbTls5NMiETDImUnIADJ1+lLVPULE62szTBFMZB54I/nUzQ7GEjRbVQdM4yfrRDABuDffI4VeCfcUjkMwX+JRj3P4dKei1RKuWFghkPyWpbCjIJB5657ECluYUkikdYwwOAEXBH59qeBKkSvLDkLwsmOn/ANakhXzLd8yK4wcGP5Sp+netL30JaKsJXd5ax4zw2G5qzHbBQ6bogZskMBzx2weDUlvFuWESNvQr/rV+Vh7EGnwOUD+azPAWAXzQDg0WvoLUrMWSJBGQjldpUr8vH8qWNg8/7oKpIA2q2Ru9fxqTUAsTrsZxE4+8BnafXjt9ajVd2zDIsgyGKn5fb6UmrOxQ6ECRm+YoApOXHzZ9KinVTGixjpnaV/p6HNOKnLhmPzcqvpREDk7Y8ED5hj+dF7oWqKsjsTIGj2sh5JPWmNCDtATBx0A6H/Cp7tQJEPltnqGz/SmSHdtdflkyMY5qXfqMo7pP3ils7V6dOO1QyjLfLkOeMY7VZlQ7XUuuWJzjt/8AWqvLI0e0M/zZzgDle3X/AD1oEVihE42gnPqetOJzkFtuTjHrSzjfgqQcjAA7iokLYALAFeOmc01ZbCkyGQ4BfJx6VUI/ejHAYcD0q7ySVAzu4OahlK+aSgxjjPatLmfQi8sxg5IPoDURI2gnndxwOlWGBR9ygYOfwqEx5JGeegIrWO1zMjkJEeMYHv1qNfLLr5wPkgjfsxnHtnvSspGQSc+/eo/KeeeOGJcyOwUAHqTwK0iTLYvvH4dUAiXVsdOkdVNcu7S6Notj5y29tB5QMwG4ncT2+tTvp+l28jRXGsZnUlWEVszop9jnn61R1Wz+xyR5mjmgmjDwyRggSLk9j0OQRitkrmTZsafaQo0csc7SSn729eM57d+a152ZmEkaQRONo8phlvrz1qlBaiBo1VpImOSMjIz9DjFaYjhMR+2+VChGd79d2O2P5VxKL9DuciO6LvLmSGTe6YZpE3bh+XH4Ux9NSGc3KokUiAOq7gVI/U1LbSTNA88d0F2EKm/v9M1Q+0zHzGlh2svViOG/pUtxjq9RpNllndJjdmAybhgs4OT7jBFOEttNMP3THOTkocKe5UZ6j61PHJf/AGeKWF5GVuJF3HGPTiqd3ObRibuwaIux2ZTgD1GeM0r2C1x5kuSCFgRUZiyP5YBKg4yTTdSsIpvLjMqTBdrmSNtwGeuAK0bVI7qOGS4j82AocLKAOTz0zwKfepaQojWol3LklRgpjP8ACB/WrVpK9yetjI8pwWUzvMmflRFwxGepPanT3BNyttHE5izggE7voasRTR28chlC7iAgX7/Prjj9adBK0Jj+zWoWdfnPXDZ79Ki/Zl+ok6AKVkkVGyDgjkccA/8A6qzbgM8aRh5TEGxhM/Mc9PatRVnmmOyJ5HwdzKcMMnr+veoBabFLF5+Mk7uT+dO19hLQqSRhY43wDwGJ2/MfYmhocz52PIzHOMZ5x6VMU2xNJHE5UH53ZuT9BiobZMzPIAQW/h4TOelZPfQuwjRKEwrzQ9No+Uc9/ek+zFYmG9/+BKOfxq0qliAAjEAkZ55HYVHdJJcW4dlkLlsHaeeeapyd7CKUdhI7iSNVAIwFTGW+tI0MBGGzI4PKO3HvVu4hMSZOFP3Sep/CnRQo7OSrIh+VVPBPvmpvdjMa4jiGEBgiAGAEGS3uKRbTczOqFQOhcZNasEFsZiqoSqcjjdz9T0qVg8sLnaPLUDaFHWjmKT7GOsJK/N8kYxvwtSuu35EjeZuqnP3RV0Whch3jJwOfm/T61ZWFgsuFVFHIBHOKXMx3MWXCKiyhCTyRn9Kniitio2oxJOSqjA+uatSQNMwlITGQeY+Pwq0ts6T+RJB8wJ3uTtyD/Shydi7pla1ebzAtuI1dTgPu4AxVjbuILlST1Xvnuamum+YIkKthfvKOv0NLDayQ5lZFQbcqXbrWcm9habj1jjLJIEDADAyvT61I6uwf5MKAANnNOgtZ7i2MoO0buAWxkf4URGRyN1s6KTtAAzuP1qlsIis5oPNZim/b8pD5GPelslzKyquyLruByDWm9lDcQeVIsaGQ4xt+bI9fanW+i4LBWVVz0DcHFUoO2moOSGGNQmwRuzsQPMbJxj+lSJDHzsVmYElickfRaneMA7PPZsAA+p+tTPsgjWJy7xZ5wcn8PStIxVjNsiSSRGIAcxlRjeOn+NDH7Oyoq7WY5DBev0p8sO6FEEhZS/XdhwOf6VJbxmFcxguTwA3Q1STFfqQhvPkZXjdYydpY9R7iorhRE6JH83ynLZyPbIq0f3ELkqPmGSrHOOc9aqyxnzQz53oRnHUZ5pyVlbqTcZHcbg8hUxtjDFDwPXj9arp5ri4BcebxuOO3rU0kaBnYLmNiFZRwQT3NRyRvHbP5POPz96yfdlEUD+ZMvP7rr3wD7f4U8spaNgxwxIPON3ak3mKQKmzkYPeoplZ4CsrnCHg4wcCpvYdhlyCrAebtbJxuPB9vrTbdQyncwxjPPUdqbKVkO0rgI2ce9Ro4G5B94H5ieDS3dxCFlDkEKSepx78VFcqGi3lR5g5qeaNcGVBxjAFQSkmMO+VJ6D3ql5iI1XEC8EMP84qFkVFIXcGPODVi5L7QS205Bz2qm/my9SRt5z7elWmiXqMm+RQNwwOpHU/jVdiVjBbHJwDUgBAUgE465FQSYCkMM87qpMhqwwlmB7c4NOJUfdyAefpxUbyjghepwaWVkJGGBOPStYqxDGS5A+Y8jvVGKWWK6DwsxmRgUYDJyDxxU7kiMleQO9U2kmDrJGWSRCGDKcEe+a2iZtm/LcxzsZrvw5uuGOWKGVASep2isfV7mW7uIzcQC2jjQJDAqFVRM9s8nvzXQXM/iu/jinji1CIiMLIyOVEpH8QXjHbpXL6hNfSTEam07XKgIRPnco/GtYmT7nbGFJ0QRvEZHbkyMT09qVwRctHexyQxbT8yHIzjqM54qC0aKKZVljWUEYAIxg1rAwxpusxIrEYwBuIP93HQ1wRfMd3w7kVqoWyBeSGVVfCqpwyj1x0/GnRSiNnjubxntj8zRkfL7ZI+tP0uAu4SFY1dQQQR82cc5B6U8287ROjXAWMSYcJxt9PY1fI1stBc67j4YI57OQQNsizlvLAJz7MTkCmSJJKoSOXbPxgffPHcmtOWwtrlYRJctcfKTwpBGPXHJ/lVa3hW1SRpZDDsIIXyy5YH1OetW4PqQpWWhXlsnhiaNZ1aVl3PKh4I7Lk96pQOZFke4kbcWAEUiEhlx044rVmjjckiVgPvIGySf9kgZAzVZAzwtvDoA21ZGYjNZSikzSDvuVtl5LA8ERWJHXc7D92HX0wetWI2uFmaESxhyo4QZAHvT/LuDB8/lmMkxhipIx9eM9KUxSMlwZVAiPyNMny7cfSlZ73K5nco37qIg8clw6424OFB+ooYzAIkod1XrGcrx6H/APXVxJ7aCyRY1ae5ZcY3fd9KbHCzKI7k4ctvcyS5OPSlKLDmTKcUcuZTHHDG3Jxt3kA/pxRb2MuxZbp/LgfLAjHbgcdambcdTa2jeL7JHwQRkE+hq69ssqna+EixuZSFBHoMVKjfUu5Sji875t4KZOY0Xb9OaryRGJJWiwoAA5GMZ759avXtyyRyx2+0K5Chye/TkmqjNDdwTW9wEiCuAESXdyO/vSdkCT3K5giAzLO3nEccZA9elSzZ2xyKgjOwlCFyTVtLaJljWBmOATIWO3PPYfSn3sXlrHGVyBkttY5APvRbW4+tira2ol3h5QFbG4KcMRVkqsG1YUHlNwGzwQPWiFgzmJInjmxj5V3Fh9KkeKSM5Jy6P8ilMr+v8qnlVtBaiwxKkjeTgELuDHnDfj0qJYBLGwkLKz5YlRVyCNioNyAoY7mGMH6H/CnXFswkh8twsS8FvvY/+vV7gUJbTZbKPNckgnaOx6dDUQUzSNksXJxuPO6tBlRA0m0Bz03dqnVI4lRwNqnBGRyc/wBKjk5i72RnCwUBnkLLxwAcYP8AWntbRybVWRigHHOcntxWi1sLmTzG2hm5x2xU5gRcRW0axjgFu596PZ+RKkjGlj8pCrs6gtjbnp9BUsALhhB5iqACoY/r9auSwq87AMdzMC24/d//AF1cjRmOxkwG6SL7+tVy+ZXNoUrKyufKDyHfIMtl/T+tWFgYufPLoo+Y4+7V4WZOYopZODnI/wA/pT0iaKORtw3EZ5OatUrmTlqUYFjXIiZZUfnD55+lSTwiaNDuO0j5+cbc/wBatPAfNTyCgdcdQOncCp/KmJYbPNJGQrVtGKRDd2UPs0cfmLHuPlEEHsfz68VFOHeZc5CKflHT8avLKCZAX2SbR3yAarw5baZyisrbSwH3h79qU9w1sRTQBFKAMN3JHpUBEkkiErhDjk9AB05q7dvC0b8qik4IHf8AGqt1IpjjI4VFyqgc8ms5tXKSuVpgYkDclclQB3+lMuf3UatEwDdkIonAzwGUjAOOnpn61XnmZvkPzHOAR6+lYtlJFeVvM5hzhhz61LHGWdN74znr04pu0sCA+0suMDsc01gwm2h87eWyPWo6jY24jDbmLAckcevrVVkTAfzOnAJ7ketXFzMrrg8HOD6//XqrMY1XKoQS2f8A62Kt26AhzSsinKgxsBg1WkkeT7qNxzx3oRyq4JG4Hcu4+/SnxNHsPIVs9OuDzxQlqKWxVaQAbeCR0GOhpNwcnLYBXsOM0jM6DO0H6e/rSBNiBi5yenGacSXsMmBQFhlvTHQ1SuS7HIGCRxxxVifzdpXbgqM9eMetVpVcpl3UewNaJGZARuXZxlf51GVRWKBiDjg9qnbBXkZPQj1qA7CoAGHreInYimhQgq74UjGR60WMn2e5glkG9IZFYr/eAINMlZWyOeKdYGIX1ubgk2okXzAem3PNXFmLNC+gs72+luf+EhG2Ry+2ZH3qD24449qp67eQ3UlnHE8k4toBEbiRdpmOSc4POBnAz6Vs6lfs2pzWGt+TJZSHMMsKqTAp+6ykdsdQazPFMYtV0qDfHN5dmqlojuVvnbkV0pIwk9ToriZXt1VY06fIQPm/+vRDPCqF0ZxMuMPHkYPTGKkRon4Ft5GF+4DwxP8AEKv21tbxrtlieOfcPnB4x7ivNjFvZnoSaS2IYCQ8TpLLPIQcARZeP6E9ea0LSaeRH3yxwy79sgmBUsf8ajgG6cyRX0scS5VSRnntg+lX4LmH7PL9oIurrnJjXkD1OOh963gra3M5O60RQSzjhu8pJc7QuXkZgQ34Z/Sr0dgxaR5pONwxFjbuUjrn/wCvTo5GeDy4wUfBGQuDz2JotNzSzxoyTSg+7HGOec1a5ewncS5k2ELOhDoQoiAAB6YOR/jUFjtnh3nft3f6psDaMdRnoPetKWFVSaRzGzbcSK2DlT6ehqCf/VozCM8hUUDAKjtiiUbiTvoU3W3S7QS7pRtJCqvT056Y+lJJGFwYo3EaAs5dw+B7jOM+1Wr20dUs5Xkg3OxJjXAIHbP+FU5TmV1ihAJPzYGVPrjpispqSZpHXUYlw0iNKwRZsZXaAPlH0qqLhPPEiAG5YYeTG5Yx2Az7VLcRpJguPISQ42gcBR1NSSwxvO2bmIxZCqUAAIrLW+htpuRIpCERqEmkfJkZRyM9jirF5JHaWwWZXlXA+XP6Cp1ghkbBG+K3XcY4xt/76J9M1FNEb2PzpY/kLHamPlBwOfeizj11DRtdipJbwXkEkqW7RBCSvJAHfoahhEItUl2IlxIMAygcKO4q/MrNGVikSFSvJc8cDr9TUNpA8diZZZN524jXAAHqai13r2KTsR2ywvAsk0nzt3DAdDVljNcO1xBhkxjaT0xS2unlGt2ldTNIGYg9R25HY1dWNbWGOIkiR+nl9fYntSinbUbfYpQwSlnkmdklY52r1XP8vpSrHkxx9EEm5pD97Prz1q9aqzO23ZHM7biWOSfw7U+YlIxz82/52bnPXpVKGm5N7kMatDG0pLyBX4AGc9elRQeaUkabG3gnHb61diaaRVbciBeFXceB7Ckui0bKijdG3DHgdfWny6XQJ62ZSDLJe+W3+rb7pIyW96tmJYigWMFlY8y8A+lWo4Dbwl7eNYw4wM8k49fSmNGJIgv3gW3EN0I65pqFlYL3InW6d1XywpAPzbsDHtVloXNwAdrEHpv29v6UGQxlFBzGRhlA96kuZI4Yyh/dpK4Cs3Ib8+lUox3ZL8hmY0RQhVsH5j3PPbFTLBFOwjMu1VOSoUjHofpU5EjW4RJVcZyMf55pGARSN3zY+YJyK1SXTYVmPs0X55IgSqnAkxweTzT3coxKNl8lm+Uce/0p8AjhjSWOYtGTgrn8h9KGk3JkRDB+UDOGXJ6Gq5UtDLW5HLGjJDLuIZTliT+vFLPE6M4VsspyeeAPapSoLFY1V0UB5DjJ4qu8gdZNh+THD+go6AUGdNzeWjCJjjzO4HWqcZYwxQyPguckZ5bjjmrN4gh2kMCpyyY5H09jUHyNOLmTaWK53dzxjAFYyV2axfujgCkBBRSquF28ZBxVa4KztN5QOF6+hGP8alkmY3LhERo9oO4Hjd/TPpUceACUABYHCkdPasna9ilsUHL7Yyi4TkMD3z/Wqrh2kPygIRuHPer0vDlpEXbxgL6/4VXk37xtQlgSACO3es2NEFy5wpICqOFJPXNSExqihhkMMZBzmmJIjKVfaUI6c5Bp42yAlnwFA6djUIGyNpfLYHbyp/P8e9Mu5WAURKpXvkdfWidS7HALBQCM+lRb8gFmXHcHtVAQSvGm8naSRwMcVVYoJP4thA/+vU9wqiQ55XrmoJQJHGw8DnmkA+Qb4yQMEd6hKsjeWWyG5HPANODscjduxzgCmyEbvkIO3kg8GtFYzIn2mRTGD1zj0qtOGZSH7H+EZ61ZK7l+Y/PnJK1XdSgXccD1FWtiZEaEsWzgMvt1qvJuZ8bccnmrUpUoFA5PeoCpKFSeByMVvHYzkVGV3YEjGR2qu4YkDueAq1blT91yce2eSaXTnW21S0nlGYo5FZhjtmtIJXIlsSHSEjXyru/gt7vOTFtZ9vsxUYB/PFZeowvZTmF1AdRuyDkMD0IPcEV2E0Lrfae8lzJG9sAFCQs5k5JLoVGG3g85981z3ix0+0QwqFV4kIcKchCXZgn/AAEECt0czep0lofOvljkGUJAxk8cdq2FQIjbSwKsRknORx60UV51Lc9OZVhmcOqbsqHzjsenWtHcrRTSeTErbtnyrjiiitYdRSHadO7xTSPhvLlVApHBBHcVsahaw2ccTRRgmRTu3c56H+tFFax+EyluOsF+1QSs52hfl2rwCOvPr0qY2yyAl3kJJZic98UUVfQz6lLyhOoectKYiEUN0wazoCZbjceGVDgiiiud7nREdrOI4hGigL5YOcc8gE1c0/TYLXTbK4iMnmGMSZZs4Y+lFFZfbLh8DM9yXui5PLEgjsRwKW8laFW2dDHjGT0/pRRUrcthM3+h28e1dpTPTPJ6n9KuD/R2ZF+YRxK67+cEiiinDdB0JreV3eLccl0yWPWnyoGycY4HTtRRVdCUWGRV85goyqgg9ecVRjuJJITKxG/j+tFFT2GXrZVeWNnVWPls3IyMipY0SOUSBFL5ByeaKK06sn7QrD7RIEk+6x5xx1qqsh8kDAwrbV46AGiik9yi6qbnhyzZY4PSrcsaIpBG8KQMPzRRWkdiWQqcMVT5FUEjFUFupZJSrEbc4wAB160UUT3GtizE7KeMYI5461K7FHgAP+sxknkj6UUULYT3JZZHjnZAxxGpxk9fY+tQ3MrGMrwEc8qBx1H+NFFUtmZMpRtiPzSAWaQxnPpis1BvVYyTtVjjBoorGeyNYbFlTsinx7Lz6Gql6TApEZIGSvPpRRWZRXUmKPCnPIXLc8elLcOzxvIThgCeOOnSiis2Bm2uXmuJWOWP5VZcYGwZAZQx96KKlCZUnOyTC9D2qBvT2oooGQuMKpHHekjOWKnpj+lFFMRFaqoDAAfdH86cUEkgDdM9qKKuJD3ILr5WfH8J4qpKoD8dxmiirWxLGv8A6rJAJxVSdicjoMDpRRW8djNlQOzMFJ4zUkx2LgdzjmiitIGcthkN/dwW80cN1PHGB9xZCF/Ks6Ycqe7DJ96KK6InPI//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Loss of eyebrow hair is present in this patient with alopecia areata.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13012=[""].join("\n");
var outline_f12_45_13012=null;
var title_f12_45_13013="Cancer of the nasal vestibule";
var content_f12_45_13013=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cancer of the nasal vestibule",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/45/13013/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13013/contributors\">",
"     Anamaria R Yeung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13013/contributors\">",
"     Robert J Amdur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13013/contributors\">",
"     John W Werning, MD, DMD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/45/13013/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13013/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13013/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13013/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/45/13013/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13013/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/45/13013/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancers of the nasal vestibule are rare and account for less than 1 percent of all tumors of the head and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13013/abstract/1\">",
"     1",
"    </a>",
"    ]. The nasal vestibule is separated anatomically from the nasal cavity by the limen nasi. Cancers originating from the nasal vestibule behave like squamous cell cancers of skin and have different clinical behavior compared with tumors arising in the nasal cavity. Thus, these tumors should be considered separately for the purposes of diagnosis and treatment.",
"   </p>",
"   <p>",
"    The presentation and treatment of cancers of the nasal vestibule are discussed here. Cancers arising in the nasal cavity and paranasal sinuses are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39206?source=see_link\">",
"     \"Tumors of the nasal cavity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23241?source=see_link\">",
"     \"Paranasal sinus cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362246102\">",
"    <span class=\"h2\">",
"     Anatomy and pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nasal vestibule is a pear-shaped cavity that functions as the entrance to the nasal cavity. Its borders are the nasal septum and columella medially, the lower lateral (alar) cartilage laterally, and the pre-maxilla inferiorly. The vestibule terminates posteriorly at the limen nasi, the junction of the lower and upper lateral cartilages, as well as the transition from skin to mucosa (",
"    <a class=\"graphic graphic_figure graphicRef75148 \" href=\"UTD.htm?15/38/15974\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54865 \" href=\"UTD.htm?40/5/41044\">",
"     figure 2",
"    </a>",
"    ). The vestibule is lined by skin bearing hair follicles, sebaceous glands, and sweat glands.",
"   </p>",
"   <p>",
"    Tumors arising in the nasal vestibule typically are squamous cell carcinomas that have a natural history similar to that of squamous cell skin cancer. Other types of skin cancers such as basal cell carcinoma and melanoma can also arise in the nasal vestibule. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362246088\">",
"    <span class=\"h2\">",
"     Epidemiology and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average age of patients presenting with nasal vestibule cancer is between 60 and 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13013/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In most series, nasal vestibule cancer is more common in men, who constitute 55 to 70 percent of cases. There appears to be an increased risk associated with smoking tobacco [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13013/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362246095\">",
"    <span class=\"h2\">",
"     Clinical presentation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary tumors of the nasal vestibule are usually relatively limited at presentation and exhibit a more favorable prognosis than tumors of the nasal cavity.",
"   </p>",
"   <p>",
"    Early tumors present as superficial ulcerations or masses of the membranous septum or columella with crusting, scabbing, and occasional minor bleeding (",
"    <a class=\"graphic graphic_picture graphicRef59174 \" href=\"UTD.htm?36/32/37379\">",
"     picture 1",
"    </a>",
"    ). More advanced lesions can perforate the septum or invade the alar cartilage and grow through the skin surface (",
"    <a class=\"graphic graphic_picture graphicRef71971 \" href=\"UTD.htm?31/60/32707\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52010 \" href=\"UTD.htm?16/41/17042\">",
"     picture 3",
"    </a>",
"    ). There can also be extension inferiorly into the gingivolabial sulcus and premaxillary soft tissues. Growth into the posterior nasal cavity occurs late or with recurrences.",
"   </p>",
"   <p>",
"    The nasal vestibule drains primarily to the submandibular lymph nodes. The facial lymph nodes are second-echelon nodes, which may become involved with recurrent disease. Only about 5 to 10 percent of patients have clinical lymph node involvement at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13013/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    History and physical examination, computed tomography (CT) scan, and biopsy for pathologic confirmation are usually sufficient to establish the diagnosis and provide information for initial staging [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13013/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two different systems have been used to stage cancers arising in the nasal vestibule:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2010 Tumor Node Metastases (TNM) system developed by the American Joint Committee on Cancer (AJCC) and the UICC includes cancers of the nasal vestibule with those arising in the nasal cavity and ethmoid sinus (",
"      <a class=\"graphic graphic_table graphicRef82601 \" href=\"UTD.htm?9/42/9902\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/45/13013/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23241?source=see_link&amp;anchor=H5#H5\">",
"       \"Paranasal sinus cancer\", section on 'Diagnosis and staging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The Wang staging system, which divides cancer of the nasal vestibule into three groups [",
"      <a class=\"abstract\" href=\"UTD.htm?12/45/13013/abstract/9\">",
"       9",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       T1",
"      </strong>",
"      &ndash; T1 lesions are relatively superficial and are limited to the nasal vestibule.",
"     </li>",
"     <li>",
"      <strong>",
"       T2",
"      </strong>",
"      &ndash; T2 lesions extend from the nasal vestibule into adjacent structures such as the nasal septum, upper lip, or skin of the nose, but are not fixed to underlying bone.",
"     </li>",
"     <li>",
"      <strong>",
"       T3",
"      </strong>",
"      &ndash; T3 lesions include those tumors with extension to the hard palate, buccogingival sulcus, upper nasal septum, turbinates, paranasal sinuses, or are fixed to deep muscle or bone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several contemporary groups advocate the use of the Wang staging system rather than the TNM system for staging of the primary tumor because of its simplicity and better correlation with prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13013/abstract/2,3,10\">",
"     2,3,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of therapy is to achieve the best oncologic outcome with the least morbidity in terms of both cosmesis and nasal function. Treatment recommendations are based upon observational data from single-institution case series.",
"   </p>",
"   <p>",
"    Definitive radiation therapy (RT) is usually preferred for localized lesions since surgical excision of these lesions usually produces significant cosmetic deformity. However, surgery is a reasonable alternative if the lesion can be removed with a good functional and cosmetic result. Extensive tumors often require a combined modality approach consisting of both surgery and RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive RT usually involves external beam RT (EBRT) followed by a boost, which can be delivered with either additional EBRT or interstitial brachytherapy one to two weeks after completing EBRT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EBRT can be delivered either with opposed lateral fields using megavoltage photons or a single anterior portal using a 4:1 mix of high-energy electrons and megavoltage photons. For both techniques, a tissue-equivalent wax bolus is placed over the entire nose to convert the irregular nasal surface to a box-like contour to improve the dose distribution. The dose delivered by the initial EBRT fields is usually 50 Gray (Gy) given in once-daily 2 Gy fractions. This is followed by a boost to the tumor of 20 to 25 Gy using either EBRT or interstitial brachytherapy. Serious complications with definitive RT are uncommon.",
"   </p>",
"   <p>",
"    Although interstitial implants of the nasal vestibule are individualized, the implant generally consists of two to four planes of needles inserted through the dorsum of the nose (",
"    <a class=\"graphic graphic_figure graphicRef78952 \" href=\"UTD.htm?7/42/7847\">",
"     figure 3",
"    </a>",
"    ). The source is iridium-192. When given as a boost after EBRT, the dose delivered by the interstitial implant is usually 25 Gy. Very early T1 tumors can be treated with interstitial brachytherapy alone, usually 55 to 75 Gy, depending on the tumor size [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13013/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362246339\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery can be a simple wide local excision with or without skin grafting, or it can involve the removal of cartilage (usually either columella or alar cartilage)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    external nasal skin depending upon the extent of the tumor.",
"   </p>",
"   <p>",
"    If surgery is being considered, the surgeon should assess the likelihood of achieving a complete resection; a lesion that is likely to result in close or positive margins with surgery would be better treated with definitive RT. The surgeon should also critically assess the tumor extent to understand which structures will need to be resected before embarking on the procedure.",
"   </p>",
"   <p>",
"    Nasal floor or lateral nasal wall tumors can be easily removed if deep invasion into the nasal cartilages is not present. Septal lesions can be removed with excellent cosmesis as long as the anterior septal support is not compromised. If needed, the external nose can be reconstructed but this often requires multiple reconstructive procedures and may be disfiguring.",
"   </p>",
"   <p>",
"    Surgical management should be performed so that complete resection is achieved with microscopically tumor-free margins. It is critical for the surgeon to appreciate the complex functional and aesthetic anatomy of the nose since it is frequently possible to customize the cancer operation so that optimal reconstruction is feasible.",
"   </p>",
"   <p>",
"    As the central aesthetic feature of the face, the nose is divided into nine aesthetic subunits, which are defined by the contours of the nasal bones, upper and lower lateral cartilages, and the nasal skin and soft tissues. Optimal nasal reconstruction requires an individualized reconstructive plan for each nasal subunit. Full-thickness defects require reconstruction of the intranasal lining, cartilaginous skeleton and overlying skin with mucosal flaps or grafts, free cartilage grafts, and skin grafts or pedicled local skin flaps such as the delayed paramedian forehead flap [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13013/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cancer of the nasal vestibule frequently necessitates resection of the caudal nasal septal cartilage, columella, and anterior nasal spine. This is the most complex region of the nose to reconstruct from an aesthetic and functional perspective. Loss of the caudal nasal septal cartilage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anterior nasal spine will result in collapse of the nasal tip and dorsum and may require reconstruction of the dorsum with calvarial bone. Prosthetic rehabilitation of the premaxillary region may also be necessary to establish separation between the nasal floor and the maxillary vestibule of the oral cavity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Locally advanced lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;More extensive tumors should be treated with a combination of surgery and RT, as these tumors have a low rate of local control with either modality alone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13013/abstract/13\">",
"     13",
"    </a>",
"    ]. When a combined modality approach is used, RT can be given either pre- or postoperatively. Preoperative RT offers the possibility of shrinking the tumor to allow for a less extensive resection, whereas postoperative RT results in less wound complications. The external beam RT dose is usually 50 to 60 Gy delivered in 2 Gy fractions.",
"   </p>",
"   <p>",
"    Resection of advanced stage lesions may require total rhinectomy. A prosthesis is usually created to cover the defect, as total nasal reconstruction is cosmetically unacceptable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Management of the neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of the literature analyzed the frequency of lymph node involvement in 20 case series that included over 1000 patients with cancer of the nasal vestibule [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13013/abstract/10\">",
"     10",
"    </a>",
"    ]. The risk of lymph node metastasis at presentation was approximately 6 percent, and another 12 percent developed delayed lymph node metastases during the period reported.",
"   </p>",
"   <p>",
"    Patients who present with lymph node-positive disease should be treated with either RT to the involved neck",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neck dissection. Elective treatment (either RT or neck dissection) is generally limited to patients with locally advanced lesions. Treatment to the neck is used to salvage patients with a regional relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13013/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key factors influencing the long-term outcome after treatment are the extent of the local disease (T stage) and the presence or absence of regional lymph node metastases. The most extensive data using contemporary treatment techniques come from a series of 174 patients treated over a 10 year period at five centers in Denmark [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13013/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The five-year locoregional control rate was 69 percent in the 164 patients without regional lymph node involvement, but none of the 10 patients who had positive lymph nodes at presentation achieved five-year locoregional disease control.",
"     </li>",
"     <li>",
"      The five-year locoregional control rate for the 109 patients with T1 lesions according to the Wang system was 79 percent. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among the 47 patients with T2 primary tumors, the five-year locoregional control rate was 54 percent.",
"     </li>",
"     <li>",
"      For the 18 patients with T3 lesions, the five-year locoregional control rate was 35 percent.",
"     </li>",
"     <li>",
"      The disease-specific survival decreased with increasing T stage according to the Wang classification (83, 63, and 39 percent for T1, T2, and T3 lesions, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular posttreatment follow-up is an essential part of the care of patients after potentially curative treatment of head and neck cancer. For patients with nasal vestibule cancers, recurrences can often be salvaged successfully. Patients should be educated about possible signs and symptoms of tumor recurrence. Our approach in these patients is to perform a follow-up examination every two months for the first year, every three months in the second year, every six months during years two to five and then annually thereafter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinomas of the nasal vestibule are essentially skin cancers and the prognosis is related to the stage of tumor at presentation. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Presentation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with early-stage tumors, we suggest primary treatment with RT alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Surgical excision is an alternative if the lesion can be removed with a good functional and cosmetic result. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Radiation therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H362246339\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with more extensive tumors that involve bone, we suggest surgical resection followed by adjuvant RT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Locally advanced lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest prophylactic nodal irradiation only for patients with advanced cancers, particularly those that are poorly differentiated",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recurrent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management of the neck'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13013/abstract/1\">",
"      Patel P, Tiwari R, Karim AB, et al. Squamous cell carcinoma of the nasal vestibule. J Laryngol Otol 1992; 106:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13013/abstract/2\">",
"      Jeannon JP, Riddle PJ, Irish J, et al. Prognostic indicators in carcinoma of the nasal vestibule. Clin Otolaryngol 2007; 32:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13013/abstract/3\">",
"      Agger A, von Buchwald C, Madsen AR, et al. Squamous cell carcinoma of the nasal vestibule 1993-2002: a nationwide retrospective study from DAHANCA. Head Neck 2009; 31:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13013/abstract/4\">",
"      't Mannetje A, Kogevinas M, Luce D, et al. Sinonasal cancer, occupation, and tobacco smoking in European women and men. Am J Ind Med 1999; 36:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13013/abstract/5\">",
"      Mendenhall WM, Stringer SP, Cassisi NJ, Mendenhall NP. Squamous cell carcinoma of the nasal vestibule. Head Neck 1999; 21:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13013/abstract/6\">",
"      Langendijk JA, Poorter R, Leemans CR, et al. Radiotherapy of squamous cell carcinoma of the nasal vestibule. Int J Radiat Oncol Biol Phys 2004; 59:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13013/abstract/7\">",
"      Dowley A, Hoskison E, Allibone R, Jones NS. Squamous cell carcinoma of the nasal vestibule: a 20-year case series and literature review. J Laryngol Otol 2008; 122:1019.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13013/abstract/9\">",
"      Wang CC. Treatment of carcinoma of the nasal vestibule by irradiation. Cancer 1976; 38:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13013/abstract/10\">",
"      Talmi YP, Ferlito A, Takes RP, et al. Lymph node metastasis in nasal vestibule cancer: A review. Head Neck 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13013/abstract/11\">",
"      Evensen JF, Jacobsen AB, Tausj&oslash; JE. Brachytherapy of squamous cell carcinoma of the nasal vestibule. Acta Oncol 1996; 35 Suppl 8:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13013/abstract/12\">",
"      Wallace A, Morris CG, Kirwan J, et al. Radiotherapy for squamous cell carcinoma of the nasal vestibule. Am J Clin Oncol 2007; 30:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13013/abstract/13\">",
"      Burget GC, Walton RL. Optimal use of microvascular free flaps, cartilage grafts, and a paramedian forehead flap for aesthetic reconstruction of the nose and adjacent facial units. Plast Reconstr Surg 2007; 120:1171.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3403 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13013=[""].join("\n");
var outline_f12_45_13013=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362246102\">",
"      Anatomy and pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362246088\">",
"      Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362246095\">",
"      Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362246339\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Locally advanced lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Management of the neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3403\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3403|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/38/15974\" title=\"figure 1\">",
"      Nasal bone and cartilage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/5/41044\" title=\"figure 2\">",
"      Coronal organ nasal view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/42/7847\" title=\"figure 3\">",
"      Implant nasal vest CA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3403|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/32/37379\" title=\"picture 1\">",
"      SCCA columella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/60/32707\" title=\"picture 2\">",
"      SCCA left vestibule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/41/17042\" title=\"picture 3\">",
"      SCCA left vest skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3403|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/42/9902\" title=\"table 1\">",
"      TNM stage sinonasal sites",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23241?source=related_link\">",
"      Paranasal sinus cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39206?source=related_link\">",
"      Tumors of the nasal cavity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_45_13014="Hilgenreiner Perkins lines";
var content_f12_45_13014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55366%7EPEDS%2F82640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55366%7EPEDS%2F82640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hilgenreiner and Perkins lines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hilgenreiner line is a horizontal line through the upper margin of the radiolucent triradiate cartilage. Perkins line is a vertical line drawn from the most lateral ossified margin of the roof of the acetabulum and perpendicular to Hilgenreiner line. In the normal hip, the medial end of the ossified upper femoral metaphysis lies medial to Perkins line and inferior to Hilgenreiner line. In the subluxated hip, it lies lateral to Perkins line. In the dislocated hip, the medial end of the ossific metaphysis of the femoral neck lies lateral to Perkins line and superior to Hilgenreiner line.",
"    <div class=\"footnotes\">",
"     DDH: developmental dysplasia of the hip.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shenton line",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 596px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shenton line as seen in an AP diagram of the hips. Shenton line is drawn from the medial border of the femoral neck to the superior border of the obturator foramen. In the normal right hip, it is a continuous contour, whereas in the hip with DDH (the left hip), it is disrupted.",
"    <div class=\"footnotes\">",
"     DDH: developmental dysplasia of the hip.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13014=[""].join("\n");
var outline_f12_45_13014=null;
var title_f12_45_13015="Tompkins metroplasty E";
var content_f12_45_13015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tompkins metroplasty (E)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (E) After which the superficial myometrium and serosa are closed with an imbricating suture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13015=[""].join("\n");
var outline_f12_45_13015=null;
var title_f12_45_13016="Overview of therapy for obesity in adults";
var content_f12_45_13016=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of therapy for obesity in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/45/13016/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13016/contributors\">",
"     George A Bray, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/45/13016/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13016/contributors\">",
"     F Xavier Pi-Sunyer, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13016/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/45/13016/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13016/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/45/13016/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morbidity and mortality associated with being overweight or obese have been known to the medical profession since the time of Hippocrates more than 2500 years ago. Overweight refers to a weight above the \"normal\" range, with normal defined on the basis of actuarial data. This is determined by calculating the body mass index (BMI, defined as the weight in kilograms divided by height in meters squared). Overweight is defined as a BMI of 25 to 29.9",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ;",
"    </span>",
"    obesity is defined as a BMI of &ge;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    Severe obesity is defined as a BMI &ge;40",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (or &ge;35",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in the presence of comorbidities). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=see_link\">",
"     \"Screening for and clinical evaluation of obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of therapy for obesity is provided here. Information on specific therapies for obesity and health hazards associated with obesity is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link\">",
"     \"Dietary therapy for obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link\">",
"     \"Drug therapy of obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=see_link\">",
"     \"Role of physical activity and exercise in obese adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several guidelines are available for the evaluation and treatment of obesity including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Gastroenterological Association (AGA) medical position statement and technical review [",
"      <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/1,2\">",
"       1,2",
"      </a>",
"      ], also available on the",
"      <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"       AGA website",
"      </a>",
"     </li>",
"     <li>",
"      American College of Physicians [",
"      <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      National Heart Lung and Blood Institute and the North American Association for the Study of Obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these approaches are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link\">",
"     \"Drug therapy of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is a chronic disease that is increasing in prevalence in the United States and worldwide. The percentage of Americans with a BMI above 25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    or 30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    has been determined in several government surveys, beginning in 1960 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/5\">",
"     5",
"    </a>",
"    ]. The data have been collected in two different ways: annual telephone surveys conducted by state Departments of Health in collaboration with the Centers for Disease Control and Prevention in Atlanta, GA (the Behavioral Risk Factor Surveillance System [BRFSS]), and direct measurement of height and weight in field surveys (National Health and Nutrition Examination surveys).",
"   </p>",
"   <p>",
"    BRFSS data give a prevalence that is about two-thirds that of the NHANES surveys (",
"    <a class=\"graphic graphic_table graphicRef57195 \" href=\"UTD.htm?33/48/34571\">",
"     table 1",
"    </a>",
"    ). This could be because people underreport their weight, over-report their height, or both, during the telephone surveys. Data would suggest that they do a bit of both. When reading the literature on prevalence of overweight in the US, it is therefore important to identify which method has been used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Behavioral risk factor (telephone) survey",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subjective prevalence of obesity (obtained by self-report) in the United States increased from a median of 19.8 percent in 2000 to 26.7 percent in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the prevalence of obesity varies across states in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/8\">",
"     8",
"    </a>",
"    ], by 2004 all states had more than 15 percent obesity. In 2009, all but one state (Colorado) reported more than 20 percent obesity while nine states reported more than 30 percent obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     National health and nutrition examination survey (NHANES)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measured prevalence of obesity is higher than the telephone prevalence (35.7 percent versus 26 percent) based upon data collected for NHANES between 2009 and 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/9\">",
"     9",
"    </a>",
"    ]. The NHANES-measured prevalence of obesity among patients with type 2 diabetes mellitus is even higher (54.8 percent measured between 1999 and 2002) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/10\">",
"     10",
"    </a>",
"    ]. The age-adjusted prevalence of class 3 obesity (BMI &ge;40), sometimes referred to as severe obesity, was 6.3 percent in 2009 to 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the prevalence of obesity increased substantially in the period between the 1976 to 1980 and 1999 to 2000 NHANES, it did not significantly change in women over the 10 year period from 1999 to 2008 or in men over the five year period from 2003 to 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/11\">",
"     11",
"    </a>",
"    ]. Compared with 2003 to 2008, there was also no change in the prevalence of obesity in 2009 to 2010 (35.5 and 35.8 percent among adult men and women, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Canada",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Canada, fewer than 10 percent of people were obese in all nine provinces in 1985, but by 1990 only three provinces had fewer than 10 percent obese people, and by 1994 no provinces were still in this low percentage category and five had obesity rates between 15 and 19 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/12\">",
"     12",
"    </a>",
"    ]. Between 2007 and 2009, more than 27 percent of men and 23 percent of women were obese, a steady and distressing increase [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/13\">",
"     13",
"    </a>",
"    ]. These data and those from other countries are indicative of a major international epidemic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Worldwide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mean body mass index is increasing worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Despite the wide range, all data suggest that most populations have increased the percentage who are overweight over the past 20 years. Reported prevalence rates of obesity include 11 percent of men and 10 percent of women in Belgium (2002 to 2004), 23 percent of men and women in the UK (2009), 24 percent of men and 34 percent of women in Mexico (2006), 9 percent of men and 27 percent of women in South Africa (2003), and 8 percent of men and 13 percent of women in Pakistan (1994) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/13,16\">",
"     13,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appears to be a changing perception of obesity. This was illustrated in a population survey study in which fewer overweight and obese individuals defined themselves as overweight in 2007 when compared to 1999, despite a significant increase in the prevalence of obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of obesity has also increased among children and adolescents in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LIFETIME RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lifetime risk of developing overweight in the United States is significant. Using the data from the Framingham Heart Study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/18\">",
"     18",
"    </a>",
"    ], the calculated four-year risk of becoming overweight (BMI &gt;25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    for men and women at ages 30, 40, and 50 who had a normal BMI at each age was 14 to 19 percent in women and 26 to 30 percent in men. The four-year risk for developing a BMI &gt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    if BMI was normal at baseline was 5 to 7 percent for women and 7 to 9 percent for men. Over the longer 30-year interval, the risks were similar in men and women, and varied somewhat with age, being lower if you were under 50 years of age. The 30-year risk was one in two (50 percent) of developing overweight (BMI &gt;25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    was one in four (25 percent) of developing a BMI &gt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    and 1 in 10 (10 percent) of developing a BMI &gt;35",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and the long-term (10 to 30 year) risk of becoming overweight [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF WEIGHT LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical rationale for weight loss in obese subjects is that obesity is associated with a significant increase in mortality (",
"    <a class=\"graphic graphic_figure graphicRef73156 \" href=\"UTD.htm?7/2/7200\">",
"     figure 1",
"    </a>",
"    ) and many health risks including type 2 diabetes mellitus, hypertension, dyslipidemia, and coronary heart disease. These risks are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Benefits of weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life insurance reports were the first to suggest that reducing body weight lowers morbidity and mortality. This notion has subsequently been supported in other studies that are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link\">",
"     \"Drug therapy of obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link\">",
"     \"Behavioral strategies in the treatment of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In spite of the known risks of obesity and the health benefits of weight loss, clinicians are diagnosing obesity and recommending therapy in only a minority of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=see_link&amp;anchor=H4#H4\">",
"     \"Screening for and clinical evaluation of obesity in adults\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Maintenance of weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Achieving and maintaining weight loss is made difficult by the reduction in energy expenditure that is induced by weight loss. In one study, as an example, maintenance of body weight at 10 percent below the baseline weight in obese subjects was associated with an 8",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    decrease in energy expenditure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recidivism, which is regaining of lost weight, is a common problem in treating obesity. Some reports suggest that subjects who lose weight during any treatment program may not maintain the weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/4\">",
"     4",
"    </a>",
"    ]. A number of strategies to help maintain weight loss are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link&amp;anchor=H20#H20\">",
"     \"Behavioral strategies in the treatment of obesity\", section on 'Maintenance of weight loss'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link&amp;anchor=H18#H18\">",
"     \"Dietary therapy for obesity\", section on 'Role of dietary counseling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Characteristics of those who are likely to succeed include a weight loss of more than 2 kg in four weeks, frequent and regular attendance at a weight loss program, and the subject's belief that his or her weight can be controlled. Behavioral interventions may also help individuals maintain their weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link\">",
"     \"Behavioral strategies in the treatment of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exercise consistently stands out as an important factor in maintaining weight loss after any weight reduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=see_link&amp;anchor=H10#H10\">",
"     \"Role of physical activity and exercise in obese adults\", section on 'Maintenance of weight loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Risks of weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have suggested that weight loss may be associated with an increased risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/20\">",
"     20",
"    </a>",
"    ]. However, these studies could not distinguish intentional from unintentional weight loss. When intentional weight loss was distinguished from unintentional weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], intentional weight reduced mortality, whereas unintentional weight was associated with increased risk of mortality.",
"   </p>",
"   <p>",
"    Weight loss may increase the likelihood of cholelithiasis because the flux of cholesterol through the biliary system increases. Diets with moderate amounts of fat that trigger gallbladder contraction may reduce this risk. Similarly, therapy with a bile acid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    ) may be advisable in selected subjects, such as those who are losing weight rapidly (&gt;1 to 1.5",
"    <span class=\"nowrap\">",
"     kg/week).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     APPROACH TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than two-thirds of adults in the United States are either trying to lose weight or to maintain their weight [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/23\">",
"     23",
"    </a>",
"    ]. However, only 20 percent are both eating fewer calories and engaging in at least 150 minutes of physical activity during leisure time each week. Thus, clinicians can play an important role in educating people regarding the need for and the optimal strategies for losing weight. For initial weight loss, treatment should be aimed at decreasing food intake and, when possible, increasing energy expenditure. The former may be accomplished by dieting, with or without the addition of anti-obesity drugs.",
"   </p>",
"   <p>",
"    All treatments of obesity entail some risk. Several groups including the Institute of Medicine, The National Heart, Lung and Blood Institute in collaboration with the North American Association for the Study of Obesity, have provided guidelines to help in making risk-benefit evaluations and deciding on therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/4\">",
"     4",
"    </a>",
"    ]. The initial approach to the treatment of overweight or obese subjects must consider the following questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What are the risks of treatment?",
"     </li>",
"     <li>",
"      Is treatment appropriate?",
"     </li>",
"     <li>",
"      What is the most appropriate treatment regimen?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     What are the risks of treatment?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatments for obesity can be divided according to the risk of side effects. Most of the currently available drugs have minor side effects that diminish with treatment; however, a few serious side effects have been identified that should preclude short-term use in subjects who wish to lose small amounts of weight (the majority of overweight people). Even with potentially dangerous drugs, chronic treatment may be needed when the magnitude of the obesity carries larger risks, eg, a BMI above 30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    or between 27 and 30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    with complicating factors such as diabetes mellitus or hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link\">",
"     \"Drug therapy of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Is treatment appropriate?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of therapy is to prevent the complications of obesity noted above. Both overall fatness and central adiposity should be assessed. The BMI is the most practical way to evaluate the overall degree of excess weight and the waist circumference is the most practical measure of central adiposity. BMI is calculated as follows:",
"   </p>",
"   <p>",
"    &nbsp;BMI &nbsp; = &nbsp; body weight (in kg) &nbsp;&divide; &nbsp;square of stature (height squared, in meters)",
"   </p>",
"   <p>",
"    The BMI can be estimated from a table or a calculator (",
"    <a class=\"graphic graphic_table graphicRef63600 graphicRef74762 \" href=\"UTD.htm?28/43/29361\">",
"     table 2A-B",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). BMI is correlated with body fat and is relatively unaffected by height. Overweight and obesity are defined as a BMI between 25 and 29.9",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and &ge;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    respectively.",
"   </p>",
"   <p>",
"    Waist circumference is measured with a metal or plastic, nondistensible tape measure, placed around the abdomen at the umbilicus parallel to the floor with the patient standing (",
"    <a class=\"graphic graphic_figure graphicRef77584 \" href=\"UTD.htm?14/15/14577\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When estimating the cardiovascular risk associated with obesity from the BMI, both regional fat distribution and comorbid conditions should be taken into account. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=see_link\">",
"     \"Screening for and clinical evaluation of obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A BMI of 20 to 25",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      is associated with little or no increased risk unless visceral fat is high, or the subject has gained more than 10 kg since age 18 years.",
"     </li>",
"     <li>",
"      Subjects with a BMI of 25 to 30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      may be described as having low risk, while those with a BMI of 30 to 35",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      are at moderate risk.",
"     </li>",
"     <li>",
"      Subjects with a BMI of 35 to 40",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      are at high risk, and those with a BMI above 40",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      are at very high risk from their obesity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Central adiposity",
"    </span>",
"    &nbsp;&mdash;&nbsp;At any given level of BMI, the risk to health is increased by more abdominal fat, dyslipidemia, hypertension, age less than 40 years, male sex, and a strong family history of diabetes, hypertension, or heart disease. With these measures, the presence of the Metabolic Syndrome can be diagnosed. Its presence suggests increased risk for diabetes and heart disease.",
"   </p>",
"   <p>",
"    Subjects in the highest risk categories should receive the most aggressive treatment.",
"   </p>",
"   <p>",
"    Some subjects may wish to lose weight, even if they are not \"overweight.\" For this group, exercise is the first recommendation. In addition, behavior modification techniques and a diet may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     What is the most appropriate treatment?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatments for obesity either decrease energy intake or increase energy expenditure. Those that decrease energy intake have a greater potential for causing weight loss than those that increase energy expenditure through exercise.",
"   </p>",
"   <p>",
"    All of our nutrient energy comes from food and beverages; thus, we can potentially reduce nutrient intake to zero (starvation). In contrast, energy expenditure has a minimum level associated with the energy required to maintain body temperature, repair tissues, and maintain function of the heart and other organs. Simply staying in bed reduces energy expenditure to approximately 0.8",
"    <span class=\"nowrap\">",
"     kcal/min",
"    </span>",
"    (1150",
"    <span class=\"nowrap\">",
"     kcal/day)",
"    </span>",
"    for a normal-weight adult. High levels of physical activity can increase energy expenditure four- to eightfold.",
"   </p>",
"   <p>",
"    Thus, for initial weight loss, treatment should be aimed at decreasing food intake and, when possible, increasing energy expenditure. The former may be accomplished by dieting, with or without the addition of anti-obesity drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Behavior modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavior modification or behavior therapy is one cornerstone in the treatment for obesity. These concepts are usually included in programs conducted by psychologists or other trained personnel as well as many self-help groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link\">",
"     \"Behavioral strategies in the treatment of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Dietary therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 22 to 25",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    is required to maintain one kilogram of body weight in a normal adult. Thus, the expected or calculated energy expenditure for a woman weighing 100 kg is approximately 2200 to 2500",
"    <span class=\"nowrap\">",
"     kcal/day.",
"    </span>",
"    The variability of &plusmn; 20 percent could make energy needs as high as 2620 to 3000",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    and as low as 1860 to 2000",
"    <span class=\"nowrap\">",
"     kcal/day.",
"    </span>",
"   </p>",
"   <p>",
"    No",
"    adult who has been studied in a metabolic chamber has needed fewer than 1000",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    for weight maintenance. Thus, even subjects who claim to be \"metabolically resistant\" to weight loss should lose weight if they comply with a diet of 800 to 1200",
"    <span class=\"nowrap\">",
"     kcal/day.",
"    </span>",
"    If subjects claim to eat less than 1200",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    and yet do not lose weight one can conclude they are recording intake erroneously and suggest that they reduce by half what they claim to eat. More severe caloric restriction might be expected to induce weight loss more quickly, but a comparison with 400 versus 800",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    diet formulas showed no difference in weight loss. We thus recommend diets with &gt;800",
"    <span class=\"nowrap\">",
"     kcal/day.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link&amp;anchor=H13#H13\">",
"     \"Dietary therapy for obesity\", section on 'Very low-calorie diets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The selection of a diet depends upon the subjects' preferences. As with any treatment recommendation, the patient's expectations should be assessed. Many patients and some clinicians have unrealistic expectations of the rate that people can lose weight. A loss of 5 percent or more by six months is realistic, but more than that is often seen. If weight loss is associated with improvement in associated risk factors and is maintained, then therapy has been \"successful\" with today's treatment programs.",
"   </p>",
"   <p>",
"    If weight loss is less than 5 percent in the first six months, something else should be tried. One option would be to use portion-controlled foods such as frozen dinners or lunch entrees, and shakes or food bars that have a defined number of calories [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/24\">",
"     24",
"    </a>",
"    ]. Weight loss of more than 5 percent of initial body weight is satisfactory; less than one-half of subjects will lose 10 percent or more of initial body weight before reaching a plateau.",
"   </p>",
"   <p>",
"    The addition of dietary counseling may facilitate weight loss, particularly during the first year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link\">",
"     \"Dietary therapy for obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing energy expenditure through physical activity has particular attractiveness in efforts at long-term maintenance of a lower body weight. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=see_link\">",
"     \"Role of physical activity and exercise in obese adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug therapy may be a helpful component of the treatment regimen for obese subjects; it can be considered for those with a BMI greater than 30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    or a BMI of 27 to 29.9",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    if they have comorbid conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. The role of drug therapy has been questioned because of concerns about efficacy, the potential for abuse, and side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link\">",
"     \"Drug therapy of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Liposuction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of fat by aspiration after injection of physiologic saline has been used to remove and contour subcutaneous fat. While this can result in a significant reduction in fat mass and weight, it does not appear to improve insulin sensitivity or risk factors for coronary heart disease. This was illustrated in a study of 15 obese women (eight with normal glucose tolerance and seven with type 2 diabetes) who underwent metabolic evaluation before and 10 to 12 weeks after large-volume abdominal liposuction with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liposuction decreased the volume of subcutaneous abdominal adipose tissue by 44 percent (9 kg) in the women with normal glucose tolerance and 28 (10.5 kg) percent in those with diabetes.",
"     </li>",
"     <li>",
"      Although waist circumference and plasma leptin concentrations were significantly decreased, no improvements in insulin sensitivity of muscle, liver, or adipose tissue were seen in either group (assessed by the stimulation of glucose disposal, the suppression of glucose production, and the suppression of lipolysis, using euglycemic hyperinsulinemic clamps and isotope-tracer infusions).",
"     </li>",
"     <li>",
"      Liposuction did not alter plasma concentrations of C-reactive protein, interleukin-6, tumor necrosis factor alpha, or adiponectin and there were no significant improvements in other risk factors for coronary heart disease including blood pressure, plasma glucose, lipid, or insulin concentrations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"       \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, removal of large volumes of subcutaneous abdominal adipose tissue with liposuction does not improve insulin sensitivity or risk factors for coronary heart disease in obese women with or without type 2 diabetes, suggesting that the negative energy balance induced by decreased nutritional intake",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    removal of visceral fat are necessary for achieving the metabolic benefits of weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link\">",
"     \"Dietary therapy for obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several surgical approaches (collectively referred to as \"bariatric surgery\") have been used to treat severe obesity that has not responded to the above approaches. Indications for the surgical management of morbid obesity were outlined by the National Institutes of Health (NIH) Consensus Development Panel in 1991 and continue to represent generally-accepted guidelines. Potentially eligible patients should:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Be well-informed and motivated",
"     </li>",
"     <li>",
"      Have a BMI &ge;40",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Have acceptable risk for surgery",
"     </li>",
"     <li>",
"      Have failed previous non-surgical weight loss",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The NIH also suggested that adults with a BMI &ge;35",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    who have serious comorbidities such as severe diabetes, sleep apnea, or joint disease may also be candidates.",
"   </p>",
"   <p>",
"    In a meta-analysis, a majority of patients undergoing bariatric surgery for obesity experienced complete resolution or improvement in diabetes, hypertension, hyperlipidemia, and obstructive sleep apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, a randomized, clinical trial found that laparoscopic adjustable gastric banding was significantly more effective than medical management at two years follow-up in patients with mild to moderate obesity (BMI 30 to 35",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Complementary therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of complementary therapies, in particular, ephedra and other dietary supplements, have been used for weight loss. These are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link&amp;anchor=H33#H33\">",
"     \"Drug therapy of obesity\", section on 'Dietary supplements'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acupuncture has also been studied for the treatment of obesity. While most studies have been uncontrolled trials, results from some, but not all controlled trials have shown modest benefit of acupuncture for weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13016/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, the majority of these controlled trials are small, of short duration, and do not include adequate placebo controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=see_link\">",
"       \"Patient information: Weight loss treatments (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"       \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The medical rationale for weight loss in obese subjects is that obesity is associated with a significant increase in mortality (",
"      <a class=\"graphic graphic_figure graphicRef73156 \" href=\"UTD.htm?7/2/7200\">",
"       figure 1",
"      </a>",
"      ) and many health risks including type 2 diabetes mellitus, hypertension, dyslipidemia, and coronary heart disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"       \"Health hazards associated with obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Selection of treatment for overweight subjects is based upon an initial risk assessment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=see_link\">",
"       \"Screening for and clinical evaluation of obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All patients who are overweight (BMI &ge;25",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      or obese (BMI &ge;30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      should receive counseling on diet, lifestyle, and goals for weight management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link\">",
"       \"Behavioral strategies in the treatment of obesity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=see_link\">",
"       \"Role of physical activity and exercise in obese adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link\">",
"       \"Dietary therapy for obesity\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For individuals with a BMI &gt;30",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      or a BMI of 27 to 29.9",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      with comorbidities, who have failed to achieve weight loss goals through diet and exercise alone, we suggest pharmacologic therapy be added to diet and exercise (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Detailed recommendations for pharmacotherapy are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link&amp;anchor=H3#H3\">",
"       \"Drug therapy of obesity\", section on 'Our approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with BMI &ge;40",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      who have failed to lose weight with diet, exercise, and drug therapy, we suggest bariatric surgery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Individuals with BMI &gt;35",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      with obesity-related comorbidities (hypertension, impaired glucose tolerance, diabetes mellitus, dyslipidemia, sleep apnea) who have failed diet, exercise, and drug therapy are also potential surgical candidates, assuming that the anticipated benefits outweigh the costs, risks, and side effects of the procedure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"       \"Surgical management of severe obesity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/1\">",
"      American Gastroenterological Association. American Gastroenterological Association medical position statement on Obesity. Gastroenterology 2002; 123:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/2\">",
"      Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology 2002; 123:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/3\">",
"      Snow V, Barry P, Fitterman N, et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 142:525.",
"     </a>",
"    </li>",
"    <li>",
"     The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. file://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf (Accessed on January 24, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/5\">",
"      Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/6\">",
"      Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289:76.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Vital Signs: State-Specific Obesity Prevalence Among Adults --- United States, 2009 file://www.cdc.gov/mmwr/preview/mmwrhtml/mm59e0803a1.htm (Accessed on February 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/8\">",
"      Finkelstein EA, Fiebelkorn IC, Wang G. State-level estimates of annual medical expenditures attributable to obesity. Obes Res 2004; 12:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/9\">",
"      Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep 2004; 53:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/11\">",
"      Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/12\">",
"      Katzmarzyk PT. The Canadian obesity epidemic, 1985-1998. CMAJ 2002; 166:1039.",
"     </a>",
"    </li>",
"    <li>",
"     International Association for the Study of Obesity. Available at: file://www.iaso.org/ (Accessed on September 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/14\">",
"      Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9&middot;1 million participants. Lancet 2011; 377:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/15\">",
"      Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011; 378:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/16\">",
"      Jafar TH, Chaturvedi N, Pappas G. Prevalence of overweight and obesity and their association with hypertension and diabetes mellitus in an Indo-Asian population. CMAJ 2006; 175:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/17\">",
"      Johnson F, Cooke L, Croker H, Wardle J. Changing perceptions of weight in Great Britain: comparison of two population surveys. BMJ 2008; 337:a494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/18\">",
"      Vasan RS, Pencina MJ, Cobain M, et al. Estimated risks for developing obesity in the Framingham Heart Study. Ann Intern Med 2005; 143:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/19\">",
"      Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/20\">",
"      Pamuk ER, Williamson DF, Serdula MK, et al. Weight loss and subsequent death in a cohort of U.S. adults. Ann Intern Med 1993; 119:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/21\">",
"      Sj&ouml;str&ouml;m L, Narbro K, Sj&ouml;str&ouml;m CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/22\">",
"      Gregg EW, Gerzoff RB, Thompson TJ, Williamson DF. Intentional weight loss and death in overweight and obese U.S. adults 35 years of age and older. Ann Intern Med 2003; 138:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/23\">",
"      Maynard LM, Serdula MK, Galuska DA, et al. Secular trends in desired weight of adults. Int J Obes (Lond) 2006; 30:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/24\">",
"      Flechtner-Mors M, Ditschuneit HH, Johnson TD, et al. Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes Res 2000; 8:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/25\">",
"      Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007; 59:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/26\">",
"      Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/27\">",
"      Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/28\">",
"      Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/29\">",
"      Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/30\">",
"      O'Brien PE, Dixon JB, Laurie C, et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med 2006; 144:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/31\">",
"      Lacey JM, Tershakovec AM, Foster GD. Acupuncture for the treatment of obesity: a review of the evidence. Int J Obes Relat Metab Disord 2003; 27:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13016/abstract/32\">",
"      Hsu CH, Hwang KC, Chao CL, et al. Effects of electroacupuncture in reducing weight and waist circumference in obese women: a randomized crossover trial. Int J Obes (Lond) 2005; 29:1379.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5371 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-D201336892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13016=[""].join("\n");
var outline_f12_45_13016=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Behavioral risk factor (telephone) survey",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - National health and nutrition examination survey (NHANES)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Canada",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Worldwide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LIFETIME RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IMPORTANCE OF WEIGHT LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Benefits of weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Maintenance of weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Risks of weight loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      What are the risks of treatment?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Is treatment appropriate?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Central adiposity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      What is the most appropriate treatment?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Behavior modification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Dietary therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Drug therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Liposuction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Complementary therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/5371\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/5371|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/2/7200\" title=\"figure 1\">",
"      Obesity all-cause mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/15/14577\" title=\"figure 2\">",
"      Waist circumference measure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/5371|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/48/34571\" title=\"table 1\">",
"      Prevalence overwt discrepancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/22/367\" title=\"table 2A\">",
"      Determining BMI A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/9/157\" title=\"table 2B\">",
"      Determining BMI B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=related_link\">",
"      Behavioral strategies in the treatment of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=related_link\">",
"      Definition; epidemiology; and etiology of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=related_link\">",
"      Drug therapy of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=related_link\">",
"      Role of physical activity and exercise in obese adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_45_13017="Mestranol and norethindrone: Drug information";
var content_f12_45_13017=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mestranol and norethindrone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/47/3830?source=see_link\">",
"    see \"Mestranol and norethindrone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Necon&reg; 1/50;",
"     </li>",
"     <li>",
"      Norinyl&reg; 1+50",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ortho-Novum&reg; 1/50",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F193682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contraceptive;",
"     </li>",
"     <li>",
"      Estrogen and Progestin Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F193666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females: Contraception: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Schedule 1 (Sunday starter):",
"     </b>",
"     Dose begins on first Sunday after onset of menstruation; if the menstrual period starts on Sunday, take first tablet that very same day.",
"     <b>",
"      With a Sunday start, an additional method of contraception should be used until after the first 7 days of consecutive administration.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      For 21-tablet package:",
"     </i>",
"     Dosage is 1 tablet daily for 21 consecutive days, followed by 7 days off of the medication; a new course begins on the 8th day after the last tablet is taken.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      For 28-tablet package:",
"     </i>",
"     Dosage is 1 tablet daily without interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Schedule 2 (Day 1 starter):",
"     </b>",
"     Dose starts on first day of menstrual cycle taking 1 tablet daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      For 21-tablet package:",
"     </i>",
"     Dosage is 1 tablet daily for 21 consecutive days, followed by 7 days off of the medication; a new course begins on the 8th day after the last tablet is taken.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      For 28-tablet package:",
"     </i>",
"     Dosage is 1 tablet daily without interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If all doses have been taken on schedule and one menstrual period is missed, continue dosing cycle. If two consecutive menstrual periods are missed, pregnancy test is required before new dosing cycle is started.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Missed doses: Monophasic formulations",
"     </b>",
"     (refer to package insert for complete information):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      One dose missed:",
"     </i>",
"     Take as soon as remembered or take 2 tablets next day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Two consecutive doses missed in the first 2 weeks:",
"     </i>",
"     Take 2 tablets as soon as remembered or 2 tablets next 2 days.",
"     <b>",
"      An additional method of contraception should be used for 7 days after missed dose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Two consecutive doses missed in week 3 or three consecutive doses missed at any time:",
"     </i>",
"     <b>",
"      An additional method of contraception must be used for 7 days after a missed dose:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Continue dose of 1 tablet daily until Sunday, then discard the rest of the pack, and a new pack should be started that same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Schedule 2 (Day 1 starter): Current pack should be discarded, and a new pack should be started that same day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F193676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Female: Contraception: Oral: See adult dosing; not to be used prior to menarche.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F193667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific guidelines not available; use with caution and monitor blood pressure closely. Consider other forms of contraception.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F193668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F193645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, monophasic formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Necon&reg; 1/50: Norethindrone 1 mg and mestranol 0.05 mg [21 light blue tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norinyl&reg; 1+50: Norethindrone 1 mg and mestranol 0.05 mg [21 white tablets and 7 orange inactive tablets] (28s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F193630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F193647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time each day. Administer at bedtime to minimize occurrence of adverse effects. Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F193646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F193679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypermenorrhea (menorrhagia); pain associated with endometriosis; dysmenorrhea; dysfunctional uterine bleeding",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F193690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Norinyl&reg; may be confused with Nardil&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F193680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arterial thromboembolism, cerebral hemorrhage, cerebral thrombosis, edema, hypertension, mesenteric thrombosis, MI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, headache, migraine, nervousness, premenstrual syndrome, stroke",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, erythema multiforme, erythema nodosum, hirsutism, loss of scalp hair, melasma (may persist), rash (allergic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breakthrough bleeding, breast enlargement, breast secretion, breast tenderness, carbohydrate intolerance, lactation decreased (postpartum), glucose tolerance decreased, libido changes, menstrual flow changes, sex hormone-binding globulins (SHBG) increased, spotting, temporary infertility (following discontinuation), thyroid-binding globulin increased, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, appetite changes, bloating, cholestasis, colitis, gallbladder disease, jaundice, nausea, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Cervical erosion changes, cervical secretion changes, cystitis-like syndrome, vaginal candidiasis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Antithrombin III decreased, folate levels decreased, hemolytic uremic syndrome, norepinephrine induced platelet aggregability increased, porphyria, prothrombin increased; factors VII, VIII, IX, and X increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Benign liver tumors, Budd-Chiari syndrome, cholestatic jaundice, hepatic adenomas",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, change in corneal curvature (steepening), contact lens intolerance, optic neuritis, retinal thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Impaired renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hemorrhagic eruption",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F193650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast cancer or other estrogen- or progestin-dependent neoplasms (current or a history of), hepatic tumors or disease, pregnancy, undiagnosed abnormal uterine bleeding, cholestatic jaundice of pregnancy, jaundice with prior combination hormonal contraceptive use",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use is also contraindicated in women at high risk of arterial or venous thrombotic diseases including: Cerebrovascular disease, coronary artery disease, DVT or PE (current or history of).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F193634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: The use of combination hormonal contraceptives has been associated with a slight increase in frequency of breast cancer; however, studies are not consistent. Use is contraindicated in women with (or history of) breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestasis: Risk of cholestasis may be increased with previous cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Combination hormonal contraceptives may affect serum triglyceride and lipoprotein levels. Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: May increase the risk of thromboembolism; discontinue use of combination hormonal contraceptives if an arterial or venous thrombotic event occurs. Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal bleeding: Presentation of irregular, unresolving vaginal bleeding warrants further evaluation including endometrial sampling, if indicated, to rule out malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with risk factors for coronary artery disease (eg, hypertension, hypercholesterolemia, morbid obesity, diabetes, or women who smoke); may lead to increased risk of myocardial infarction. May have a dose-related risk of vascular disease and hypertension; women with hypertension should be encouraged to use a nonhormonal form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: May have a dose-related risk of gallbladder disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic adenomas: Extremely rare adenomas and focal nodular hyperplasia resulting in fatal intra-abdominal hemorrhage have been reported in association with long-term oral contraceptive use. Presentation of an abdominal mass, acute abdominal pain, or intra-abdominal bleeding warrants further evaluation to rule out source.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Combination hormonal contraceptives may be poorly metabolized in women with hepatic impairment. Discontinue if jaundice develops during therapy or if liver function becomes abnormal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use with caution in patients with a history of migraine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Women with renal disease should be encouraged to use a nonhormonal form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers:",
"     <b>",
"      [U.S. Boxed Warning]: The risk of cardiovascular side effects is increased in women who smoke cigarettes; risk increases with age (especially women &gt;35 years of age) and the number of cigarettes smoked; women who use combination hormonal contraceptives should be strongly advised not to smoke. Should not be used in patients &gt;35 years of age who smoke.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, should be discontinued at least 4 weeks prior to and for 2 weeks following elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV infection protection: Combination hormonal contraceptives do not protect against HIV infection or other sexually-transmitted diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Minimum effective dosage: The minimum dosage combination of estrogen/progestin that will effectively treat the individual patient should be used. New patients should be started on products containing &le;0.035 mg of estrogen per tablet.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F193677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F193639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use of a non-hormone-based contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Progestins). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Armodafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with armodafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Estrogens) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Progestins) may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Progestins). Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with norethindrone. Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Progestins). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Norethindrone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May decrease the serum concentration of Norethindrone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Oral Contraceptive (Progestins). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Estrogens). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least one month following the last fosaprepitant/aprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May increase the metabolism of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use an alternative, nonhormonal form of contraception, or use an alternative to griseofulvin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Contraceptives (Estrogens) may decrease the serum concentration of LamoTRIgine.  Management: Monitor for increased serum concentrations/effects of lamotrigine in patients in whom a hormonal contraceptive is discontinued/dose decreased (this includes during a pill-free week). A reduced dosage of lamotrigine may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May decrease the serum concentration of Contraceptives (Progestins). Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Estrogens). Mifepristone may increase the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Modafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with modafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Estrogens). Average AUC values were unchanged, but there was evidence of substantial patient-to-patient variability in response to this combination. Management: Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Progestins). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Contraceptives (Estrogens). Management: Use of an alternative, nonhormonal form of contraception during nafcillin therapy is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Progestins). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May decrease the serum concentration of Contraceptives (Progestins). Management: Patients should use an alternative, non-hormonal based form of contraception for the duration of concurrent perampanel.  Both oral and non-oral progestin-based contraceptives are likely to be impacted by this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: May decrease the serum concentration of Norethindrone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Estrogens) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Progestins) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Consider an alternative to St John's wort if possible.  If this combination is used, an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Progestins). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Contraceptives (Estrogens) may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: Contraceptives (Estrogens) may increase the serum concentration of TiZANidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Progestins). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Estrogens) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Estrogens) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Progestins) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F193659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: CNS effects of caffeine may be enhanced if oral contraceptives are used concurrently with caffeine. Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well; clinical implications are unclear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease the effectiveness of combination hormonal contraceptives by inducing hepatic enzymes. Avoid dong quai and black cohosh (have estrogen activity). Avoid saw palmetto, red clover, ginseng.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F193641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F193652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy should be ruled out prior to treatment and discontinued if pregnancy occurs. In general, the use of combination hormonal contraceptives when inadvertently taken early in pregnancy have not been associated with teratogenic effects. Hormonal contraceptives may be less effective in obese patients. An increase in oral contraceptive failure was noted in women with a BMI &gt;27.3 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Similar findings were noted in patients weighing &ge;90 kg (198 lb) using the contraceptive patch.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to increased risk of venous thromboembolism (VTE) postpartum, combination hormonal contraceptives should not be started in any woman &lt;21 days following delivery. Women without risk factors for VTE and who are not breast-feeding may start combination hormonal contraceptives during 21-42 days postpartum. After 42 days postpartum, restrictions for use are not related to postpartum status and should be based on other medical conditions (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F193671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F193653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Jaundice and breast enlargement in the nursing infant have been reported following the use of combination hormonal contraceptives. May decrease the quality and quantity of breast milk; a nonhormonal form of contraception is recommended (per manufacturer). The theoretical concerns about decreased milk production are greatest early in the postpartum period when milk production is being established. Postpartum risk status for VTE should be considered when initiating combination hormonal contraceptives after delivery. Combined hormonal contraceptives should not be started &lt;21 days postpartum due to increased risk of VTE. Risk of VTE is still elevated in breast-feeding women until ~42 days postpartum and is greater in women with additional risk factors. After 42 days postpartum, restrictions for use are not related to postpartum VTE risk and should be based on other medical conditions (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F193654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken at same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Necon 1/50 (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-50 mg-mcg (28): $29.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Norinyl 1+50 (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-50 mg-mcg (28): $81.31",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F193643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before starting therapy, a physical exam with reference to the breasts and pelvis are recommended, including a Papanicolaou smear. Exam may be deferred if appropriate; pregnancy should be ruled out prior to use. Monitor patient closely for loss of vision; sudden onset of proptosis, diplopia, or migraine; blood pressure; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glycemic control in patients with diabetes; or lipid profiles in patients being treated for hyperlipidemias. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F193655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Combiginor (UY);",
"     </li>",
"     <li>",
"      Norace (MX);",
"     </li>",
"     <li>",
"      Norinyl-1 (AU, BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Norinyl-1 28 (AU, ZA);",
"     </li>",
"     <li>",
"      Ortho-Novin (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ortho-Novum 1 50 (AE, AT, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F193633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination oral contraceptives inhibit ovulation via a negative feedback mechanism on the hypothalamus, which alters the normal pattern of gonadotropin secretion of a follicle-stimulating hormone (FSH) and luteinizing hormone by the anterior pituitary. The follicular phase FSH and midcycle surge of gonadotropins are inhibited. In addition, combination hormonal contraceptives produce alterations in the genital tract, including changes in the cervical mucus, rendering it unfavorable for sperm penetration even if ovulation occurs. Changes in the endometrium may also occur, producing an unfavorable environment for nidation. Combination hormonal contraceptive drugs may alter the tubal transport of the ova through the fallopian tubes. Progestational agents may also alter sperm fertility.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F193649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mestranol:",
"     </b>",
"     Metabolism: Hepatic via demethylation to ethinyl estradiol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Norethindrone:",
"     </b>",
"     See Norethindrone monograph for additional information.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/45/13017/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burkman R, Schlesselman JJ, and Zieman M, &ldquo;Safety Concerns and Health Benefits Associated With Oral Contraception,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2004, 190(4 Suppl):5-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(26):878-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/45/13017/abstract-text/21734635/pubmed\" id=\"21734635\" target=\"_blank\">",
"        21734635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/45/13017/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. Panel on Clinical Practices for Treatment of HIV Infection,&rdquo; August 13, 2001. Available at",
"      <a href=\"file://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL08132001007.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL08132001007.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holt VL, Scholes D, Wicklund KG, et al, &ldquo;Body Mass Index, Weight, and Oral Contraceptive Failure Risk,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 105(1):46-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/45/13017/abstract-text/15625141/pubmed\" id=\"15625141\" target=\"_blank\">",
"        15625141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orme ML, Back DJ, and Breckenridge AM, &ldquo;Clinical Pharmacokinetics of Oral Contraceptive Steroids,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1983, 8(2):95-136.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/45/13017/abstract-text/6342899/pubmed\" id=\"6342899\" target=\"_blank\">",
"        6342899",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shenfield GM and Griffin JM, &ldquo;Clinical Pharmacokinetics of Contraceptive Steroids. An Update,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1991, 20(1):15-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/45/13017/abstract-text/2029800/pubmed\" id=\"2029800\" target=\"_blank\">",
"        2029800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitruk-Ware R and Nath A, \"Metabolic Effects of Contraceptive Steroids,\"",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2011, 12(2):63-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/45/13017/abstract-text/21538049/pubmed\" id=\"21538049\" target=\"_blank\">",
"        21538049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/45/13017/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9618 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-655B890CD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13017=[""].join("\n");
var outline_f12_45_13017=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709033\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193662\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193663\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193682\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193666\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193676\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193667\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193668\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193645\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193630\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193647\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193646\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193679\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193690\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193680\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193650\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193634\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193677\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193639\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193659\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193641\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193652\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193671\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193653\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193654\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524683\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193643\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193655\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193633\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193649\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9618\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9618|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/47/3830?source=related_link\">",
"      Mestranol and norethindrone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_45_13018="Clinical manifestations, diagnosis, and natural history of Wilson disease";
var content_f12_45_13018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and natural history of Wilson disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/45/13018/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13018/contributors\">",
"     Michael L Schilsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/45/13018/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13018/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13018/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13018/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/45/13018/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/45/13018/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/45/13018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H69501357\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wilson disease (hepatolenticular degeneration) is due to a genetic abnormality inherited in an autosomal recessive manner that leads to impairment of cellular copper transport. It is found worldwide, with a prevalence of approximately 1 case in 30,000 live births in most populations. Impaired biliary copper excretion leads to accumulation of copper in several organs, most notably the liver, brain, and cornea. Over time, the liver is progressively damaged and eventually becomes cirrhotic. In addition, patients may develop neurologic complications, which can be severe.",
"   </p>",
"   <p>",
"    This topic will review the clinical manifestations, diagnosis, and natural history of Wilson disease. The epidemiology, pathogenesis, and treatment of Wilson disease, as well as a detailed discussion of the individual tests used to diagnose Wilson disease, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=see_link\">",
"     \"Epidemiology and pathogenesis of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link\">",
"     \"Tests used in the diagnosis of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=see_link\">",
"     \"Treatment of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69500435\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of Wilson disease are predominantly hepatic, neurologic, and psychiatric, with many patients having a combination of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/1\">",
"     1",
"    </a>",
"    ]. Hemolysis is also a common finding in patients with Wilson disease, particularly among patients with acute liver failure.",
"   </p>",
"   <p>",
"    Patients may present with a wide variety of symptoms (especially those with neurologic symptoms) and there is no \"typical\" clinical presentation for Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/2\">",
"     2",
"    </a>",
"    ]. Even within a given family, patients often present with different symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/3\">",
"     3",
"    </a>",
"    ]. There is wide variability in the reported rates of the different clinical manifestations seen at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/2,4-14\">",
"     2,4-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Liver disease: 18 to 84 percent of patients",
"     </li>",
"     <li>",
"      Neurologic symptoms: 18 to 73 percent of patients",
"     </li>",
"     <li>",
"      Psychiatric symptoms: 10 to 100 percent of patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The wide variability in the estimates may in part be attributable to ascertainment bias based upon the clinical specialty to which the patient was referred (eg, neurologists are likely see patients with neurologic symptoms and thus report that the majority of patients with Wilson disease have neurologic involvement).",
"   </p>",
"   <p>",
"    Regardless of the clinical manifestations present initially, patients often develop other clinical manifestations as the disease progresses (eg, patients who present with liver disease may subsequently develop neurologic symptoms).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57950462\">",
"    <span class=\"h2\">",
"     Age at symptom onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Copper deposition begins at birth in patients with Wilson disease and gradually produces clinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/15\">",
"     15",
"    </a>",
"    ]. The majority of patients with Wilson disease are diagnosed between the ages of 5 and 35 years (mean age of 12 to 23 years), though it has been diagnosed in younger patients and in patients in their 70s [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/1,12,16-21\">",
"     1,12,16-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=see_link\">",
"     \"Epidemiology and pathogenesis of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children most often initially present with liver disease, at an average age of 9 to 13 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/16,22\">",
"     16,22",
"    </a>",
"    ], with Wilson disease accounting for 8 to 10 percent of chronic active hepatitis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/23\">",
"     23",
"    </a>",
"    ]. Children may be diagnosed through screening because of an affected sibling. They also may be diagnosed when being evaluated for asymptomatic liver enzyme elevations or for symptoms and signs of liver disease. In other patients, liver disease may progress silently until adolescence, when complications of cirrhosis or acute liver failure may develop. In some cases, neurologic or psychiatric manifestations may precede overt liver disease.",
"   </p>",
"   <p>",
"    Unlike children, who are more likely to present with hepatic manifestations, older patients (mid-teens and older) are more likely to present with neurologic manifestations. The mean age at presentation for patients with neurologic symptoms ranges between 15 and 21 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/2,16,24,25\">",
"     2,16,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The variability in the age of onset of Wilson disease probably reflects differences in mutations and penetrance, as well as nongenetic factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and pathogenesis of Wilson disease\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69500442\">",
"    <span class=\"h2\">",
"     Hepatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the initial site of copper accumulation in patients with Wilson disease, and there are several different clinical manifestations of hepatic copper accumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Hepatic manifestations include acute liver failure with a Coombs-negative hemolytic anemia, acute hepatitis, chronic hepatitis, cirrhosis, steatosis, and asymptomatic liver biochemical abnormalities. Regardless of presenting symptoms, some degree of liver disease is usually present at the time Wilson disease is diagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The signs, symptoms, laboratory findings, and imaging findings in patients with hepatic Wilson disease vary with the degree of liver damage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/1,2,29\">",
"     1,2,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signs and symptoms of hepatic Wilson disease may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymptomatic (seen with chronic hepatitis, compensated cirrhosis)",
"     </li>",
"     <li>",
"      Abdominal pain (acute hepatitis, acute liver failure)",
"     </li>",
"     <li>",
"      Jaundice (acute hepatitis, acute liver failure, cirrhosis)",
"     </li>",
"     <li>",
"      Hepatomegaly (acute and chronic hepatitis, acute liver failure)",
"     </li>",
"     <li>",
"      Splenomegaly (cirrhosis)",
"     </li>",
"     <li>",
"      Ascites (cirrhosis)",
"     </li>",
"     <li>",
"      Upper gastrointestinal bleeding (cirrhosis with varices or portal hypertensive gastropathy)",
"     </li>",
"     <li>",
"      Peripheral stigmata of chronic liver disease (cirrhosis)",
"     </li>",
"     <li>",
"      Mental status changes (acute liver failure, cirrhosis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory test findings may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevated aminotransferases (seen with all forms of liver involvement)",
"     </li>",
"     <li>",
"      Thrombocytopenia (cirrhosis)",
"     </li>",
"     <li>",
"      Coagulopathy (cirrhosis or acute liver failure)",
"     </li>",
"     <li>",
"      Coombs-negative hemolytic anemia (often seen in conjunction with acute liver failure)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abdominal imaging may show:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hepatic steatosis (chronic hepatitis)",
"     </li>",
"     <li>",
"      A small, nodular liver (cirrhosis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequencies of various findings have been reported in several series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/1,12,16,22,30-33\">",
"     1,12,16,22,30-33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute liver failure: 17 percent",
"     </li>",
"     <li>",
"      Hepatomegaly",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      splenomegaly: 15 to 49 percent",
"     </li>",
"     <li>",
"      Jaundice, anorexia, and vomiting: 14 to 44 percent",
"     </li>",
"     <li>",
"      Fatty liver: 13 percent",
"     </li>",
"     <li>",
"      Ascites",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      edema: 5 to 50 percent",
"     </li>",
"     <li>",
"      Variceal hemorrhage: 3 to 10 percent",
"     </li>",
"     <li>",
"      Hemorrhagic diathesis: 3 to 8 percent",
"     </li>",
"     <li>",
"      Hemolysis: 1 to 20 percent",
"     </li>",
"     <li>",
"      No symptoms: 5 to 23 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69501971\">",
"    <span class=\"h3\">",
"     Acute hepatitis and acute liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Wilson disease may develop acute hepatitis that is indistinguishable from acute viral hepatitis, with elevated aminotransferase levels, jaundice, and abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/1\">",
"     1",
"    </a>",
"    ]. In some patients, the symptoms will resolve spontaneously (though Wilson disease is still present and requires treatment), whereas others may rapidly deteriorate and develop acute liver failure. Acute liver failure refers to the rapid development of severe acute liver injury with impaired synthetic function and encephalopathy in a person who previously had a normal liver or had well-compensated liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link&amp;anchor=H1#H1\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with acute liver failure due to Wilson disease are often children or young adults, and in most cases, underlying cirrhosis is present. Wilson disease accounts for 6 to 12 percent of patients with acute liver failure who are referred for emergency transplantation. The female to male ratio of patients with acute liver failure due to Wilson disease is 2:1 to 4:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/1,34\">",
"     1,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Features seen in patients with acute liver failure due to Wilson disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Coombs-negative hemolytic anemia. This is usually present in patients with acute liver failure due to Wilson disease and results from the release of copper ions into the circulation due to hepatocellular necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/27,35-38\">",
"       27,35-38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=see_link&amp;anchor=H20#H20\">",
"       \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\", section on 'Copper'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum aminotransferases that are typically less than 2000 int.",
"      <span class=\"nowrap\">",
"       unit/L.",
"      </span>",
"      The ratio of the AST to ALT is often &gt;1.",
"     </li>",
"     <li>",
"      The alkaline phosphatase may be normal or markedly subnormal (&lt;40 int.",
"      <span class=\"nowrap\">",
"       unit/L),",
"      </span>",
"      and the ratio of the alkaline phosphatase (int.",
"      <span class=\"nowrap\">",
"       unit/L)",
"      </span>",
"      to total bilirubin",
"      <span class=\"nowrap\">",
"       (mg/dL)",
"      </span>",
"      is typically less &lt;2.",
"     </li>",
"     <li>",
"      Low uric acid levels.",
"     </li>",
"     <li>",
"      A coagulopathy that is unresponsive to vitamin K.",
"     </li>",
"     <li>",
"      Rapidly progressive renal failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69501979\">",
"    <span class=\"h3\">",
"     Chronic hepatitis and cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic hepatitis due to Wilson disease are often asymptomatic from their liver disease. Such patients are typically diagnosed through family screening, after being found to have abnormal liver tests, or after presenting with neurologic or psychiatric manifestations of Wilson disease. In addition, Wilson disease often results in hepatic steatosis and may be diagnosed in a patient being evaluated for nonalcoholic fatty liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the disease progresses, patients develop hepatic fibrosis and may present with evidence of compensated or decompensated cirrhosis, such as ascites, thrombocytopenia, splenomegaly, palmar erythema, and variceal hemorrhage. In addition, patients may come to attention when abdominal imaging obtained for other reasons reveals evidence of cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cirrhosis is present at the time of diagnosis of Wilson disease in approximately 35 to 45 percent of patients overall [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/39-41\">",
"     39-41",
"    </a>",
"    ], including those presenting with neuropsychiatric symptoms or who are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/25,34,40,42\">",
"     25,34,40,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series that included 14 patients over the age of 40 years who presented with neurologic symptoms and underwent liver biopsy, significant fibrosis was present in 10 (71 percent; 9 with cirrhosis and 1 with advanced fibrosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series with 34 patients with neurologic Wilson disease, 14 (41 percent) were found to have cirrhosis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study that included 18 asymptomatic patients detected through screening because of an affected sibling, 2 (11 percent) had cirrhosis at the time of diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69501597\">",
"    <span class=\"h2\">",
"     Neurologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported neurologic manifestations of Wilson disease are broad, and diagnosing neurologic Wilson disease can be challenging because patients present in a myriad of ways. Neurologic symptoms may be very subtle or may be rapidly progressive, leading to severe disability over the course of months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/1\">",
"     1",
"    </a>",
"    ]. In patients with known cirrhosis, neurologic manifestations may be mistaken for hepatic encephalopathy.",
"   </p>",
"   <p>",
"    The majority of patients with neurologic Wilson disease fall into one of several categories: dysarthric, dystonic, tremulous, pseudosclerotic (tremor with or without dysarthria), or parkinsonian [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/2\">",
"     2",
"    </a>",
"    ]. Initially, only one symptom may be present (often unilaterally), but as the disease progresses, complex combinations of neurologic signs and symptoms may develop.",
"   </p>",
"   <p>",
"    Some of the more common neurologic manifestations include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dysarthria &ndash; 85 to 97 percent of patients with neurologic Wilson disease",
"     </li>",
"     <li>",
"      Gait",
"      <span class=\"nowrap\">",
"       abnormalities/ataxia",
"      </span>",
"      &ndash; 30 to 75 percent",
"     </li>",
"     <li>",
"      Dystonia &ndash; 11 to 69 percent",
"     </li>",
"     <li>",
"      Tremor &ndash; 22 to 55 percent",
"     </li>",
"     <li>",
"      Parkinsonism &ndash; 19 to 62 percent",
"     </li>",
"     <li>",
"      Drooling &ndash; 48 to 86 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other neurologic manifestations include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Risus sardonicus (sardonic expression produced by dystonic spasm of the facial muscles)",
"     </li>",
"     <li>",
"      Chorea",
"     </li>",
"     <li>",
"      Athetosis",
"     </li>",
"     <li>",
"      Cognitive",
"      <span class=\"nowrap\">",
"       impairment/dementia",
"      </span>",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Hyperreflexia",
"     </li>",
"     <li>",
"      Myoclonia",
"     </li>",
"     <li>",
"      Urinary incontinence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) or computed tomographic (CT) scanning of the brain may reveal structural abnormalities in the basal ganglia in patients with neurologic Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/43\">",
"     43",
"    </a>",
"    ]. Common findings in the regions of the basal ganglia include increased density on CT scan and hyperintensity on T2-weighted MRI images. Other findings include hyperintensities in the tectal-plate and central pons. Simultaneous involvement of the basal ganglia, thalamus, and brainstem is highly suggestive of Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cerebrospinal fluid (CSF) copper concentrations in patients with neurologic Wilson disease are elevated three to fourfold relative to those in patients without Wilson disease or with Wilson disease without neurologic signs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/45\">",
"     45",
"    </a>",
"    ]. These values fall with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H126976162\">",
"    <span class=\"h3\">",
"     Dysarthria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with neurologic Wilson disease, dysarthria is the most common neurologic symptom. The type of dysarthria may vary: patients may have ataxic dysarthria (irregular word spacing and volume), or the speech may be athetoid, hypophonic, or spastic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H246330820\">",
"    <span class=\"h3\">",
"     Dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dystonia associated with Wilson disease may range in severity from mild to debilitating and often worsens with disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/2\">",
"     2",
"    </a>",
"    ]. It may be focal, segmental, multifocal, or generalized. While it often starts unilaterally, it may eventually become bilateral or generalized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=see_link\">",
"     \"Classification and evaluation of dystonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Focal manifestations of dystonia include blepharospasm, cervical dystonia (torticollis), writer's cramp, and a dystonic facial expression in which the patient appears to have an exaggerated smile (risus sardonicus). With focal dystonia of the vocal cords, muscles of articulation, or swallowing muscles, patients may develop dysphonia, dysarthria, or dysphagia, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H246330844\">",
"    <span class=\"h3\">",
"     Tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tremors in Wilson disease may occur at rest or with action and may have multiple position and task-dependent characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/2\">",
"     2",
"    </a>",
"    ]. Some of the tremors seen include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A tremor that resembles essential tremor (variable amplitude and frequency, with arm, and sometimes head and leg involvement). Unlike essential tremor, the tremor in patients with Wilson disease often persists in its asymmetry and may not involve the voice. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of tremor\", section on 'Essential tremor'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An intention (kinetic) tremor (low amplitude, medium-to-high frequency), seen most often in a distal upper extremity. Intention tremors typically increase in severity as the patient's hand moves closer to its target. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=see_link&amp;anchor=H16#H16\">",
"       \"Overview of tremor\", section on 'Intention tremor'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A postural tremor that occurs when the patient assumes a particular position. The classic tremor associated with Wilson disease is a wing-beating tremor, though it is not the most common type of tremor [",
"      <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/2\">",
"       2",
"      </a>",
"      ]. The tremor is a low frequency, high amplitude tremor that is most prominent when the patient's arms are held outstretched laterally or with the arms extended in front of the patient with the palms facing downward and the elbows flexed. The tremor increases in amplitude with increased duration of posture holding. The name comes from the fact that the movement of the patient's arms may be reminiscent of a bird's flapping wings.",
"     </li>",
"     <li>",
"      A unilateral, rest tremor may be present, but is rarely seen in isolation. When present, it is typically accompanied by postural and intention tremors that often dominate the clinical picture [",
"      <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H246331158\">",
"    <span class=\"h3\">",
"     Parkinsonism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parkinsonian features that may be seen in Wilson disease include bradykinesia, cogwheel rigidity, and postural instability. Parkinsonism is rarely an isolated clinical feature in patients with Wilson disease and is typically accompanied by other neurologic deficits. [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H246330836\">",
"    <span class=\"h3\">",
"     Choreoathetosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorea&nbsp;is characterized by rapid and unpredictable contractions affecting mostly distal limbs, but it can also affect the face and trunk. The movements are involuntary and non-patterned with variable speed, timing, and direction, flowing from one body part to another. In less severe cases, this can result in an appearance of fidgetiness. The unpredictable nature of chorea is a feature that distinguishes it from tremor and dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/47\">",
"     47",
"    </a>",
"    ]. When severe and with proximal muscle involvement, choreic movements may result in violent, uncontrolled flailing movements of the extremities (ballism). Athetosis refers to slower writhing movements with a sinuous quality. The term choreoathetosis is used when typical choreic movements coexist with athetosis.",
"   </p>",
"   <p>",
"    Chorea as an initial clinical feature is more often seen in younger patients (&le;16 years). It has been reported in 20 percent of patients with a young age of symptom onset, compared with 3 percent of patients with an older age of onset [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/8\">",
"     8",
"    </a>",
"    ]. It typically is not present in isolation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H246330852\">",
"    <span class=\"h3\">",
"     Cerebellar ataxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebellar ataxia is generally not seen as the sole neurologic manifestation of Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/2\">",
"     2",
"    </a>",
"    ]. The ataxia is typically not clinically relevant, and frank limb ataxia is uncommon.",
"   </p>",
"   <p>",
"    Patients with cerebellar ataxia have difficulty changing voluntary force levels abruptly, with impaired acceleration and braking [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/48\">",
"     48",
"    </a>",
"    ]. This leads to [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overshoot in point-to-point movements (dysmetria)",
"     </li>",
"     <li>",
"      In multijoint movements, breakdown of normal coordination of joint rotations, with trajectory abnormalities (dyssynergia)",
"     </li>",
"     <li>",
"      Breakdown in the rhythm of repetitive, alternating single movements, such as finger tapping (dysrhythmia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dysfunction in the vermis or paleocerebellum results in truncal and gait ataxia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/12/9417?source=see_link&amp;anchor=H12#H12\">",
"     \"Gait disorders of elderly patients\", section on 'Cerebellar ataxia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H246330860\">",
"    <span class=\"h3\">",
"     Cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two main categories of cognitive impairment in Wilson disease have been described, a frontal syndrome and subcortical dementia, with some patients having features of both [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/2\">",
"     2",
"    </a>",
"    ]. In patients with cognitive impairment, the findings can be subtle and may only be recognized retrospectively. In addition, some have suggested that the apparent cognitive impairment may be primarily the result of psychiatric and motor manifestations of Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/13,50\">",
"     13,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a frontal syndrome may demonstrate impulsivity, promiscuity, impaired judgement, apathy, executive dysfunction (poor planning and decision making), decreased attention, and emotional lability. When severe, patients may have pseudobulbar features (sudden outbursts of inappropriate laughter or tearfulness). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link&amp;anchor=H4#H4\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\", section on 'Behavioral variant'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings in subcortical dementia include slowed thinking, memory loss, and executive dysfunction. It lacks cortical signs such as aphasia, apraxia, or agnosia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H246330868\">",
"    <span class=\"h3\">",
"     Other neurologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures, while rarely the presenting feature, are seen in approximately 6 percent of patients with Wilson disease and have been associated with the initiation of chelation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/51\">",
"     51",
"    </a>",
"    ]. Other neurologic manifestations include hyperreflexia, tics, and unusual stereotyped movements [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69500449\">",
"    <span class=\"h2\">",
"     Behavioral and psychiatric symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral and psychiatric symptoms are more common in patients with neurologic involvement than in patients with hepatic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/50,52\">",
"     50,52",
"    </a>",
"    ]. The most common behavioral and psychiatric symptoms include depression (reported in 20 to 30 percent of patients with Wilson disease), personality change, incongruous behavior, and irritability [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/2,50\">",
"     2,50",
"    </a>",
"    ]. However, behavioral and psychiatric symptoms due to Wilson disease are often misdiagnosed (eg, they may be attributed to puberty). As a result, it is uncommon for patients to be diagnosed with Wilson disease when the only manifestations are behavioral or psychiatric.",
"   </p>",
"   <p>",
"    Behavioral and psychiatric manifestations of Wilson disease include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/1,2,26,50,53-55\">",
"     1,2,26,50,53-55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depression",
"     </li>",
"     <li>",
"      Declining school performance",
"     </li>",
"     <li>",
"      Personality changes (which may be subtle)",
"     </li>",
"     <li>",
"      Irritability",
"     </li>",
"     <li>",
"      Impulsiveness",
"     </li>",
"     <li>",
"      Labile mood",
"     </li>",
"     <li>",
"      Sexual exhibitionism",
"     </li>",
"     <li>",
"      Inappropriate behavior",
"     </li>",
"     <li>",
"      Dysthymia",
"     </li>",
"     <li>",
"      Bipolar affective disorder",
"     </li>",
"     <li>",
"      Psychosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57950503\">",
"    <span class=\"h2\">",
"     Hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;While not a common finding in isolation, Coombs-negative hemolytic anemia may be the initial symptom of Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/16,56\">",
"     16,56",
"    </a>",
"    ]. In a series of 283 patients, hemolytic anemia was the sole presenting feature in only three patients (1 percent), but it was present in a 19 of 77 patients (28 percent) who had jaundice at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/16\">",
"     16",
"    </a>",
"    ]. The anemia may occur as a single acute episode, or it may be low-grade and chronic.",
"   </p>",
"   <p>",
"    Patients who report a history of jaundice prior to the diagnosis of Wilson disease may have had previously unrecognized hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/57\">",
"     57",
"    </a>",
"    ]. If acute hepatitis and hemolysis due to Wilson disease develop during pregnancy, it may be mistaken for HELLP syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=see_link&amp;anchor=H20#H20\">",
"     \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\", section on 'Copper'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"     \"HELLP syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H246330944\">",
"    <span class=\"h2\">",
"     Ocular manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kayser-Fleischer rings are brownish or gray-green rings that are due to fine pigmented granular deposits of copper in Descemet's membrane in the cornea (",
"    <a class=\"graphic graphic_picture graphicRef65925 \" href=\"UTD.htm?19/26/19887\">",
"     picture 1",
"    </a>",
"    ). Kayser-Fleischer rings are a characteristic feature of Wilson disease and are seen in more than 90 percent of patients with neurologic manifestations and 50 to 60 percent of patients with hepatic manifestations. While often only detected by slit-lamp examination (typically done in a patient already suspected of having Wilson disease), Kayser-Fleischer rings are sometimes visible without a slit-lamp examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link\">",
"     \"Tests used in the diagnosis of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44486?source=see_link\">",
"     \"Slit lamp examination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sunflower cataracts are another ocular manifestation of Wilson disease and occur when copper deposits accumulate in the lens. These, too, are generally seen with a slit-lamp examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69500456\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wilson disease can cause abnormalities related to copper deposition in other organs. Other manifestations of Wilson disease that are less common include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/1,58-60\">",
"     1,58-60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fanconi syndrome, in which proximal tubular dysfunction leads to glucosuria, aminoaciduria, hypouricemia, and proximal renal tubular acidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link&amp;anchor=H4#H4\">",
"       \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Proximal (type 2) RTA'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nephrolithiasis secondary to distal renal tubular acidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23973?source=see_link\">",
"       \"Nephrolithiasis in renal tubular acidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arthropathy with features of premature arthritis and occasionally chondrocalcinosis, most commonly in the knee.",
"     </li>",
"     <li>",
"      Gigantism.",
"     </li>",
"     <li>",
"      Cardiomyopathy.",
"     </li>",
"     <li>",
"      Myopathy.",
"     </li>",
"     <li>",
"      Hypoparathyroidism.",
"     </li>",
"     <li>",
"      Pancreatitis.",
"     </li>",
"     <li>",
"      Impotence.",
"     </li>",
"     <li>",
"      Infertility or repeated spontaneous abortions.",
"     </li>",
"     <li>",
"      A variety of dermatologic disorders. These include blue lunulae, acanthosis nigricans, and pretibial hyperpigmentation. Dermatologic manifestations may also occur from treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      , including bullous pemphigoid, elastosis perforans serpiginosa, and pseudoxanthoma elasticum [",
"      <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/61-63\">",
"       61-63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83323995\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83324023\">",
"    <span class=\"h2\">",
"     Abnormal liver tests or cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal transaminases may be seen in viral hepatitis, alcohol abuse, autoimmune hepatitis, hepatotoxicity due to drugs or supplements, hereditary hemochromatosis, and alpha-1 antitrypsin deficiency. In patients with Wilson disease, the serum aminotransferases are usually mildly to moderately elevated, and the aspartate aminotransferase (AST) concentration is usually higher than the alanine aminotransferase (ALT) concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, in patients presenting with cirrhosis, other causes of chronic liver disease, such as viral hepatitis, need to be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link\">",
"     \"Diagnostic approach to the patient with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83324030\">",
"    <span class=\"h2\">",
"     Acute liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute liver failure can be caused by viral hepatitis, toxins, alcohol, ischemia, inherited metabolic diseases, and autoimmune hepatitis. Among patients with acute liver failure due to Wilson disease, the serum aminotransferases are typically less than 2000 with an",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    ratio of &gt;1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, the alkaline phosphatase level is typically normal or subnormal, with an alkaline phosphatase (int.",
"    <span class=\"nowrap\">",
"     unit/L)",
"    </span>",
"    to total bilirubin",
"    <span class=\"nowrap\">",
"     (mg/dL)",
"    </span>",
"    ratio of less &lt;2. Finally, patients with acute liver failure due to Wilson disease typically have a Coombs-negative hemolytic anemia and may have a low uric acid level. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=see_link\">",
"     \"Acute liver failure in children: Etiology and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83324037\">",
"    <span class=\"h2\">",
"     Neurologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic manifestations of Wilson disease are numerous and can mimic other neurologic disorders, especially any type of movement disorder. Disorders that should be considered include essential tremor, young-onset Parkinson's disease, and generalized dystonia. Disorders that may rarely mimic Wilson disease include Huntington disease, pantothenate kinase-associated neurodegeneration (Hallervorden-Spatz disease), idiopathic torsion dystonia, chorea-acanthocytosis, and benign familial chorea. The presence of Kayser-Fleischer rings, seen in more than 90 percent of patients with neurologic Wilson disease, can help differentiate Wilson disease from these other disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=see_link\">",
"     \"Overview of tremor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=see_link\">",
"     \"Classification and evaluation of dystonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=see_link\">",
"     \"Bradykinetic movement disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83324044\">",
"    <span class=\"h2\">",
"     Psychiatric manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for the psychiatric manifestations of Wilson disease includes disorders such as depression, bipolar disorder, schizophrenia, dementia, and drug abuse. As with the neurologic manifestations, the presence of Kayser-Fleischer rings can help differentiate patients with Wilson disease from these other disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65234856\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Wilson disease starts with recognition of the clinical features suggestive of the disease or identification of family members who require screening. Testing begins with serologic testing (liver biochemical tests, a complete blood count, serum ceruloplasmin level), an ocular slit-lamp examination, and 24-hour urinary copper excretion. Only about one-half of patients ultimately diagnosed with Wilson disease present with the classic clinical picture of a patient who is between the ages of 5 and 35 years, has a decreased serum ceruloplasmin, and has detectable Kayser-Fleischer rings [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H69500435\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65234572\">",
"    <span class=\"h2\">",
"     When to consider Wilson disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wilson disease should be considered in any patient with unexplained liver, neurologic, or psychiatric abnormalities or in a first-degree relative of a patient with Wilson disease. Serum aminotransferases are usually mildly to moderately elevated in patients with Wilson disease, including children and other patients diagnosed in a presymptomatic stage. The degree of elevation correlates poorly with the extent of histologic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/31,64\">",
"     31,64",
"    </a>",
"    ]. The aspartate aminotransferase (AST) concentration is usually higher than the alanine aminotransferase concentration (ALT). (See",
"    <a class=\"local\" href=\"#H69500442\">",
"     'Hepatic disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Neurologic disorders in patients with Wilson disease include a parkinsonian-like rest tremor, rigidity, clumsiness of gait, slurring of speech, facial grimacing (risus sardonicus), and drooling. Patients may also present with psychiatric problems, ranging from subtle personality changes and deteriorating performance at school, to overt depression or psychosis. (See",
"    <a class=\"local\" href=\"#H69501597\">",
"     'Neurologic manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H69500449\">",
"     'Behavioral and psychiatric symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    While the majority of patients diagnosed with Wilson disease are between the ages of 5 and 35 years, Wilson disease has been diagnosed in patients as young as three years-old and in patients who are in their 70s. (See",
"    <a class=\"local\" href=\"#H57950462\">",
"     'Age at symptom onset'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In particular, Wilson disease should be considered in (",
"    <a class=\"graphic graphic_table graphicRef79927 \" href=\"UTD.htm?9/10/9389\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/34,65\">",
"     34,65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients between the ages of 3 and 55 years with liver abnormalities of uncertain etiology",
"     </li>",
"     <li>",
"      Patients with unexplained liver disease accompanied by neurologic or psychiatric symptoms",
"     </li>",
"     <li>",
"      Pediatric patients with clinical features suggestive of autoimmune hepatitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=see_link\">",
"       \"Clinical manifestations and diagnosis of autoimmune hepatitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adult patients with atypical autoimmune hepatitis or autoimmune hepatitis that does not respond well to standard glucocorticoid therapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=see_link&amp;anchor=H150844268#H150844268\">",
"       \"Treatment of autoimmune hepatitis\", section on 'Initial treatment of patients without fulminant hepatitis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis (steatosis is a common finding in Wilson disease) with atypical features for nonalcoholic fatty liver disease (such as absence of obesity) or who are under the age of 35 years (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link\">",
"       \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Patients with acute liver failure with features suggestive of Wilson disease (see",
"      <a class=\"local\" href=\"#H69501971\">",
"       'Acute hepatitis and acute liver failure'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      First-degree relatives of a patient diagnosed with Wilson disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65234579\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of a patient suspected of having Wilson disease starts with noninvasive testing (serologic tests, ocular examination, determination of urinary copper excretion). Additional testing, such as a liver biopsy, may be required if the initial testing is inconclusive.",
"   </p>",
"   <p>",
"    We start the evaluation with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determination of liver biochemical tests to look for evidence of active inflammation and to assess the AST to ALT ratio (often &gt;1 in patients with Wilson disease)",
"     </li>",
"     <li>",
"      A complete blood count to look for anemia (followed by testing for Coombs-negative hemolytic anemia if indicated) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link\">",
"       \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Measurement of the serum ceruloplasmin concentration (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link&amp;anchor=H59391355#H59391355\">",
"       \"Tests used in the diagnosis of Wilson disease\", section on 'Serum ceruloplasmin concentration'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An ocular slit-lamp examination (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link&amp;anchor=H59391898#H59391898\">",
"       \"Tests used in the diagnosis of Wilson disease\", section on 'Ocular slit-lamp examination'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Determination of 24-hour urinary copper excretion (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link&amp;anchor=H59396783#H59396783\">",
"       \"Tests used in the diagnosis of Wilson disease\", section on 'Urinary copper excretion'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tests to rule out other causes of hepatic, neurologic, or psychiatric symptoms that could mimic Wilson disease (see",
"      <a class=\"local\" href=\"#H83323995\">",
"       'Differential diagnosis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65235710\">",
"    <span class=\"h2\">",
"     Interpretation of test results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our interpretation of the initial laboratory test results and our approach to additional testing is as follows. This approach is similar to that outlined in a 2008 consensus guideline from the",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     American Association for the Study of Liver Diseases",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef79927 \" href=\"UTD.htm?9/10/9389\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef56720 \" href=\"UTD.htm?7/36/7744\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef75631 \" href=\"UTD.htm?30/9/30864\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef69940 \" href=\"UTD.htm?22/22/22880\">",
"     algorithm 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/34,65\">",
"     34,65",
"    </a>",
"    ] and a 2012 guideline from the",
"    <a class=\"external\" href=\"file://www.easl.eu/_clinical-practice-guideline\">",
"     European Association for the Study of the Liver",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/1\">",
"     1",
"    </a>",
"    ], though subtle differences exist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65235537\">",
"    <span class=\"h3\">",
"     Low ceruloplasmin (&lt;20 mg/dL or 200 mg/L)",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kayser-Fleischer rings present:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A diagnosis of Wilson disease is established if 24-hour urinary copper excretion is &gt;40 mcg (0.64 micromol)",
"     </li>",
"     <li>",
"      If urinary copper excretion is &le;40 mcg (0.64 micromol), a liver biopsy should be obtained to stain for copper and to determine the hepatic copper concentration (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link&amp;anchor=H59395417#H59395417\">",
"       \"Tests used in the diagnosis of Wilson disease\", section on 'Liver biopsy'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kayser-Fleischer rings absent: &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A diagnosis of Wilson disease is established if the 24-hour urinary copper excretion is &gt;100 mcg (1.6 micromol)",
"     </li>",
"     <li>",
"      If the urinary copper excretion is &le;100 mcg (1.6 micromol), a liver biopsy should be obtained to stain for copper and to determine the hepatic copper concentration",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65235544\">",
"    <span class=\"h3\">",
"     Normal or elevated ceruloplasmin (&ge;20 mg/dL or 200 mg/L)",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kayser-Fleischer rings present:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A liver biopsy should be obtained to stain for copper and to determine the hepatic copper concentration, regardless of urinary copper excretion (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link&amp;anchor=H59395417#H59395417\">",
"       \"Tests used in the diagnosis of Wilson disease\", section on 'Liver biopsy'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kayser-Fleischer rings absent:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A diagnosis of Wilson disease is excluded if the urinary copper excretion is &le;40 mcg (0.64 micromol)",
"     </li>",
"     <li>",
"      If the urinary copper excretion is &gt;40 mcg (0.64 micromol), a liver biopsy should be obtained to stain for copper and to determine the hepatic copper concentration",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65235551\">",
"    <span class=\"h3\">",
"     Hepatic copper concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo a liver biopsy should have their hepatic copper concentration determined (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link&amp;anchor=H59392499#H59392499\">",
"     \"Tests used in the diagnosis of Wilson disease\", section on 'Hepatic copper concentration'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A diagnosis of Wilson disease is established if the hepatic copper concentration is &ge;250",
"      <span class=\"nowrap\">",
"       mcg/g",
"      </span>",
"      dry weight (4",
"      <span class=\"nowrap\">",
"       micromol/g",
"      </span>",
"      dry weight).",
"     </li>",
"     <li>",
"      A diagnosis of Wilson disease is excluded if the hepatic copper concentration is &lt;50",
"      <span class=\"nowrap\">",
"       mcg/g",
"      </span>",
"      dry weight (0.8",
"      <span class=\"nowrap\">",
"       micromol/g",
"      </span>",
"      dry weight). Rarely, sampling variation (eg, sampling only scar tissue in a patient with cirrhosis) may lead to a false normal hepatic copper concentration in a patient with Wilson disease [",
"      <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/27,40,66,67\">",
"       27,40,66,67",
"      </a>",
"      ]. If the urinary copper excretion is &gt;100 mcg (1.6 micromol), the patient most likely has Wilson disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the hepatic copper concentration is between 50 and 250",
"    <span class=\"nowrap\">",
"     mcg/g",
"    </span>",
"    dry weight, especially if histology reveals evidence of active liver disease, genetic testing is indicated to establish the diagnosis. Genetic testing is also indicated if there is suspicion of sampling variation leading to a falsely normal hepatic copper concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link&amp;anchor=H59392926#H59392926\">",
"     \"Tests used in the diagnosis of Wilson disease\", section on 'Genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65234586\">",
"    <span class=\"h2\">",
"     Screening family members",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-degree relatives of patients diagnosed with Wilson disease should be screened for the disease (",
"    <a class=\"graphic graphic_algorithm graphicRef69940 \" href=\"UTD.htm?22/22/22880\">",
"     algorithm 3",
"    </a>",
"    ). Among siblings, genotyping studies based upon the proband should be performed if possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link&amp;anchor=H59392926#H59392926\">",
"     \"Tests used in the diagnosis of Wilson disease\", section on 'Genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the child of a patient with Wilson disease and in cases where genetic testing is not possible, the evaluation is the same as that for a patient with clinical features suggestive of Wilson disease. (See",
"    <a class=\"local\" href=\"#H65234579\">",
"     'Initial evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69501333\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3288980\">",
"    <span class=\"h2\">",
"     Progression of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated, Wilson disease is universally fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/1\">",
"     1",
"    </a>",
"    ]. Copper accumulation in the liver eventually leads to the development of cirrhosis and, among patients with neurologic Wilson disease, the neurologic disease may progress until the patient becomes severely dystonic, akinetic, and mute. Progression is usually gradual, but sudden deterioration may also occur. The majority of patients will die from liver disease (cirrhosis or acute liver failure), while the remainder die due to progressive neurologic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3288987\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are lacking regarding life expectancy among untreated patients with Wilson disease. One study found that the median survival following the development of neurologic symptoms was approximately five years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients who develop acute liver failure due to Wilson disease have an acute mortality rate of at least 95 percent in the absence of a liver transplantation, with death occurring in days to weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis for patients who receive and are adherent to treatment for Wilson disease is excellent, provided advanced liver disease is not already present. In such patients, life expectancy is normal, though treatment may lead to worsening of neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/12,42\">",
"     12,42",
"    </a>",
"    ]. Among patients requiring liver transplantation, one-year survival following transplantation has been reported to be 79 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/34,68\">",
"     34,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=see_link\">",
"     \"Treatment of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69500463\">",
"    <span class=\"h2\">",
"     Cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether patients with Wilson disease are at increased risk for hepatocellular carcinoma or other malignancies is unclear. Occasional reports have described hepatocellular carcinoma and cholangiocarcinoma occurring in the setting of Wilson disease, and screening for hepatocellular carcinoma is recommended for patients with cirrhosis due to Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link&amp;anchor=H61643928#H61643928\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\", section on 'Patients with cirrhosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the largest series to address the association of Wilson disease with cancer included a total of 363 patients seen at three centers in England since 1955, eleven of whom had been diagnosed with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/45/13018/abstract/71\">",
"     71",
"    </a>",
"    ]. The cancers included cholangiocarcinoma (three patients), poorly differentiated adenocarcinoma of undetermined primary site (five patients) and hepatocellular carcinoma (three patients). The incidence of cancer appeared to be related to the duration of disease. No cancers were seen in patients followed for less than ten years, compared with an incidence of 4.2 percent in those followed for 10 to 19 years, 5.3 percent for those followed for 20 to 29 years, and 15 percent for those followed for 30 to 39 years.",
"   </p>",
"   <p>",
"    Whether the risk of cancer was increased compared with the general population is difficult to determine from this report since it did not include a control group. The higher incidence of cancer in those followed for longer may have been at least in part related to their older age and longer duration of follow-up. On the other hand, the types of cancer seen (occurring in organs affected by copper deposition) support a possible association with Wilson disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69501155\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations of Wilson disease are predominantly hepatic, neurologic, and psychiatric, with many patients having a combination of symptoms. (See",
"      <a class=\"local\" href=\"#H69500435\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with Wilson disease are diagnosed between the ages of 5 and 35, though it has been diagnosed in younger patients and in patients in their 70s. (See",
"      <a class=\"local\" href=\"#H57950462\">",
"       'Age at symptom onset'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hepatic manifestations include acute liver failure with a Coombs-negative hemolytic anemia, acute hepatitis, chronic hepatitis, cirrhosis, steatosis, and asymptomatic liver biochemical abnormalities. Regardless of presenting symptoms, some degree of liver disease is usually present at the time of diagnosis of Wilson disease. (See",
"      <a class=\"local\" href=\"#H69500442\">",
"       'Hepatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The reported neurologic manifestations of Wilson disease are broad, and diagnosing neurologic Wilson disease can be challenging because patients present in many different ways. The majority of patients with neurologic Wilson disease have dysarthria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      movement disorders. Initially, it is common for one symptom to be present (often unilaterally), but as the disease progresses, complex combinations of neurologic signs and symptoms may develop. (See",
"      <a class=\"local\" href=\"#H69501597\">",
"       'Neurologic manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Behavioral and psychiatric symptoms are more common in patients with neurologic involvement than in patients with hepatic involvement. The most common behavioral and psychiatric symptoms include depression (reported in 20 to 30 percent of patients with Wilson disease), personality change, incongruous behavior, and irritability.",
"     </li>",
"     <li>",
"      Other clinical manifestations of Wilson diseased include Coombs-negative hemolytic anemia and Kaiser-Fleischer rings. (See",
"      <a class=\"local\" href=\"#H57950503\">",
"       'Hemolysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H246330944\">",
"       'Ocular manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H69500456\">",
"       'Other manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with clinical features suggestive of Wilson disease, we start by obtaining liver biochemical tests, a complete blood count, a serum ceruloplasmin level, an ocular slit-lamp examination, and a 24-hour urinary copper excretion. The serum ceruloplasmin level, slit-lamp examination results, and 24-hour urinary copper excretion determine the need for additional testing. (See",
"      <a class=\"local\" href=\"#H65234856\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Untreated, Wilson disease is universally fatal. Copper accumulation in the liver eventually leads to the development of cirrhosis and, among patients with neurologic Wilson disease, the neurologic disease may progress until the patient becomes severely dystonic, akinetic, and mute. The majority of patients will die from liver disease (cirrhosis or acute liver failure), while the remainder die due to progressive neurologic disease. (See",
"      <a class=\"local\" href=\"#H69501333\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis for patients who receive and are adherent to treatment for Wilson disease is excellent, provided advanced liver disease is not already present. In such patients, life expectancy is normal, though treatment may lead to worsening of neurologic symptoms. Among patients requiring liver transplantation, one-year survival following transplantation has been reported to be 79 to 90 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=see_link\">",
"       \"Treatment of Wilson disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26428567\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's past work as an author for this topic, as well as his work as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/1\">",
"      European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012; 56:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/2\">",
"      Lorincz MT. Neurologic Wilson's disease. Ann N Y Acad Sci 2010; 1184:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/3\">",
"      Takeshita Y, Shimizu N, Yamaguchi Y, et al. Two families with Wilson disease in which siblings showed different phenotypes. J Hum Genet 2002; 47:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/4\">",
"      Gollan JL, Gollan TJ. Wilson disease in 1998: genetic, diagnostic and therapeutic aspects. J Hepatol 1998; 28 Suppl 1:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/5\">",
"      Taly AB, Meenakshi-Sundaram S, Sinha S, et al. Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore) 2007; 86:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/6\">",
"      Machado A, Chien HF, Deguti MM, et al. Neurological manifestations in Wilson's disease: Report of 119 cases. Mov Disord 2006; 21:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/7\">",
"      Soltanzadeh A, Soltanzadeh P, Nafissi S, et al. Wilson's disease: a great masquerader. Eur Neurol 2007; 57:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/8\">",
"      Walshe JM, Yealland M. Wilson's disease: the problem of delayed diagnosis. J Neurol Neurosurg Psychiatry 1992; 55:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/9\">",
"      Noureen N, Rana MT. Neurological Wilson disease in children: a three years experience from Multan. J Pak Med Assoc 2011; 61:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/10\">",
"      Roberts EA, Cox DW. Wilson disease. Baillieres Clin Gastroenterol 1998; 12:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/11\">",
"      Asadi Pooya AA, Eslami NS, Haghighat M. Wilson disease in southern Iran. Turk J Gastroenterol 2005; 16:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/12\">",
"      Stremmel W, Meyerrose KW, Niederau C, et al. Wilson disease: clinical presentation, treatment, and survival. Ann Intern Med 1991; 115:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/13\">",
"      Akil M, Brewer GJ. Psychiatric and behavioral abnormalities in Wilson's disease. Adv Neurol 1995; 65:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/14\">",
"      Moores A, Fox S, Lang A, Hirschfield GM. Wilson disease: Canadian perspectives on presentation and outcomes from an adult ambulatory setting. Can J Gastroenterol 2012; 26:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/15\">",
"      Manolaki N, Nikolopoulou G, Daikos GL, et al. Wilson disease in children: analysis of 57 cases. J Pediatr Gastroenterol Nutr 2009; 48:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/16\">",
"      Saito T. Presenting symptoms and natural history of Wilson disease. Eur J Pediatr 1987; 146:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/17\">",
"      Bachmann H, L&ouml;ssner J, Biesold D. [Wilson's disease in the German Democratic Republic. I. Genetics and epidemiology]. Z Gesamte Inn Med 1979; 34:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/18\">",
"      BEARN AG. A genetical analysis of thirty families with Wilson's disease (hepatolenticular degeneration). Ann Hum Genet 1960; 24:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/19\">",
"      Dastur DK, Manghani DK, Wadia NH. Wilson's disease in India. I. Geographic, genetic, and clinical aspects in 16 families. Neurology 1968; 18:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/20\">",
"      Sternlieb I, Scheinberg IH. Prevention of Wilson's disease in asymptomatic patients. N Engl J Med 1968; 278:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/21\">",
"      Strickland GT, Frommer D, Leu ML, et al. Wilson's disease in the United Kingdom and Taiwan. I. General characteristics of 142 cases and prognosis. II. A genetic analysis of 88 cases. Q J Med 1973; 42:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/22\">",
"      Walshe JM. Wilson's disease presenting with features of hepatic dysfunction: a clinical analysis of eighty-seven patients. Q J Med 1989; 70:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/23\">",
"      Gitlin JD. Wilson disease. Gastroenterology 2003; 125:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/24\">",
"      Oder W, Grimm G, Kollegger H, et al. Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases. J Neurol 1991; 238:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/25\">",
"      Ferenci P, Czonkowska A, Merle U, et al. Late-onset Wilson's disease. Gastroenterology 2007; 132:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/26\">",
"      Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine (Baltimore) 1992; 71:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/27\">",
"      Steindl P, Ferenci P, Dienes HP, et al. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997; 113:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/28\">",
"      Ferenci P. Pathophysiology and clinical features of Wilson disease. Metab Brain Dis 2004; 19:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/29\">",
"      Huster D. Wilson disease. Best Pract Res Clin Gastroenterol 2010; 24:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/30\">",
"      Scott J, Gollan JL, Samourian S, Sherlock S. Wilson's disease, presenting as chronic active hepatitis. Gastroenterology 1978; 74:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/31\">",
"      Schilsky ML, Scheinberg IH, Sternlieb I. Liver transplantation for Wilson's disease: indications and outcome. Hepatology 1994; 19:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/32\">",
"      Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003; 23:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/33\">",
"      Kumagi T, Horiike N, Michitaka K, et al. Recent clinical features of Wilson's disease with hepatic presentation. J Gastroenterol 2004; 39:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/34\">",
"      Roberts EA, Schilsky ML, American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/35\">",
"      Kraut JR, Yogev R. Fatal fulminant hepatitis with hemolysis in Wilson's disease. Criteria for diagnosis. Clin Pediatr (Phila) 1984; 23:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/36\">",
"      Kiss JE, Berman D, Van Thiel D. Effective removal of copper by plasma exchange in fulminant Wilson's disease. Transfusion 1998; 38:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/37\">",
"      Hartleb M, Zahorska-Markiewicz B, Ciesielski A. Wilson's disease presenting in sisters as fulminant hepatitis with hemolytic episodes. Am J Gastroenterol 1987; 82:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/38\">",
"      Walia BN, Singh S, Marwaha RK, et al. Fulminant hepatic failure and acute intravascular haemolysis as presenting manifestations of Wilson's disease in young children. J Gastroenterol Hepatol 1992; 7:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/39\">",
"      Pfeiffenberger J, Gotthardt DN, Herrmann T, et al. Iron metabolism and the role of HFE gene polymorphisms in Wilson disease. Liver Int 2012; 32:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/40\">",
"      Ferenci P, Steindl-Munda P, Vogel W, et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease. Clin Gastroenterol Hepatol 2005; 3:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/41\">",
"      Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut 2007; 56:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/42\">",
"      Bruha R, Marecek Z, Pospisilova L, et al. Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver Int 2011; 31:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/43\">",
"      van Wassenaer-van Hall HN, van den Heuvel AG, Algra A, et al. Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. Radiology 1996; 198:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/44\">",
"      Prashanth LK, Sinha S, Taly AB, Vasudev MK. Do MRI features distinguish Wilson's disease from other early onset extrapyramidal disorders? An analysis of 100 cases. Mov Disord 2010; 25:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/45\">",
"      Kodama H, Okabe I, Yanagisawa M, et al. Does CSF copper level in Wilson disease reflect copper accumulation in the brain? Pediatr Neurol 1988; 4:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/46\">",
"      Hartard C, Weisner B, Dieu C, Kunze K. Wilson's disease with cerebral manifestation: monitoring therapy by CSF copper concentration. J Neurol 1993; 241:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/47\">",
"      Cardoso F, Seppi K, Mair KJ, et al. Seminar on choreas. Lancet Neurol 2006; 5:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/48\">",
"      Mai N, Bolsinger P, Avarello M, et al. Control of isometric finger force in patients with cerebellar disease. Brain 1988; 111 ( Pt 5):973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/49\">",
"      Massaquoi S, Hallett M. Kinematics of initiating a two-joint arm movement in patients with cerebellar ataxia. Can J Neurol Sci 1996; 23:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/50\">",
"      Dening TR, Berrios GE. Wilson's disease: a longitudinal study of psychiatric symptoms. Biol Psychiatry 1990; 28:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/51\">",
"      Dening TR, Berrios GE, Walshe JM. Wilson's disease and epilepsy. Brain 1988; 111 ( Pt 5):1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/52\">",
"      Dening TR, Berrios GE. Wilson's disease. Psychiatric symptoms in 195 cases. Arch Gen Psychiatry 1989; 46:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/53\">",
"      Jackson GH, Meyer A, Lippmann S. Wilson's disease. Psychiatric manifestations may be the clinical presentation. Postgrad Med 1994; 95:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/54\">",
"      Davis EJ, Borde M. Wilson's disease and catatonia. Br J Psychiatry 1993; 162:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/55\">",
"      Shanmugiah A, Sinha S, Taly AB, et al. Psychiatric manifestations in Wilson's disease: a cross-sectional analysis. J Neuropsychiatry Clin Neurosci 2008; 20:81.",
"     </a>",
"    </li>",
"    <li>",
"     Walshe JM. The liver in Wilson's disease. In: Diseases of the liver, 6th ed, SchiffL, Schiff ER.  (Eds), Lippincott, Philadelphia 1987. p.1037-1050.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/57\">",
"      Czlonkowska A. A study of haemolysis in Wilson's disease. J Neurol Sci 1972; 16:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/58\">",
"      MORGAN HG, STEWART WK, LOWE KG, et al. Wilson's disease and the Fanconi syndrome. Q J Med 1962; 31:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/59\">",
"      Wiebers DO, Wilson DM, McLeod RA, Goldstein NP. Renal stones in Wilson's disease. Am J Med 1979; 67:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/60\">",
"      Menerey KA, Eider W, Brewer GJ, et al. The arthropathy of Wilson's disease: clinical and pathologic features. J Rheumatol 1988; 15:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/61\">",
"      Hill VA, Seymour CA, Mortimer PS. Pencillamine-induced elastosis perforans serpiginosa and cutis laxa in Wilson's disease. Br J Dermatol 2000; 142:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/62\">",
"      Deguti MM, Mucenic M, Cancado EL, Tietge UJ. Elastosis perforans serpiginosa secondary to D-penicillamine treatment in a Wilson's disease patient. Am J Gastroenterol 2002; 97:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/63\">",
"      Popadic S, Skiljevic D, Medenica L. Bullous pemphigoid induced by penicillamine in a patient with Wilson disease. Am J Clin Dermatol 2009; 10:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/64\">",
"      Schilsky ML, Scheinberg IH, Sternlieb I. Prognosis of Wilsonian chronic active hepatitis. Gastroenterology 1991; 100:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/65\">",
"      Roberts EA, Schilsky ML. A practice guideline on Wilson disease. Hepatology 2003; 37:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/66\">",
"      Faa G, Nurchi V, Demelia L, et al. Uneven hepatic copper distribution in Wilson's disease. J Hepatol 1995; 22:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/67\">",
"      McDonald JA, Snitch P, Painter D, et al. Striking variability of hepatic copper levels in fulminant hepatic failure. J Gastroenterol Hepatol 1992; 7:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/68\">",
"      Arnon R, Annunziato R, Schilsky M, et al. Liver transplantation for children with Wilson disease: comparison of outcomes between children and adults. Clin Transplant 2011; 25:E52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/69\">",
"      Kosminkova EN, Generalova SIu, Ponomarev AB. [The development of diffuse cholangiocarcinoma in a female patient with long-term undiagnosed Wilson's disease]. Ter Arkh 1995; 67:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/70\">",
"      Madden JW, Ironside JW, Triger DR, Bradshaw JP. An unusual case of Wilson's disease. Q J Med 1985; 55:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/45/13018/abstract/71\">",
"      Walshe JM, Waldenstr&ouml;m E, Sams V, et al. Abdominal malignancies in patients with Wilson's disease. QJM 2003; 96:657.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83837 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13018=[""].join("\n");
var outline_f12_45_13018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H69501155\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69501357\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69500435\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57950462\">",
"      Age at symptom onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69500442\">",
"      Hepatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69501971\">",
"      - Acute hepatitis and acute liver failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69501979\">",
"      - Chronic hepatitis and cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69501597\">",
"      Neurologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H126976162\">",
"      - Dysarthria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H246330820\">",
"      - Dystonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H246330844\">",
"      - Tremor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H246331158\">",
"      - Parkinsonism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H246330836\">",
"      - Choreoathetosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H246330852\">",
"      - Cerebellar ataxia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H246330860\">",
"      - Cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H246330868\">",
"      - Other neurologic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69500449\">",
"      Behavioral and psychiatric symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57950503\">",
"      Hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H246330944\">",
"      Ocular manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69500456\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83323995\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83324023\">",
"      Abnormal liver tests or cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83324030\">",
"      Acute liver failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83324037\">",
"      Neurologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83324044\">",
"      Psychiatric manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H65234856\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65234572\">",
"      When to consider Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65234579\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65235710\">",
"      Interpretation of test results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H65235537\">",
"      - Low ceruloplasmin (&lt;20 mg/dL or 200 mg/L)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H65235544\">",
"      - Normal or elevated ceruloplasmin (&ge;20 mg/dL or 200 mg/L)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H65235551\">",
"      - Hepatic copper concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65234586\">",
"      Screening family members",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69501333\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3288980\">",
"      Progression of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3288987\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69500463\">",
"      Cancer risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69501155\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26428567\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/83837\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/83837|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?7/36/7744\" title=\"algorithm 1\">",
"      Dx WD unexplained liver dz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?30/9/30864\" title=\"algorithm 2\">",
"      Dx WD neurological disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/22/22880\" title=\"algorithm 3\">",
"      Screen Wilson sibling child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/83837|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/26/19887\" title=\"picture 1\">",
"      Kayser Fleischer ring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/83837|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/10/9389\" title=\"table 1\">",
"      AASLD diagnosis screening Wilson",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=related_link\">",
"      Acute liver failure in children: Etiology and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=related_link\">",
"      Bradykinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=related_link\">",
"      Classification and evaluation of dystonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=related_link\">",
"      Clinical manifestations and diagnosis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=related_link\">",
"      Epidemiology and pathogenesis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=related_link\">",
"      Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=related_link\">",
"      Frontotemporal dementia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/12/9417?source=related_link\">",
"      Gait disorders of elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23973?source=related_link\">",
"      Nephrolithiasis in renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=related_link\">",
"      Overview of tremor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=related_link\">",
"      Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44486?source=related_link\">",
"      Slit lamp examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=related_link\">",
"      Tests used in the diagnosis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=related_link\">",
"      Treatment of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_45_13019="Brain CT in stage III melanoma";
var content_f12_45_13019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Computerized tomography of the brain in asymptomatic patients with stage III melanoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Institution",
"       </td>",
"       <td class=\"subtitle1\">",
"        N",
"       </td>",
"       <td class=\"subtitle1\">",
"        True positive, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        False positive, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MDACC",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        1.2*",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MSKCC",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        3.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        University of Michigan",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MDACC: The University of Texas M.D. Anderson Cancer Center; MSKCC: Memorial Sloan-Kettering Cancer Center.",
"     <br>",
"      * This single true-positive case showed bone involvement and not brain metastasis.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Antonio Buzaid, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13019=[""].join("\n");
var outline_f12_45_13019=null;
var title_f12_45_13020="Screening von Hippel Lind";
var content_f12_45_13020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for screening for von Hippel Lindau disease*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Any blood relative of an individual diagnosed with VHL disease by gene analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Individuals with a VHL associated lesion&bull; and a family history of VHL associated-lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Individuals with two or more VHL-associated lesions&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Individuals with any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hemangioblastoma (HB) diagnosed at age &lt;30 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &gt;2 CNS hemangioblastomas (diagnosed at any age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Clear cell renal carcinoma (RCC) diagnosed at age &lt;40 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bilateral and/or multiple RCC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pheochromocytoma (PHEO) diagnosed at age &lt;40 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bilateral and/or multiple PHEO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Personal and family history of pheochromocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &gt;1 Pancreatic serous cystadenoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &gt;1 Pancreatic neuroendocrine tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Multiple pancreatic cysts + any VHL associated lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Middle ear endolymphatic sac tumor (unilateral or bilateral)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Epididymal papillary cystadenoma (unilateral or bilateral)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bilateral epididymal cysts",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * As used by the Massachusetts General Hospital Center for Cancer Risk Analysis and the VHL Clinic.",
"     <br>",
"      &bull; VHL associated-lesions include any of the following: Hemangioblastoma, Clear cell renal carcinoma, Pheochromocytoma, Middle ear endolymphatic sac tumor, Epididymal papillary cystadenoma, Pancreatic serous cystadenomas (but not mucinous cystadenoma), Pancreatic neuroendocrine tumor. (Note: Simple cysts of the kidneys, pancreas or liver are not considered VHL-associated lesions.)",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13020=[""].join("\n");
var outline_f12_45_13020=null;
var title_f12_45_13021="Ramipril post revascularization";
var content_f12_45_13021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ramipril improves outcome after revascularization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 341px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 159 patients with chronic stable angina and reduced left ventricular function undergoing revascularization with angioplasty or bypass surgery, Kaplan-Meier plot shows that ramapril signficantly reduces the triple-composite end point (cardiac death, acute myocardial infarction or clinical heart failure) compared to placebo (10 versus 23 percent, p = 0.03).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kjoller-Hansen L, Steffensen R, Grande P. J Am Coll Cardiol 2000; 35:881.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13021=[""].join("\n");
var outline_f12_45_13021=null;
var title_f12_45_13022="Vit D deficiency rickets";
var content_f12_45_13022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vitamin D deficiency rickets in a child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 221px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Characteristic findings of rickets in children often include radiographic evidence of decreased mineralization around the epiphyses and bowing of the lower extremities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     file://www.asbmr.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13022=[""].join("\n");
var outline_f12_45_13022=null;
var title_f12_45_13023="Atrophy vulva";
var content_f12_45_13023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atrophy vulva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from&nbsp;Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_45_13023=[""].join("\n");
var outline_f12_45_13023=null;
